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Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a disease characterized by chronic 
inflammatory joint disease with persistent synovitis and systemic 
inflammation.[1] It can cause permanent deformities by destruction of 
cartilage and bone.[1] If left untreated, RA will often lead to loss of physical 
functioning, the inability to carry out activities of daily living and a 
reduction of work ability. 
RA is one of the most common inflammatory arthritides, and it has been 
estimated that RA affects about 1% of the population.[2] Occurrence of 
RA is more frequent on the Northern hemisphere and in urban areas.
[2,3]  Data collected by Dutch general practitioners determined that the 
prevalence of RA in the Netherlands in 2017 was approximately 1.5%.
[4] RA predominantly occurs in females (female to male ratio: 3:1) and 
the prevalence rises with age, although it can arise at all ages.[5] Several 
risk factors for RA have been assessed in recent years.[6] These include 
genetic risk factors[7] as well as environmental risk factors[8], of which 
repeated activation of innate immunity and exposure to tobacco smoke are, 
putatively, the most important.[9]
Evidence suggests that RA arises from a combination of multiple hits, 
in which environmental, lifestyle, and stochastic insults occurring in a 
genetically predisposed, epigenetically modified individual leads to a 
breakdown of immunological tolerance.[1] This breach leads to a crucial 
transition towards the chronic (non-resolving) autoimmune synovitis 
delineating RA.[1]
The typical presentation of ‘classic’ RA is a middle-aged woman 
with subacute smouldering polyarticular, symmetric arthralgia and 
swelling of small joints in the hands and feet. Quintessentially, the 
metacarpophalangeal (MCP), proximal interphalangeal (PIP), wrist and 
metatarsophalangeal (MTP) joints are involved. Other characteristic 
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signs and symptoms include morning stiffness, fatigue and weight 
loss. Furthermore, extraarticular manifestations may exist, such as skin 
abnormalities (rheumatoid nodules), pulmonary or cardiac involvement, 
decreased psychological well-being and vasculitis.[10,11] Systemic 
comorbidities (e.g. cardiovascular) can be present.[10,12] Physical 
examination should always assess joints for the presence and distribution 
of tender and swollen joints. Laboratory testing may yield elevated levels 
of autoantibodies: anti-citrullinated protein antibodies (ACPA) and 
rheumatoid factor (RF). Furthermore, acute phase reactants such as the 
erythrocyte sedimentation rate and C-reactive protein levels are typically 
elevated in RA.
Identification and development of RA
Identifying patients in the early symptomatic phase of RA may present a 
challenge to clinicians. Especially in primary care, the high incidence of 
consultations for various common musculoskeletal symptoms is mirrored 
by a low incidence of actual early RA.[4] The consultation prevalence of 
any musculoskeletal symptom in primary care approximates 2405 per 
10,000 per year [4,13], making it the most common organ system consulted 
for at GP practices.[4,13,14] Despite this, the majority of all arthralgia 
patients will never develop RA, with the average full-time GP diagnosing 
only one new patient with RA each year.[15] Nevertheless, general 
practitioners (GPs) in the Netherlands generally do well in titrating those 
patients with RA for referral for secondary care. From that point onwards, 
diagnostic workup should be executed by rheumatologists. 
The existence of a phase of preclinical disease in RA was evinced by 
observations from studies in blood donors from whom multiple blood 
samples were available years before their arthritis became clinically 
apparent.[16–18] These observations, in addition to evidence of epitope 
spreading[19,20] and elevated markers of systemic inflammation[21,22] 
suggest a maturation of the inflammatory response during the years before 
a patient will present with RA.  
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During these years, patients can already advance to a symptomatic phase in 
which RA could, ideally, be identified.[23]
One might wonder why early identification of RA is such a key issue 
from a clinician’s point of view. Early identification allows the initiation 
of early treatment. The 2016 update of EULAR recommendations for the 
management of RA recommends starting therapy with Disease-modifying 
antirheumatic drugs (DMARDs) as soon as the diagnosis of RA is made.
[24] Underlying the significance of early treatment initiation is the 
possibility of a ‘window of opportunity’.[25] This ‘window’ presumes 
the existence of a confined period in which RA is most susceptible to the 
disease-modifying effects of treatment. It is postulated that the disease is 
more prone to respond to DMARDs because underlying disease processes 
have not yet fully matured.[26] The main therapeutic target is indeed 
reversal of the inflammatory response; if inflammation diminishes rapidly, 
structural damage is prevented and physical functioning can be amended 
without sequelae. Delay of treatment initiation was shown to be associated 
with worse disease outcomes, including more severe structural damage 
and a lower likelihood of achieving remission.[25,27,28]
A study group from the European League Against Rheumatism (EULAR) 
defined recommendations for nomenclature to be used to describe the 
aforementioned (pathophysiological) phases in the development of 
RA.[5] Phase A comprises genetic risk factors, whereas phase B specifies 
environmental risk factors. Next, phase C is characterized by autoimmunity 
associated with RA. Phase D is the first phase in which symptoms are 
present: patients experience arthralgia but no synovitis. Unclassified 
arthritis (and clinical synovitis) is present in phase E and, finally, there is 
phase F in which patients can be classified as having RA. These phases are 
depicted in Figure 1.
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Figure 1. EULAR-defined pathophysiological phases in the development of RA
Legend: Image from: van Steenbergen et al, Arthritis Rheum. 2013.[23]
The paramount challenge from a clinician’s standpoint is to identify 
patients with RA in an early phase of clinical arthritis. A key question is 
whether patients with RA can be identified in an even earlier phase, before 
clinical arthritis occurs. The presumption of the latter is that intervention in 
the symptomatic preclinical phase of RA would be even more effective than 
during the phase of early clinical arthritis.
Strategies to identify RA in the phase preceding clinically apparent arthritis
One strategy for the identification of persons at risk for RA is laboratory 
testing of autoantibodies in at-risk populations (e.g. in persons with a 
positive family history, or in non-selected populations such as persons 
visiting health fairs) in which rheumatoid factor (RF) and anti-citrullinated 
protein antibodies (ACPA) will be determined. If these antibodies are 
present, persons are considered to be at risk for the development of 
RA.[16,29] The additional value of other predictors (such as imaging 
abnormalities) in these populations has also been studied.[30,31] A 
potential advantage of this approach is that it can be applied by primary 
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care physicians as well, and rheumatologic evaluation is not required 
before performing autoantibody testing. Disadvantageous of this approach 
is that the prior risk is lower if the clinical expertise is not used as selection 
criterion. In addition, this strategy excludes early identification of RA 
patients in which these factors are not present.
Another strategy to identify patients at risk for developing RA is 
to start with clinical evaluation and use of the clinical expertise of 
rheumatologists. Throughout this thesis, this method is used for the 
identification of patients at risk for RA. Using pattern recognition in signs 
and symptoms reported by patients, rheumatologists can identify patients 
with Clinically Suspect Arthralgia (CSA). This approach is likely applied 
by all rheumatologists – whether knowingly or unknowingly – in their 
daily practise when evaluating patients presenting with (recent-onset) 
arthralgia. It is noteworthy that patients that are identified with CSA by 
their rheumatologists comprise a small group of all patients presenting 
with arthralgia to secondary care (<6%).[32] Despite encompassing a 
small group, the odds ratio of CSA patients to be subsequently diagnosed 
with RA was high: 55.[32] However, the CSA-approach is only feasible 
in secondary care. It is independent of autoantibodies and therefore 
includes autoantibody-positive and -negative patients. Thereafter, the 
discriminative value of different biomarkers such as autoantibodies and 
imaging can be studied. A disadvantage of this approach is that it is to 
some extent subjective, as CSA is demarcated by the clinical expertise of 
rheumatologists. 
To increase homogeneity, a EULAR taskforce recently defined a set of 
clinical characteristics for arthralgia suspicious for progression to RA.[33] 
It has been shown that this definition indeed increased the inclusion of 
homogeneous sets of patients with an increased rate of RA development: 
patients with a clinical suspicion and a positive EULAR definition had a 
two times increased hazard to progress to RA compared to patients with 
a clinical suspicion but a negative definition.[34] The parameters defined 
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are: 1. symptom duration <1 year, 2. symptoms localized in the MCP joints, 
3. morning stiffness lasting ≥60 min, 4. most severe symptoms experienced 
in the early morning, 5. having a first-degree relative with RA, 6. difficulty 
with making a fist, and 7. a positive squeeze test of the MCP joints (Table 
1). If a sensitive definition is preferred, the suggested cut off is 3 parameters 
present.[33] This definition will be used in several of the chapters included 
in this thesis.
Table 1. EULAR-defined characteristics describing arthralgia at risk for RA
History taking:
•	 Joint symptoms of recent onset (duration <1 year)
•	 Symptoms located in MCP joints
•	 Duration of morning stiffness ≥60 min
•	 Most severe symptoms present in the early morning
•	 Presence of a first-degree relative with RA
Physical examination:
•	 Difficulty with making a fist
•	 Positive squeeze test of MCP joints
The Clinically Suspect Arthralgia cohort
CSA patients are included in a longitudinal cohort in Leiden since 2012; this 
cohort formed the basis for the studies presented in this thesis. The Leiden 
Clinically Suspect Arthralgia cohort is an inception cohort at the rheumatology 
outpatient clinic of the Leiden University Medical Centre, the Netherlands. Per 
definition, CSA patients had recent-onset (<1 year) arthralgia of hand (MCP, 
PIP, wrist) or feet (MTP) joints, and they were considered at risk for RA. 
Patients were indicated as having CSA based on the first clinical presentation. 
Patients did not have CSA – and would therefore not be included in the cohort 
– if clinical arthritis was already present at baseline physical examination, or 
if another explanation for the pain was more likely. Examples of this includes 
presence of tenderpoints (indicative of fibromyalgia), or presence of Heberden 
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or Bouchard nodules (indicating osteoarthritis).
As GPs in the Leiden region are discouraged from performing 
autoantibody testing before referral to secondary care, ACPA- and 
RF-status were generally unknown at baseline presentation. Hence, 
autoantibody-positive patients could also be included in the cohort as long 
as the rheumatologists considered the pattern of CSA present. This is a 
clear distinction with the approach in which only autoantibody-positive 
at-risk patients are studied. Furthermore, MR-imaging in the CSA cohort 
was performed within 2 weeks after inclusion and therefore the status 
regarding the presence or absence of baseline imaging abnormalities was 
also unknown at inclusion in the cohort. 
At baseline inclusion in the CSA cohort, questionnaires were completed, 
physical examination performed, blood obtained and imaging (X-rays and 
MRI) performed. MR-imaging is performed on the MCP2–5, wrist and 
MTP1–5 joints of the most painful side, or the dominant side case of equally 
severe symptoms at both sides. The joints were scanned with an 1.5 Tesla 
extremity MRI-scanner using contrast-enhancement with gadolinium and 
scored according to the RA MRI scoring system (RAMRIS) protocol.[35,36]
Patients were prospectively followed with scheduled visits at 4, 12 and 
24 months. If necessary (for instance when the patient experienced more 
symptoms or noticed a swollen joint) patients were seen in between the 
scheduled visits by their rheumatologist. This provided early access to 
rheumatology care if patients developed clinically evident synovitis and 
thus inflammatory arthritis was identified at the first possible opportunity. 
Follow-up in the CSA cohort ended if either clinical arthritis was identified 
or at the final visit at 24 months.
Notably, patients were included in the cohort based on the clinical 
suspicion only. Fulfillment of the EULAR definition of arthralgia at risk 
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for RA[33] was not required, but the different items were collected and the 
definition could be applied in retrospect.
Outcomes measures in RA
RA is a heterogeneous disease and its course and outcomes are highly 
variable between patients. For instance, it has been suggested that ACPA-
positive RA and ACPA-negative RA are two different disease subsets.
[37,38] The presence of ACPA is considered to be associated with worse 
prognosis[39–41], although this differences seems to be diminishing in 
recent years.[42] Notwithstanding, whereas some patients may experience 
a mild disease course, other patients will suffer from severe and disabling 
inflammation of the joints. Accurate prediction of whom will suffer from a 
severe or mild disease course is still inaccurate.[43,44] Monitoring disease 
activity in RA is one of the rheumatologist’s core tasks. Several measures 
exist to assess the disease outcomes in RA. 
First and foremost is the Disease Activity Score (DAS) which is a composition 
of tender and swollen joint counts, a patient-reported global assessment of 
disease activity as well as the level of acute phase reactants.[45] Another 
measure is functional ability, which is measured by the Health Assessment 
Questionnaire Disability Index (HAQ-DI).[46,47] The HAQ-DI consists of 20 
questions in eight categories of functioning: dressing, rising, eating, walking, 
hygiene, reach, grip, and usual activities.[48] Scores for each category consist 
of a scale that is scored 0–3, representing normal (no difficulty: 0), some 
difficulty (1), much difficulty (2), and unable to do (3).[48] The median HAQ 
score for patients presenting with RA is generally 1.0.[49]
Progression of RA can also be monitored through assessment of X-rays of 
joints.[50] Radiographs provides a permanent record of evaluation of joint 
damage through which the outcome of RA can be longitudinally analysed. 
For research purposes, several scoring methods exist, of which the Sharp/
van der Heijde method as proposed in 1989 is most commonly used.[50] 
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Although permanent deformities are become increasingly rare in RA, 
evaluating articular bone erosions can still provide key information on the 
burden of disease and its state of both long- and short-term activity.
Other studies have demonstrated that local subclinical inflammation 
as observed by imaging modalities may already be present during the 
earliest phases of RA.[51–55] MRI can be used to depict inflammation of 
the synovium of the joints (synovitis) as well as the tendons (tenosynovitis) 
and edema in the bone marrow (bone marrow edema; BME) and function 
as an outcome measure. In current research, the most used scoring method 
is the validated semi-quantitively scoring methodology as developed by 
Outcome Measures in Rheumatology Clinical Trials (OMERACT): the 
Rheumatoid Arthritis MRI Scoring system (RAMRIS).[35,36]
Aims of this thesis
This thesis will focus on unravelling the earliest disease phase of RA. As 
previous studies in autoantibody positive individuals at risk for RA have 
reported rates of progression around 30–50%,[29,52,56–58], there remains a 
need for more accurate methods to recognise imminent RA. Furthermore, 
understanding the burden of disease in the earliest phases of RA is required 
as this phase is increasingly significant due to the burgeoning interest in 
this phase. Finally, understanding the processes involved and affected in 
the early phases of RA might reduce the lacunae in current knowledge of 
development of RA and necessitate longitudinal studies.  
 
The aim of this thesis is to unravel and decipher the early phases of RA and 
its concomitant characteristics and burden of disease.
Outline of this thesis
Part 1: Predicting progression to RA 
The thesis will focus on patients with Clinically Suspect Arthralgia 
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identified in secondary care. Importantly, early identification of patients at 
risk for inflammatory arthritis and RA in secondary care is only possible 
if such patients are recognized and referred by GPs. Although GPs realize 
the need of early identification and despite the fact that national and 
international guidelines recommend prompt referral of patients presenting 
with inflammatory arthritis (IA), GPs feel uncertain in their proficiency to 
detect synovitis through joint examination. Our objective in chapter 2 was 
to develop and validate a rule composed of clinical characteristics to assist 
GPs and other physicians in identifying IA.
As mentioned in the Introduction section of this thesis, autoantibody 
testing is helpful for predicting the risk of progression to clinical arthritis 
in subjects at risk. However, most previous longitudinal studies selected 
autoantibody-positive arthralgia patients, and consequently the predictive 
values of autoantibodies were evaluated relative to one another. In chapter 
3, the risk of individual autoantibodies, autoantibody combinations and 
levels for arthritis development CSA was studied, which also had an 
autoantibody-negative reference group. In addition to this chapter, we also 
investigated the implications of screening for two or three autoantibodies 
in persons at risk for RA in chapter 4.
Functional limitations in daily life in patients with Clinically Suspect 
Arthralgia were investigated in chapter 5. It is still unknown to what extent 
patients with arthralgia at risk for RA experience functional disability, 
despite the large impact of functional disability on quality of life.
Part 2: Disease mechanisms involved in progression from CSA to RA 
Occurrence of structural damage (bone erosions) is one of the hallmarks of 
progressive disease in RA. Recent in vitro and murine studies indicate that 
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ACPA can directly activate osteoclasts leading to bone erosions and pain. 
The study in chapter 6 sought evidence for this hypothesis in humans and 
evaluated whether in the earliest phases of RA, ACPA is associated with 
erosions (detected by MRI) independent of inflammation and/or RF.
Subclinical inflammation, detected by MRI, in patients with arthralgia is 
predictive for development of inflammatory arthritis. However, within 
patients that develop IA, the course of inflammation at joint level during 
this transition is unknown. Chapter 7 assessed progression of inflammation 
at joint level.
Furthermore, the time course in which bone marrow edema, synovitis, 
and/or tenosynovitis (the inflammatory features that can be visualized 
using MRI) progress is unsettled. The longitudinal study in chapter 8 
evaluated the course of MRI-detected subclinical joint inflammation during 
progression to RA.
Finally in chapter 9, our objective was to determine the course of joint 
symptoms and mutual time relationships with MRI-detected subclinical 
inflammation in CSA patients that did not progress to RA.
Chapter 10 provides a summary of the thesis and formulates the general 
conclusion of the studies performed as well as general providing future 
perspectives. In Chapter 11, the summary and general conclusions are 
provided in Dutch.
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Abstract
Objectives: National and international guidelines recommend prompt referral of 
patients presenting with inflammatory arthritis (IA), but general practitioners 
(GPs) feel uncertain in their proficiency to detect synovitis through joint 
examination, the method of choice to identify IA. Our objective was to develop 
and validate a rule composed of clinical characteristics to assist GPs and other 
physicians in identifying IA when in doubt.
Design: Split-sample derivation and validation study.
Setting: The Leiden Early Arthritis Recognition Clinic (EARC); a screening clinic 
for patients in whom GPs suspected but were unsure of the presence of IA.
Participants: 1,288 consecutive patients visiting the EARC .
Primary and secondary outcome measures: Associations of clinical characteristics 
with presence of IA were determined using logistic regression in 644 patients, 
while validating the results in the other 644 patients (split-sample validation). 
To facilitate application in clinical practice, a simplified rule (with scores 
ranging 0 to 7.5) was derived and validated. 
Results: IA was identified by a rheumatologist in 41% of patients. In univariable 
analysis, male gender, age ≥60 years, symptom duration <6 weeks, morning 
stiffness >60 minutes, a low number of painful joints (1-3 joints), presence 
of patient-reported joint swelling, and difficulty with making a fist were 
associated with IA in the derivation dataset. Using multivariable analysis, 
a simplified rule consisting of these seven items was derived and validated, 
yielding an Area Under the Receiver Operator Characteristic curve (AUC) of 
0.74 (95%CI 0.70-0.78) in the derivation dataset. Validation yielded an AUC 
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of 0.71 (95%CI 0.67-0.75). Finally, the model was repeated to study predicted 
probabilities with a lower prevalence of inflammatory arthritis to simulate 
performance in primary care settings.
Conclusions: Our rule, composed of clinical parameters, had reasonable 
discriminative ability for IA and could assist physicians in decision-making 
in patients with suspected IA, increasing appropriateness of health care 
utilization.
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Background
Early initiation of disease modifying anti-rheumatic drugs is strongly 
associated with improved outcomes of rheumatoid arthritis (RA).
[1] National and international guidelines attempt to facilitate this by 
emphasizing prompt referral of patients presenting with inflammatory 
arthritis (IA) to a rheumatologist. The European League Against 
Rheumatism (EULAR) taskforce for the management of early IA 
recommends referral within 6 weeks of onset of symptoms[2], while in 
the United Kingdom (UK) the National Institute for Health and Care 
Excellence (NICE) guidelines advises referral to a rheumatologist in 
patients with new, persistent (>3–4 weeks) synovitis within three working 
days.[3] However, it was demonstrated that this referral timeline is 
achieved in only 17% of patients.[4] On average, RA patients are seen four 
(and sometimes more than eight) times by general practitioners (GPs) 
before they refer to secondary care[5-8], which may reflect the difficulty 
of differentiating patients with early IA from patients with other types of 
common musculoskeletal symptoms. A recent qualitative study revealed 
that GPs acknowledge the importance of early detection and referral, 
but feel uncertain in their proficiency to detect synovitis through joint 
examination, the method of choice to identify IA.[2,9] As a consequence, the 
referral to a rheumatologist may be delayed, which contributes to overall 
treatment delay in early RA, as observed in Europe.[10,11]
This is further complicated by the high incidence of consultations for various 
common musculoskeletal symptoms and the low incidence of early IA 
in primary care.[12] The consultation prevalence of any musculoskeletal 
symptom in primary care in the UK approximates 2405 per 10,000 per year 
[13], making it the most common organ system consulted for at GP practices.
[12-14] Although musculoskeletal symptoms are common, GPs suspect IA 
(based on pattern recognition) in only a very small minority of patients.[5] In 
these patients, GPs often lack confidence in joint assessment for synovitis. 
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To support early detection, several initiatives have been developed, 
including triage systems. The best studied triage system (the Early 
Inflammatory Arthritis Questionnaire) was developed and validated for 
patients attending secondary and tertiary care.[15-17] Furthermore, several 
referral guidelines for GPs[6,18-22], and public awareness campaigns 
have been developed, for instance one attempting to simplify pattern 
recognition to the “S-Factor”: Stiffness, Swelling, Squeezing. However, 
none of these initiatives were designed using primary care data, and all 
assume that GPs can differentiate between the presence and absence of 
joint swelling[6,18-20], which continues to be a barrier to the early detection 
of IA. 
Altogether there is a contradiction with the need to refer as quickly as 
possible while evidence who must be referred or, in line with this, in whom 
additional investigations are appropriate is lacking. To solve the issue, we 
have developed and validated a rule composed of clinical characteristics, by 
taking advantage of data from a setting intermediate between primary and 
secondary care. This intermediate setting of an Early Arthritis Recognition 
Clinic was a local solution to promote early referrals and is not easy 
implementable in other regions. The clinical rule derived from these data 
however, is easy to apply and may assist in the decision-making process in 
patients with musculoskeletal symptoms with suspected IA at other places, 
in order to promote early identification of IA.
Methods
Study population 
To promote early recognition of early IA, the Early Arthritis Recognition 
Clinic (EARC) was initiated in September 2010 in Leiden, the Netherlands. 
The outpatient clinic of the department of Rheumatology of the Leiden 
28 Chapter 2
University Medical Centre (LUMC) is the only referral centre in a 
healthcare region of ~400,000 people. GPs were instructed to refer patients 
to the EARC in whom they were unsure about the presence of IA (instead 
of a ‘wait-and-see’ approach or performing additional tests). The EARC 
system has reduced referral delay from 8 to 2 weeks, and improved 
early identification of IA.[11,23] To emphasize the importance of early 
identification of IA and aiming to inform on the purpose of the EARC, a 
region-wide educational campaign was conducted among regional GPs. 
In addition to (and distinct from) the EARC, the LUMC also has an 
Early Arthritis Clinic (EAC). The EAC was established in 1993 to include 
and follow patients with early arthritis and to offer the possibility of 
rapid access to rheumatology care, usually within a week of referral. To 
differentiate between the clinics, GPs were instructed to refer to the EAC if 
there was a clear synovitis or very high suspicion of IA (i.e. to continue as 
they had before, since there was no benefit for such patients to go the EARC 
first) and to refer to the EARC when in doubt about the presence of IA (i.e. 
to not ‘wait-and-see’ or order additional tests). Thus, patients included in 
this study represent the difficult group in whom GPs were uncertain of the 
presence of suspected IA; patients with a very high degree of suspicion 
were referred directly to the EAC.
The EARC screening clinic was held twice a week between 2010–2014 and 
once a week from 2014 onwards. After GP referral, patients can visit the 
EARC without an appointment. All patients that visited the EARC between 
2010 and September 2015 were studied.
Data collection
At the EARC, patients completed a short questionnaire about their joint 
symptoms, after which they were seen by an experienced rheumatologist 
(AvdHvM or other senior rheumatologists) who performed a full 66-joint 
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examination. If synovitis was determined by physical examination, patients 
were fast-tracked to visit the EAC within 1 week for further evaluation 
and treatment. Patients without IA were discharged to primary care. The 
questionnaire completed by patients, provided in S1 Appendix, contained 
questions on age, gender, date of symptom onset, date of first visit to GP, 
presence of a (sub)acute symptom onset (versus a gradual symptom-onset), 
morning stiffness (duration in minutes), which part of the day symptoms 
were worst, and whether they had difficulty with making a fist. Patients 
were asked to indicate on a 52-joint mannequin which joints were painful 
and which joints they considered to be swollen. IA, defined as synovitis 
confirmed by the rheumatologist at physical examination, was used as 
outcome.
Collected data was anonymized and entered in a research database 
at chronological order of visiting the EARC. The local medical ethical 
committee approved this study.
Derivation and validation of the model
We used half of the dataset for derivation and the other half for validation 
of results (split-sample validation). To prevent bias by (unknown) effects of 
inclusion period, patients with odd ID-numbers (1,3,etc) were included in 
the derivation dataset and those with even ID-numbers (2,4,etc) were used 
for validation.
To prevent exclusion of patients with one or more missing variables, 
we imputed missing values using chained equations[24]; frequencies of 
missing variables are presented in S2 Appendix. The variables ‘difficulty 
with making a fist’ and ‘self-reported joint swelling’ were most frequently 
missing as these were added to the questionnaire after April 1st 2012, thus 
absence of these data was considered to occur completely at random.
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We conducted logistic regression analysis modelling with presence of IA 
(defined as rheumatologist-confirmed synovitis on physical examination) 
as dependent variable. Continuous variables were categorized using 
clinically relevant cut-offs: age: <40 / 40–59.9 / ≥60 years; duration of 
symptoms: <6 / 6–11 / 12–51.9 / ≥52 weeks; duration of morning stiffness: 
≤60 / >60 minutes; number of painful joints: 0 / 1–3 / 4–10 / ≥11; number 
of swollen joints: 0 / 1–3 / 4–10 / ≥11. We performed univariable logistic 
regression to evaluate associations between dependent variables and 
presence of IA. Variables with p-values <0.05 in univariable analyses 
were entered in multivariable regression analyses (enter model) to obtain 
a model with a small number of variables. If several categories within a 
variable had similar regression coefficients in multivariable modelling, 
we pooled these categories and repeated the analysis. In sub-analysis, we 
also performed a multivariable logistic regression model with the pooled 
categories using backward selection.
To obtain a simplified rule applicable in daily care, we rounded the 
regression coefficients of the final multivariable logistic regression model 
to the nearest 0.5 (irrespective of p-value). This resulted in an easily 
calculable risk score. For each value of the risk score, we determined test 
characteristics (i.e. sensitivity and specificity) and predicted probabilities of 
the presence of inflammatory arthritis.
We evaluated the overall discriminative ability of the models using the Area 
Under the Receiver Operating Characteristic curve (AUC). The model’s 
calibration was assessed by generating a calibration plot to measure goodness 
of fit, where the data was partitioned in 10 equally sized groups based on 
the predicted probabilities using the final fitted multivariable model. In 
each group, the average predicted probability on current IA was compared 
with the observed prevalence, both in the derivation and validation dataset. 
Additionally, the Hosmer-Lemeshow statistic was calculated.
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To estimate performance of our simplified rule in a setting with a different 
prevalence of IA (e.g. primary care), a simulation was performed. Accurate 
data on prevalence of IA in GP practices is lacking, and therefore an 
estimation was made based on previous literature. One study revealed 
that 27% assigned with the International Classification of Primary Care-1 
code for suspected IA in their medical record had confirmed RA (n=38), 
polyarthritis (n=5), or oligoarthritis (n=8) following rheumatologist’s 
assessment. Another study among GPs found that 18% of patients with 
suspected IA was referred; though data on rheumatologists’ diagnoses was 
not provided.[25] Guided by these scarce data obtained in GP practices, 
performance of the model was simulated with an estimated prevalence of 
20%.[5] The intercept of the regression model was adjusted as described in 
[26,27] and we plotted average estimated predicted probabilities against the 
regression and simplified risk score. Statistical analyses were performed 
using Statistical Package for the Social Sciences (SPSS, version 23.0). 
P-values <0.05 were considered significant.
Patient involvement
Patient research partners agreed with the pathway of care at the EARC. 
They also provided feedback on the questionnaire, which was expanded in 
2012 with two questions.
Results
Patients
1,288 patients in whom GPs were unsure about the presence of IA 
visited the EARC between 2010 and 2015; of these, 41% had synovitis at 
joint examination. The frequency of inflammatory arthritis was stable 
throughout the study years (S3 Appendix). Baseline characteristics of 
patients in both derivation and validation dataset are presented in Table 1.
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Model derivation
In univariable analyses, male gender, age ≥60 years, symptom duration 
of <6 weeks, an acute onset of symptoms, morning stiffness >60 minutes, 
a low number of painful joints (1–3 joints), presence of patient-reported 
joint swelling (1–3 joints), and difficulty with making a fist were associated 
with the presence of IA in the derivation dataset (Table 2). ‘Symptoms 
worst in the early morning’ was not associated with IA and therefore 
not included in multivariable analysis. Two multivariable models were 
created with categorized variables; first a model with categories similar to 
the univariable analysis (Table 3, model 1), and secondly a model pooling 
categories per variable with similar regression coefficients (Table 3, model 
2). Performing this second model in the derivation dataset revealed that 
male gender, age ≥60 years, symptom duration of <6 weeks, a low number 
of painful joints (1–3 joints), and presence of patient-reported joint swelling 
were independently associated with the presence of IA (Table 3). The 
AUC of model 2 was 0.75 (95%CI 0.70–0.79) in the derivation dataset. In 
sub-analysis, model 2 was repeated with a backward selection procedure, 
showing similar regression coefficients (S4 Appendix).
Generation of a simplified rule
In order to facilitate usage in routine clinical practice, a simplified model 
was generated (S5 Appendix). The obtained regression coefficient of acute 
onset of symptoms in multivariable modelling was -0.015, yielding 0 points. 
Also after exclusion of this variable, the regression coefficients of the other 
seven variables in the model did not change yielding similar points. This 
resulted in a simplified rule consisting of seven scored items and a total 
score ranging from 0 to 7.5 with corresponding predicted risks (Figure 1). 
Risks of IA predicted by the model as a function of the regression score (i.e. 
the sum of the regression coefficients times the value of the corresponding 
covariates) are presented in Figure 2A; as shown, simplification did not 
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majorly affect the predicted risks. The calibration plot shows that predicted 
probabilities correlated well with the observed proportions of patients with 
IA (S6 Appendix). The Hosmer-Lemeshow test for the derivation dataset 
yielded a P-value of 0.36. If cut-offs are required and a highly sensitive 
approach is preferred (>90% sensitivity), this is obtained by a cut-off score 
of ≥4. When a highly specific approach is preferred (>90% specificity), this 
is obtained by a cut-off score of ≥6. Test characteristics for all cut-off points 
are presented in S7 Appendix. The AUC of the simplified score, measuring 
discrimination, was 0.74 (95%CI 0.70–0.78; S8 Appendix).
Validation
The final multivariable model (model 2) was applied in the validation 
dataset, revealing similar results (Table 3). The AUC was 0.72 (95%CI 
0.68–0.77). Figure 2A shows the predicted probabilities of the simplified 
rule are almost similar to those obtained in the derivation data. The AUC of 
the simplified rule was 0.71 (95%CI 0.67–0.75) in the validation dataset. The 
calibration plot is shown in S6 Appendix, the Hosmer-Lemeshow test for 
the validation dataset yielded a P-value of 0.43.
Simulation of accuracy in a setting with a lower prevalence of IA
In contrast to test characteristics, predicted probabilities depend on the 
prior risk (i.e. prevalence) of IA. The frequency of IA among primary care 
patients with GP-determined clinical suspicion of IA may be different than 
that observed in the EARC. Based on observations in GP practices[5,25], 
a simulation was run for the regression and simplified score with a 
prevalence of inflammatory arthritis set at 20%. Estimated predicted 
probabilities for different scores of the multivariable model and simplified 
rule (in derivation and validation datasets) are presented in Figure 2B.
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Our simplified rule was implemented in a web application that provides 
predictions on the presence of current IA for individual patients; a 
screenshot is presented in Figure 3. The web application is accessible online 
at http://caretool.eu/
Discussion
GPs play a crucial role in the early identification of RA and often lack 
confidence in detecting joint synovitis.[9] In an attempt to solve the 
contradiction between the need to refer very early and absence of evidence 
who must be referred, we provided an evidence-based and simple method 
to identify the presence of IA in patients in whom IA is suspected. This 
clinical rule helps to select patients to refer for additional investigations 
(laboratory or imaging) or to secondary care. Hence, the Clinical Arthritis 
RulE could increase appropriateness of health care utilization. 
This study is different from studies that derived tools to facilitate triage 
of patients that have been referred to secondary or tertiary care[15-17] as 
our study did not aim to prioritize patients that are already referred. In 
addition, we aimed to facilitate recognition of IA (as this would necessitate 
prompt referral to a rheumatologist) and did not perform a longitudinal 
study to predict development of specific diagnoses (e.g. RA) later-on. This 
explains why several factors were found to be associated with presence 
of IA that are not generally considered typical for RA (male gender, a low 
number of painful joints, a short symptom duration). GPs generally do well 
in identifying those at high risk for development of RA (i.e. women with 
subacute smouldering polyarticular, symmetric complaints), and therefore 
we aimed this tool to assist GPs in decision-making for more atypical or 
non-classical presentations of IA (e.g. due to overlap of symptoms with 
other diagnoses) leading to doubt. Indeed, many of the patients that did 
not have synovitis at the EARC had symptoms due to diagnoses that are 
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characterized by longstanding or extensive joint pain (e.g. osteoarthritis, 
fibromyalgia), explaining higher scores for a short symptom duration or a 
low number of symptomatic joints.
Adding other clinical variables might increase the discriminative 
ability of the model. Potential examples include the squeeze test of the 
metacarpophalangeal joints (although the diagnostic accuracy was shown 
to be only moderate[28]), information on family history, or functional 
impairments. These items were not routinely collected before December 
2015. Adding data on laboratory investigations to our rule could potentially 
also increase its discriminative ability. However, our data do not permit us 
to evaluate this, as additional investigations were done afterwards and only 
in patients with synovitis at joint examination.
A strength of our EARC for the purpose of this study is that GPs in our 
region are familiar with the need for early referral and that regional 
healthcare logistics make rheumatology care rapidly available for patients 
with arthritis, with the EARC as ultimate service for patients in whom GPs 
suspect (but are unsure about) IA. With the availability of the EARC every 
week and lack of any waiting list for the EARC, we assume a low number 
of patients not showing up at the EARC despite being encouraged by their 
GP to visit the EARC. As the EARC serves as a unique bridge between 
primary and secondary care, its patients closely resemble the population 
GPs have contact with and have doubts about. Although the EARC is 
successful in our region[11,23], this approach may be more difficult to 
implement in other centres or regions due to a shortage of rheumatologists, 
or long traveling distances to rheumatology outpatient clinics, and as such 
a different system is needed to aid GPs in identifying IA. This prompted 
us to derive a validated rule composed of clinical characteristics that could 
assist GPs in decision-making for more atypical or non-classical (but 
nevertheless suspect) presentations of IA, as classical presentations usually 
don’t cause GPs concern.
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GPs were discouraged (both by our local communication with GPs and 
according to national guidelines for GPs) to perform autoantibody testing.
[29] Autoantibody testing in primary care in this region was infrequent[5], 
unlike in other parts of the world. Autoantibody testing may falsely 
reassure doctors and patients, especially when results are negative, and as 
such we believe a model based on clinical presentation is more appropriate 
to facilitate rapid referral.
Another strength is that we studied patients in whom the GPs have 
indicated a lack of confidence to identify the presence of synovitis. Patients 
with clinically obvious IA had early access to rheumatologic care already. 
This may enhance the generalizability of the present data to the setting of 
doubt in primary care. Furthermore, the use of real-life observational data 
in our study may boost external validity of the results.
A disadvantage of our setting is that the data were not collected in primary 
care itself, but in a setting intermediary between primary and secondary 
care. Although musculoskeletal symptoms are a very common reason 
for consulting primary care, suspected IA is relatively unusual, and the 
average full-time GP diagnoses only one new patient with RA each year.
[30] Additionally, although the EARC is easily accessible on a weekly 
basis, the exact number of patients that were referred but did not visit the 
EARC is unknown. Validation in primary care is required. We studied ‘the 
difficult group’ of patients in whom GPs were uncertain of the presence 
of suspected IA. The prevalence of such patients in primary care may be 
higher and as a consequence the actual prevalence of IA among suspected 
IA patients may be lower than 41% in primary care. Since the post-test 
probabilities strongly depend on the prevalence (i.e. pre-test probability), 
a simulation was performed with an estimated prevalence of IA that was 
half of the prevalence as observed in our data (20%). The choice of 20% was 
based on literature from primary care; although not much is known about 
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suspected IA in primary care, two study suggested a prevalence of IA 
among suspected patients of 18-27%[5, 25]. We demonstrated the predictive 
accuracy of the model using a simulated prevalence of 20%. Because of the 
limitation that no other data are available on the prevalence of IA when 
GPs suspect IA, this estimated prevalence could be an overestimation. 
However, the observed data could also be an underestimation as in our 
setting GPs were instructed to refer patients with high suspicion/definite 
arthritis to the regular outpatient clinic. Further external validation in GP 
settings is therefore required.
GPs in our region are well informed about the importance of the early 
detection of IA, but the GPs in our region feel that their actual detection 
skills are not different from that of GPs elsewhere. However if the detection 
skills of our GPs are different from that of GPs in other regions, a lower 
prevalence of IA (and therefore lower pre-test probabilities) may be 
present. As a consequence, the rule may yield lower post-test probabilities. 
This effect may have been dealt with in the simulation analysis but still 
external validation in primary care and preferably in different regions or 
countries is necessary.
We expect that our rule (Clinical Arthritis RulE - CARE) might support 
GPs and other health care professionals in the decision-making process 
in patients with musculoskeletal symptoms in whom they suspect IA, 
regardless of the region. Of course, the consequences of an increased score 
will likely depend on the setting and relation with secondary care: it can 
either influence the decision to directly refer a patient or to first ask for 
additional laboratory tests (e.g. acute phase reactants or autoantibodies; 
Figure 4). A clinical decision aid may be of value to this end as well, as 
for most laboratory investigations the diagnostic accuracy depends on 
the prior risk. Using a simple clinical decision aid first may be more cost-
effective than performing additional investigations in all patients in whom 
there is doubt about IA. Depending on the setting and consequences 
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of a high score, either a sensitive method or a specific method may be 
preferred; for this reason cut-offs for both situations are provided. The web 
application, also easily assessable by phone, facilitates implementation 
of the Clinical Arthritis RulE by GPs, physicians, and other health care 
professionals such as physiotherapists in their daily work.
Conclusion
In conclusion, this study developed a clinical rule that supports the 
identification of patients suspected of having IA by physicians that feel 
insufficiently experienced in assessment of synovitis by joint examination. 
We hope the current data are a prelude to a data-driven method that 
supports GPs, physicians, and other health care professionals in decision-
making in patients with suspected early IA.
Supporting information 
Supplementary data is available at the website of BMJ Open, or can be obtained by 
contacting the first author.
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Table 1. Characteristics of patients visiting the Early Arthritis 
Recognition Clinic
Derivation 
(N=644)
Validation 
(N=644) P-value**
Male, n (%) 190 (30) 198 (31) 0.62
Age in years, mean ± SD 52 16 51 17 0.27
Symptom duration in weeks, median 
(IQR) 10 (3–45) 12 (4–45) 0.18
Acute onset of symptoms *, n (%) 252 (39) 238 (37) 0.45
Symptoms worst in the early morn-
ing, n (%) 372 (58) 351 (55) 0.10
Morning stiffness in minutes, median 
(IQR) 10 (0–30) 10 (0–30) 0.33
Number of painful joints, median 
(IQR) 7 (2–15) 6 (3–15) 0.69
Number patient-reported swollen 
joints, median (IQR) 2 (1–5) 2 (1–5) 0.19
Difficulty with making a fist, n (%) 329 (51) 301 (47) 0.06
Arthritis present at joint examination 
by experienced rheumatologist, n (%) 271 (42) 252 (39) 0.28
Legend:  
* Patients were asked to define onset of symptoms; either acute onset of symptoms 
or gradual onset of symptoms, see S1 Appendix. Abbreviations: IQR = interquartile 
range; SD = standard deviation. ** Unpaired t-tests, chi-squared tests and Mann-
Whitney U tests were used as appropriate.
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Table 2. Univariable logistic regression in the derivation dataset 
with presence of synovitis upon joint examination as outcome.
Arthritis 
(N=271)
No artritis 
(N=373) OR (95% CI)
Male, n (%) 104 (38) 86 (23) 2.1 (1.5–2.9)
Age, n (%) <40 49 (18) 104 (28) (ref)
40–59.9 109 (40) 172 (46) 1.3 (0.89–2.0)
≥60 113 (42) 97 (26) 2.5 (1.6–3.8)
Symptom duration in weeks, n (%) <6 124 (46) 103 (28) 3.8 (2.4–5.9)
6–11 38 (14) 62 (17) 1.9 (1.1–3.9)
12–51.9 66 (24) 75 (20) 2.7 (1.7–4.5)
≥52 43 (16) 132 (36) (ref)
Acute onset of symptoms *, n (%) 122 (45) 131 (35) 1.5 (1.1–2.1)
Symptoms worst in early morning, 
n (%)
158 (58) 214 (57) 1.1 (0.69–1.6)
Morning stiffness >60 min, n (%) 45 (17) 40 (11) 1.7 (1.03–2.7)
Number of painful joints, n (%) 0 1 (0) 10 (3) (ref)
1–3 110 (41) 82 (22) 13.2 (1.7–105.5)
4–10 76 (28) 123 (33) 6.1 (0.77–49.0)
≥11 84 (31) 158 (42) 5.2 (0.65–41.3)
Number of patient-reported     
swollen joints, n (%)
0 18 (7) 71 (19) (ref)
1–3 115 (42) 119 (32) 3.7 (2.0–6.9)
4–10 87 (32) 115 (31) 2.9 (1.5–5.5)
≥11 51 (19) 68 (18) 2.9 (1.4–5.9)
Difficulty with making a fist, n (%)  156 (58) 172 (46) 1.6 (1.1–2.4)
Legend: 
* Patients were asked to define onset of symptoms; either acute onset of symptoms 
or gradual onset of symptoms, see S1 Appendix. Abbreviations: CI = confidence 
interval; OR = odds ratio.
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Table 3. Multivariable logistic regression analyses with synovitis 
upon joint examination as outcome. 
Model 1 Model 2
Derivation Derivation Validation
OR (95% CI) OR (95% CI) B OR (95% CI)
Male 1.7 (1.1–2.5) 1.7 (1.1–2.5) 0.517 1.7 (1.1–2.4)
Age (years) <40 (ref) 0–59.9 (ref) (ref) (ref)
40–59.9 1.5 (0.96–2.5) ≥60 2.1 (1.4–3.1) 0.750 2.1 (1.5–3.0)
≥60 2.9 (1.7–4.8)
Symptom dura-
tion (weeks)
<6 3.8 (2.3–6.4) <6 3.6 (2.2–6.0) 1.279 3.4 (2.0–5.7)
6–11 1.7 (0.92–3.1) 6–51.9 2.2 (1.4–3.6) 0.797 1.9 (1.2–3.0)
12–51.9 2.9 (1.7–5.0) ≥52 (ref) (ref) (ref)
≥52 (ref)
Acute onset of 
symptoms* 1.0 (0.67–1.5) 0.99 (0.66–1.5) -0.015 1.0 (0.70–1.5)
Morning stiff-
ness (minutes)
>60 1.6 (0.88–2.9) >60 1.6 (0.91–2.9) 0.485 1.2 (0.62–2.3)
Number of 
painful joints
0 (ref) 0 (ref) (ref) (ref)
1–3 9.3 (1.1–78.2) 1–3 10.0 (1.2–83.4) 2.300 7.9 (0.91–68.6)
4–10 4.5 (0.53–37.6) ≥4 4.5 (0.54–37.1) 1.497 5.2 (0.61–45.1)
≥11 3.3 (0.39–28.4)
Number of 
patient-reported 
swollen joints
0 (ref) 0 (ref) (ref) (ref)
1–3 3.2 (1.6–6.4) ≥1 3.5 (1.9–6.6) 1.253 3.7 (1.9–7.0)
4–10 3.4 (1.7–7.0)
≥11 4.3 (1.9–10.0)
Difficulty with 
making a fist
1.6 (0.97–2.5) 1.6 (0.99–2.6) 0.467 1.4 (0.91–2.2)
Intercept -4.8 -4.6 -4.6
AUC
0.76 
(0.71–0.80)
0.75
(0.70–7.79)
0.72
(0.68–0.77)
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Legend: 
Model 1 includes categories of clinically applicable cut-offs; if within variables several 
categories had similar regression coefficients, categories were pooled (Model 2).  
* Patients were asked to define onset of symptoms; either acute onset of symptoms 
or gradual onset of symptoms, see S1 Appendix. Variables with p-values <0.05 in 
univariable analysis in the derivation set were entered in multivariable regression 
analyses. Abbreviations: B = beta; CI = confidence interval; OR = odds ratio. 
Figure 1. The Clinical Arthritis RulE (CARE) and corresponding predicted risks of presence of 
inflammatory arthritis per score.
Legend: 
Observed risks of current inflammatory arthritis were obtained by calculating the proportion of patients with a positive 
outcome (rheumatologist-confirmed synovitis) for each value of the risk score in the derivation dataset.
Figure 2. The Clinical Arthritis RulE (CARE) and presentation of the predicted probabilities of the 
presence of current inflammatory arthritis based on the regression model, and the simplified score 
as observed in the derivation and validation datasets (A), and estimated predicted probabilities in a 
simulation with a pre-test probability (i.e. prevalence) of inflammatory arthritis of 20% (B).
Legend: 
Predicted probabilities of the final multivariable logistic regression model, fitted in the derivation set as function of the 
regression score (i.e. the sum of the regression coefficients times the value of the corresponding covariates (green line)). 
Furthermore, for each value of the simplified score the mean predicted probability is plotted in the derivation and validation 
dataset (blue and orange dots).
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Figure 3. A stylized representation of the Clinical Arthritis RulE, 
to be used in patients in whom GPs doubt about the presence of 
inflammatory arthritis. 
Legend: 
The web application that provides predictions on the predicted risk of inflammatory 
arthritis for individual patients as can be accessed at http://caretool.eu/
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Figure 4. Flowchart of decision-making in patients with suspected 
early IA based on clinical characteristics and the role of the Clinical 
Arthritis RulE.
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Abstract 
Introduction: Autoantibody testing is helpful to predict the risk of progression 
to clinical arthritis in subjects at risk. Previous longitudinal studies have mainly 
selected autoantibody-positive arthralgia patients and, consequently, the predictive 
values of autoantibodies were evaluated relative to each other. This study assessed 
risks for arthritis development of anti-citrullinated protein antibodies (ACPA), 
rheumatoid factor (RF) and/or anti-carbamylated protein antibodies (anti-CarP) in 
arthralgia patients considered at risk for RA by rheumatologists based on clinical 
characteristics (Clinically Suspect Arthralgia, CSA).
Methods: Baseline ACPA, RF and anti-CarP autoantibody-status of 241 patients, 
consecutively included in the CSA-cohort, was studied for risk of developing 
clinical arthritis during a median follow-up of 103 (IQR 81-114) weeks.
Results: Univariable associations for arthritis development were observed for 
ACPA, RF and anti-CarP antibodies; Hazard Ratios (95%CI) were 8.5 (4.7-15.5), 
5.1 (2.8-9.3) and 3.9 (1.9-7.7) respectively. In multivariable analysis, only ACPA 
was independently associated (HR 5.1; 2.0-13.2). Relative to autoantibody-
negative CSA-patients, ACPA-negative/RF-positive patients had HRs of 2.6 
(1.04-6.6), ACPA-positive/RF-negative patients 8.0 (2.4-27.4), and ACPA-
positive/RF-positive patients 10.5 (5.4-20.6). Positive predictive values (PPV) 
for development of clinical arthritis within two years were: 38% for ACPA-
negative/RF-positive, 50% for ACPA-positive/RF-negative and 67% for ACPA-
positive/RF-positive patients. Higher ACPA-levels were not significantly 
associated with increased progression to clinical arthritis, in contrast to higher 
RF-levels. Autoantibody levels were stable during follow-up.
Conclusion: ACPA conferred the highest risk for arthritis development and had 
an additive value to RF. However, >30% of ACPA-positive/RF-positive CSA-
patients did not develop arthritis during two-year follow-up. Thus, CSA and 
information on autoantibodies is insufficient to accurately identify imminent 
autoantibody-positive RA. 
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Introduction
Anti-Citrullinated Protein Antibodies (ACPA), Rheumatoid Factor (RF) and 
antibodies against carbamylated proteins (anti-CarP) can be present years 
before the first onset of symptoms of rheumatoid arthritis (RA)[1-3]. Initial 
observations on the association between autoantibodies and progression 
to clinical arthritis were largely done in nested case-control studies[2,3]. 
Results of these studies cannot be directly used for risk assessment in 
clinical practice; longitudinal studies performed in daily rheumatologic 
practice are needed to this end[4-6]. 
Most published longitudinal studies in arthralgia determined predictive 
values of ACPA and RF in persons that were selected for the presence 
of these autoantibodies[4,5,7,8]. Consequently, as a reference group of 
arthralgia patients without autoantibodies was not available, predictive 
values of the different autoantibodies were evaluated relative to each 
other[4,5]. RF-positive patients were often used as reference group, as 
presence of RF yielded the lowest risk of progression to clinical arthritis[5]. 
In addition, some of the patients in these studies had musculoskeletal 
symptoms but were not referred to secondary care because of these 
symptoms[7]. The selection method and reference group used in these 
studies may affect generalizability for arthralgia patients presenting 
to rheumatology outpatients clinics. Therefore, the risks provided by 
(combinations of) different autoantibodies in patients presenting with 
arthralgia at risk for RA is still undetermined. 
The present study evaluated patients with clinically suspect arthralgia 
(CSA); these are patients without clinical arthritis that are considered at 
risk of progression to RA by their rheumatologists based on the clinical 
presentation. Identification of patients at risk based on clinical expertise is 
to some extent subjective and to allow inclusion of a more homogeneous 
group of patients in studies, a EULAR-definition for arthralgia suspicious 
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for progression to rheumatoid arthritis was recently developed[9]. This 
definition is intended for use in arthralgia patients without clinical arthritis 
in whom imminent RA is considered more likely than other explanations. 
This will generate a more homogenous set of arthralgia patients at risk for 
RA and may facilitate generalizability of findings to arthralgia patients in 
other outpatient clinic settings.
To determine the value of RA-related autoantibodies in patients with 
CSA, this study aimed to: 1) Determine progression to clinical arthritis 
and the absolute risks provided by ACPA, RF and anti-CarP antibodies. 
2) Determine the risk provided by combinations of the commercially 
available autoantibody-tests: ACPA and RF. 3) Evaluate if higher ACPA- 
and RF-levels conferred higher rates of progression to clinical arthritis. In 
addition, sub-analyses were performed in which we aimed to 4) Investigate 
differences in baseline characteristics of ACPA-positive/RF-positive patients 
that did and that did not progress to clinical arthritis and 5) Assess ACPA- 
and RF-levels over time, both in patients that progressed from CSA to 
arthritis and in patients that did not progress.
Methods
Patients
Two hundred and forty-one patients were consecutively included in the 
Leiden Clinically Suspect Arthralgia (CSA) cohort between April 2012 and 
March 2015, an inception cohort at the rheumatology outpatient clinic of 
the Leiden University Medical Centre, the Netherlands. Per definition, 
CSA-patients had no clinical arthritis, but recent-onset (<1 year) arthralgia 
of hand or feet joints and were considered at risk for RA based on the 
clinical expertise of the rheumatologists, as described previously[10]. 
Hence, patients were indicated as having CSA based on the first clinical 
presentation. As general practitioners in the region are discouraged to 
perform autoantibody testing before referral[11,12], information on ACPA- 
and RF-status were generally unknown at secondary care presentation. 
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After inclusion, questionnaires were filled by patients and rheumatologists, 
joint counts performed, blood samples taken, and a unilateral contrast-
enhanced MRI was made of 2nd-5th metacarpophalangeal, wrist and 
1st-5th metatarsophalangeal joints of the most painful side (or dominant 
side in case of equally severe symptoms at both sides) using an MSK-
extremity 1.5T MRI-scanner as described elsewhere[10,11] and in the 
Supplementary Methods. Regular follow-up visits were scheduled at 
4,12 and 24 months and additional visits occurred in between if indicated 
(either if felt necessary by rheumatologists or at request of patients because 
of an increase in symptom severity). Treatment with Disease-Modifying 
Antirheumatic Drugs (DMARDs) was not allowed during the CSA study, 
NSAIDs were allowed. The CSA-cohort has been approved by the local 
medical ethical committee (named “Commissie Medische Ethiek”). 
All participants provided written informed consent according to the 
declaration of Helsinki.
Autoantibody determination
At baseline visit, Immunglobulin-G ACPA (EliA CCP (anti-CCP2), Phadia, 
Nieuwegein, the Netherlands), Immunoglobulin-M RF (as described 
previously, in-house ELISA[13]), and Immunoglobulin-G anti-CarP 
antibodies were determined. The cut-off for ACPA-positivity was >7 U/
mL; for RF-positivity it was >3.5 IU/mL, according to the manufacturer’s 
instructions. ACPA- and RF-status were repeated after two years, or at 
the time of conversion to clinical arthritis. Anti-CarP was determined as 
described previously[14]. As no commercial kit is available for anti-CarP 
antibodies, we have used our in-house developed anti-CarP assay based 
on carbamylated Fetal Calf Serum (FCS) and as a control the non-modified 
FCS as the coating antigens in ELISA[14]. The cut-off was equivalent to 2 
Standard Deviations (SD) above the mean in a group of healthy controls. 
The controls consisted of a group of 197 healthy blood donors. Mean age 
of the controls was 44.4 years (range 20-70 years, SD 14). 50.8% of controls 
were female. Controls were not allowed to have a rheumatic disease. 65.5% 
of controls had never smoked, 26.9% had previously smoked, 6.6% were 
current smokers and in two controls data on smoking status was missing. 
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Outcome
All patients were followed for ≥56 weeks. Median follow-up duration was 
103 weeks, interquartile range 81 to 114 weeks. None of the patients were 
treated with DMARDs or corticosteroids in the phase of CSA. Primary 
endpoint was development of arthritis detected at physical examination (66 
joints assessed) by the rheumatologist. Medical records of all patients were 
studied for established clinical arthritis until April 22nd 2016. Persistent 
arthritis was studied as secondary endpoint (through study of the medical 
record), which was defined as clinical arthritis that persisted at two 
subsequent visits or when DMARDs were prescribed when clinical arthritis 
was identified. The 2010 classification criteria for RA[15] were considered 
less suitable as secondary outcome, as autoantibody-negative patients 
require >10 involved joints to fulfil these criteria[16]. DMARDs were 
generally started shortly after patients had developed clinically evident 
arthritis and this may have prevented progression from unclassified 
arthritis to RA, particularly for autoantibody-negative patients. 
Statistical analyses
Univariable and multivariable Cox proportional hazards regression 
analyses were performed with clinical arthritis as outcome. Time to 
clinical arthritis was defined as time from inclusion date in the cohort to 
the date of first detection of clinical arthritis. Patients who did not develop 
arthritis were censored at either the date that all medical files were studied 
on arthritis development or at the date of the 24-month follow-up visit. 
When evaluating hazard ratios and absolute risks for combinations of 
autoantibodies, we mainly restricted ourselves to the two commercially 
available autoantibodies (ACPA and RF), because otherwise small 
subgroups would be obtained (Supplementary Figure 1). To determine 
the association for arthritis development with autoantibody level, patients 
were categorized into tertiles based on ACPA-levels of ACPA-positive 
patients in our cohort or RF-levels in RF-positive patients in our cohort 
(hence creating three groups of similar size). For ACPA, these categories 
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were 7-95 U/ml (with N=10), 96-325 U/ml (N=11) and ≥326 U/ml (N=11). For 
RF, the categories were 3.5-10 IU/ml (N=17), 11-40 IU/ml (N=17) and ≥41 IU/
ml (N=17). Test characteristics and predictive values with 95% confidence 
intervals were calculated. Patient characteristics were compared using 
Mann-Whitney U tests, t-tests and χ2 tests as appropriate. 
In addition to the analyses on all CSA-patients, the most important 
analyses were repeated in the subgroup of patients that also fulfilled the 
EULAR-definition of arthralgia suspicious for progression to RA (3/7 
items present)[9]. Statistical analyses were carried out using the Statistical 
Package for the Social Sciences (SPSS, version 23.0). P-values <0.05 were 
considered significant.
Results
Patients with CSA
Baseline characteristics of the 241 CSA-patients are shown in Table 1. 
During a median follow-up period of 103 (IQR 81-114) weeks, 44 patients 
progressed to clinical arthritis (Figure 1). The secondary endpoint was 
obtained in 41 patients: 3 patients had clinical arthritis on only one occasion 
that resolved spontaneously (without DMARD treatment) before the next 
visit; one patient had clinical arthritis in a wrist joint and two patients in 
the elbow joint. 
Presence of autoantibodies and hazard ratio for progression to clinical arthritis
In univariable Cox regression, presence of ACPA was associated with 
arthritis development (Hazard Ratio 8.5; 95%CI 4.7-15.4). A similar 
observation was made for presence of RF (HR 5.1; 95%CI 2.8-9.3) or anti-
CarP antibodies (HR 3.9; 95%CI 1.9-7.7). Multivariable analysis including 
all three autoantibodies – to correct for simultaneous presence of the 
autoantibodies – revealed an independent significant association for ACPA 
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only (HR 5.1; 95%CI 2.0-13.2); the HR for RF and anti-CarP antibodies 
were 2.0 (95%CI 0.81-4.9) and 1.04 (95%CI 0.46-2.4) respectively. When age, 
gender, smoking and positive family history for RA were also included 
in the multivariable model, only ACPA was significantly associated with 
progression to RA (HR 5.3; 95%CI 2.0-14.2).
Combinations of ACPA and RF and associated hazards
Combinations of ACPA and RF were studied next, as these are the 
commercially available tests and are most commonly used in daily 
rheumatologic care. With autoantibody-negative CSA patients as reference, 
ACPA-negative/RF-positive patients had a HR of 2.6 (95%CI 1.04-6.6) 
for developing clinical arthritis. ACPA-positive/RF-negative had a HR of 
8.0 (95%CI 2.4-27.4), and ACPA-positive/RF-positive patients had a HR 
of 10.5 (95%CI 5.4-20.6), see Figure 2. The hazard was not significantly 
different between ACPA-positive/RF-negative and ACPA-positive/RF-
positive patients (p=0.78), but there was a significantly different hazard 
ratio between ACPA-negative/RF-positive and ACPA-positive/RF-positive 
patients (p=0.005). 
Although subgroups became small when anti-CarP was also considered 
(Supplementary Figure 1), there were no significant associations of anti-
CarP with arthritis development within ACPA-negative/RF-negative or 
within ACPA-positive/RF-positive patients (HR 2.7; 95%CI 0.62–11.9 and 
HR 1.0; 95%CI 0.37–2.7 respectively).
Association of autoantibody levels and arthritis development
In RA, presence of multiple autoantibodies is associated with higher 
autoantibody levels[17,18]. In CSA-patients, higher ACPA-levels were 
observed in ACPA-positive/RF-positive patients than in ACPA-positive/
RF-negative patients (median 237.5 U/mL versus 94 U/mL, p=0.17). Within 
ACPA-positive patients, ACPA-levels were not associated with higher 
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hazards for progression to clinical arthritis (Figure 3A). RF-levels were 
significantly higher in ACPA-positive/RF-positive patients compared to 
ACPA-negative/RF-positive patients (median 36 IU/mL versus 12.5 IU/
mL respectively, p=0.007). In addition, patients with RF-levels ≥41 IU/ml 
(highest tertile) had significantly increased hazard to progress to clinical 
arthritis (HR 3.3; 95%CI 1.1-9.6) compared to patients with RF-levels 3.5-10 
IU/ml (lowest tertile, Figure 3B). 
Absolute risks and test characteristics for arthritis development at 2 years 
follow-up. 
In order to arrive at absolute risks for developing clinical arthritis of 
individual autoantibodies and combinations of ACPA and RF, patients that 
completed two-year follow-up were studied (n=144). Positive predictive 
values (PPV) for arthritis development within two years were: 63% 
for ACPA, 53% for RF and 50% for anti-CarP antibodies. Considering 
combinations of ACPA and RF, the PPV for ACPA-negative/RF-positive 
patients was 38%. For ACPA-positive/RF-negative patients, PPV was 50% 
and for ACPA-positive/RF-positive patients 67% (Table 2). Thus, of the 
ACPA-positive/RF-positive patients, 33% did not develop arthritis within 
two years. Sub-analyses with the secondary endpoint (persistent clinical 
arthritis) showed almost similar results (Supplementary Table 1). 
Similar findings in patients that fulfilled the EULAR-definition of 
arthralgia suspicious for progression to RA
178 of the 241 patients (74%) that were identified as CSA by their 
rheumatologists also fulfilled the EULAR-definition. The HRs for 
progression to arthritis within 2-years were: 2.4 (95%CI 0.89-6.5) for ACPA-
negative/RF-positive patients, 5.9 (95%CI 1.4-25.8) for ACPA-positive/RF-
negative patients, and 9.7 (95%CI 4.7-20.2) for ACPA-positive/RF-positive 
patients (Supplementary Figure 2). Predictive values and test characteristics 
are presented in Supplementary Table 2. Of the ACPA-positive/RF-positive 
patients that fulfilled the EULAR-definition, 31% did not progress to RA.
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Baseline characteristics of ACPA-positive/RF-positive CSA-patients that 
progressed to arthritis versus those that did not.
We hypothesized that patients progressing to clinical arthritis had 
either higher autoantibody levels or more extended (systemic or local 
subclinical) inflammation than patients that did not progress. Therefore, 
we then explored if ACPA-positive/RF-positive CSA-patients that did 
not progress to arthritis during 2 years follow-up differed in baseline 
characteristics from those that progressed. Although the number of patients 
in both groups was small, no statistically significant or clinically relevant 
differences were observed (Table 3). 
Serum levels of ACPA and RF over time 
Of the 44 CSA-patients that progressed to clinical arthritis, 20 were ACPA-
positive with a median ACPA-level at CSA-inclusion of 266 U/ml (IQR 
130-340) and 200 U/ml (IQR 91.75-340) at arthritis development (p=0.39). 
Similarly, of the 44 patients that progressed, 23 were RF-positive with a 
median RF-level of 29 IU/ml at CSA-inclusion and 39.5 IU/ml at arthritis 
development (p=0.99).
Autoantibody status and autoantibody levels were also assessed in patients 
who had completed two-year follow-up and did not progress to clinical 
arthritis (N=114). Of these patients, 10 were ACPA-positive at inclusion 
and none of these patients changed in ACPA-status during follow-up. 
The median ACPA-level in these non-converting patients was 304 U/ml at 
baseline and 340 U/ml after 2-years. Similarly, 16 patients not progressing 
to clinical arthritis were RF-positive at baseline; during follow-up, one 
RF-positive patient became RF-negative (levels 4.3 IU/mL and 3.0 IU/mL 
respectively) and one RF-negative patient became RF-positive after 2 years 
(levels <0.4 IU/mL and 12.0 IU/mL respectively). The median RF-level in 
non-converting patients was 16.5 IU/ml at baseline and 11 IU/ml after 2 
60 Chapter 3
years. Overall, status and levels of ACPA and RF were rather stable during 
two year follow-up, both in patients that progressed to clinical arthritis and 
in patients that did not progress to clinical arthritis.
Discussion
Early recognition of patients with imminent RA is an important but 
challenging topic. Autoantibodies have proven to be the most powerful 
predictors for development of clinical arthritis currently available. This 
study thoroughly determined the risks of individual autoantibodies, 
combinations of autoantibodies and autoantibody-levels in patients 
that were considered at risk for RA based on their clinical presentation. 
The absolute risks for progression to arthritis may be useful for daily 
clinical practice at places where patients present with arthralgia to 
rheumatology outpatient clinics. We observed that ACPA, RF and anti-
CarP antibodies were associated with increased risks, but that only ACPA 
was independently associated with development of RA in multivariable 
analysis. Furthermore, although ACPA was clearly additive to RF in 
predicting risks, vice versa, RF was less additive to ACPA.
A previous study by Van Steenbergen evaluated the risk of ACPA, but not 
the other autoantibodies in CSA[11]. The current study explored different 
characteristics of several different autoantibodies in CSA, in a larger study 
population and during a longer duration of follow-up. As previously 
described, the absolute risk of ACPA for arthritis development within two 
years was 63%. Previous studies in other at-risk populations found lower 
positive predictive values. A study in ACPA-positive patients with non-
specific musculoskeletal complaints showed progression to clinical arthritis 
of 47% within 12 months[7]. A study in ACPA-positive and/or RF-positive 
arthralgia patients found a PPV of 35% during the first year[8]. Positive 
predictive values are dependent on enrichment (i.e. prevalence) of cases 
in cohort studies, meaning that the same test may yield different results 
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depending on the setting. Patients that are identified as having CSA by 
rheumatologists comprise a small group of all patients presenting with 
arthralgia to secondary care (<6%)[19]. This yielded higher prior chances 
for RA-development in CSA-patients than patients with non-specific 
arthralgia in secondary or primary care. Presumably, this explains the 
higher post-test chances of ACPA in this setting.
CSA is defined by the clinical expertise of rheumatologists and is therefore 
subjective. A EULAR-taskforce has recently derived a definition of 
arthralgia suspicious for progression to RA, in order to strip CSA from 
its subjectivity and to allow evaluation of a more homogeneous group 
of patients. Although further longitudinal studies on the accuracy of the 
EULAR-definition are required, the present data suggest that the clinical 
expertise of the rheumatologists was often in line with the EULAR-
definition.
In the present data, despite small numbers, higher RF-levels were 
associated with an increased risk of progression to clinical arthritis. 
Furthermore, patients with higher RF-levels were also more often 
ACPA-positive. RF-positive/ACPA-positive patients had a higher risk of 
developing clinical arthritis than RF-positive/ACPA-negative patients. 
Hence, these findings are compatible with each other. ACPA-levels were 
not associated with a significantly increased risk of developing arthritis. 
This finding is in line with that of non-significant differences in the risk 
of developing arthritis between ACPA-positive/RF-positive and ACPA-
positive/RF-negative patients, as both groups also had no significant 
differences in ACPA-level. However, it should be noted that subgroups of 
patients with different autoantibody levels were small. 
This is the first longitudinal study evaluating the effect of anti-CarP 
antibodies in relation to RF and ACPA in CSA. A previous study observed 
an association of anti-CarP antibodies with arthritis development in non-
62 Chapter 3
specific autoantibody-positive arthralgia, but did not perform multivariable 
analysis including all three autoantibodies with an autoantibody-negative 
group as reference[6]. In our study, anti-CarP antibodies were not 
independently associated with arthritis development and a significant 
effect of anti-CarP, additive to ACPA and RF, could not be shown. 
However, the current anti-CarP antibody test is not commercially available 
which allows further optimization and afterwards evaluation in larger 
studies.
ACPA- and RF-levels were rather stable over time, both in CSA-patients 
that developed clinical arthritis and in patients that did not progress. 
Seroconversion during the study was rarely observed for RF and absent for 
ACPA. The finding of stable ACPA-levels in the phase of CSA and during 
progression to clinical (persistent) arthritis suggests that the broadening of 
the autoantibody response may already have occurred in an earlier, and 
perhaps asymptomatic, pre-arthritis phase.
A large limitation of this study is the sample size of subgroup analyses; 
especially the ACPA-positive/RF-negative subgroup was small. Validation 
of the presented findings in other cohorts of arthralgia suspicious for 
progression to RA is needed. The primary outcome used was clinically 
apparent arthritis. As arthritis can be subtle in early stages and variation 
in the sensitivity to detect clinical arthritis between rheumatologists exists, 
sub-analyses were performed with clinical arthritis that was persistent at 
two subsequent visits or that was treated with DMARDs as outcome (both 
outcomes reflect chronic disease). These analyses provided similar results. 
Based on results of case-control studies, revealing that simultaneous 
presence of ACPA and RF almost does not occur in healthy controls[20,21], 
it is sometimes suggested that presence of both ACPA and RF in arthralgia 
is a guarantee for progression to clinical arthritis and RA. However, this 
was not observed in the present study and our findings are in line with 
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results of other longitudinal studies. Bos et al[5] showed that 60% of ACPA-
positive/RF-positive patients with non-specific arthralgia did not progress 
to clinical arthritis. Another study showed that 42% of ACPA-positive/
anti-CarP-positive patients did not progress to arthritis[6]. Thus, previous 
studies also showed that presence of several autoantibodies in arthralgia 
was not always associated with arthritis development. 
We hypothesized that ACPA-positive/RF-positive patients that did or 
did not progress would have lower autoantibody levels or less severe 
subclinical inflammation. However, no apparent differences were 
observed. An explanation for patients not progressing to clinical arthritis 
might be that the remaining ACPA-positive/RF-positive CSA patients 
will progress to clinical arthritis later on. Although we cannot exclude 
this, the Kaplan-Meier curves indicate that ACPA-positive/RF-positive 
patients mostly progressed in the first year and few converted in the 
second year. This makes the hypothesis that many subjects will progress 
after additional follow-up less likely. Other explanations are that patients 
that are truly pre-RA have differences in molecular characteristics of the 
autoantibodies themselves, or that another trigger (on top of the presence 
of autoantibodies) is required to develop clinically evident arthritis. This is 
a subject of further research.
In summary, presence of autoantibodies in CSA conferred increased 
absolute risks to develop clinical arthritis. Furthermore, positive predictive 
values in CSA were higher than that reported in non-specific arthralgia. 
However, also within CSA, presence of ACPA alone or a combination of 
ACPA and RF is insufficient to identify patients with imminent ACPA-
positive RA with high accuracy (e.g. with PPVs >80%). Thus, in addition to 
clinical characteristics and autoantibodies, other biomarkers are needed for 
optimal prognostication.
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Supporting information 
Supplementary data is available at the website of Rheumatology (Oxford), or can be 
obtained by contacting the first author.
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Table 1. Baseline characteristics of the CSA-patients (N=241).
Patient characteristic 
Age in years, mean (SD) 44 (13)
Female sex, n (%) 187 (78)
Caucasian, n (%) 224 (93)
Family history of RA, n (%) 71 (30)
Symptom duration in weeks, median (IQR) 18 (10 – 48)
Presence of morning stiffness ≥60 minutes, n (%) 80 (33)
Current smoker, n (%) 54 (22)
BMI in kg/m2, median (IQR) 26 (24 – 30)
Baseline HAQ-score, median (IQR) 0.50 (0.20 – 0.88)
68-TJC, median (IQR) 6 (3 – 10)
Increased CRP (>10 mg/L), n (%) 53 (22)
Positive for EULAR-definition for arthralgia suspicious 
for progression to rheumatoid arthritis[9], n (%) 178 (74)
Autoantibody status 
IgM-RF-positive (>3.5 IU/mL), n (%) 51 (21)
ACPA-positive (>7 U/mL), n (%) 32 (13)
Anti-CarP positive (>2 SD), n (%) 23 (10)
Legend: 
ACPA = anti-citrullinated peptide antibody; BMI = body mass index; CRP 
= C-reactive protein; HAQ = Health Assessment Questionnaire; IgM-RF = 
immunoglobulin M rheumatoid factor; IQR = interquartile range; RA = rheumatoid 
arthritis; SD = standard deviation; TJC = tender joint count.
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Table 2. Test characteristics for Anti-Citrullinated Protein 
antibodies, Rheumatoid Factor and Anti-Carbamylated protein 
antibodies and conversion to clinical arthritis within two years as 
outcome (N=144).
Sensitivity
(95%CI)
Specificity
(95%CI)
PPV
(95%CI)
NPV
(95%CI)
LR +
(95%CI)
LR –
(95%CI)
Evaluating antibodies individually
ACPA +
50% 
(32%–68%)
92% 
(85%–96%)
63% 
(41%–80%)
88% 
(80%–93%)
6.3 
(3.1–13.0)
0.54 
(0.38–0.78)
IgM-RF +
60% 
(41%–77%)
86% 
(78%–92%)
53% 
(35%–70%)
89% 
(81%–94%)
4.3 
(2.5–7.3)
0.47 
(0.30–0.72)
Anti-CarP +
24% 
(11%–44%)
94% 
(87%–97%)
50% 
(24%–76%)
82% 
(74%–88%)
3.8 
(1.4–9.9)
0.81 
(0.66–1.0)
Evaluating combinations of ACPA and RF (ACPA- RF- as reference)
ACPA + 
IgM-RF + 
57% 
(34%–77%)
94% 
(87%–98%)
67% 
(41%–86%)
91% 
(84%–96%)
9.6 
(4.1–22.7)
0.46 
(0.28–0.75)
ACPA+ 
IgM-RF –
25% 
(6.7%–57%)
97%  
(91%–99%)
50%  
(14%–86%)
91% 
(84%–96%)
8.2  
(1.9–36.0)
0.77  
(0.56–1.1)
ACPA – 
IgM-RF +
40%  
(17%–67%)
90%  
(83%–95%)
38%  
(16%–64%)
91% 
(84%–96%)
4.2  
(1.8–9.9)
0.66  
(0.44–1.0)
Legend: 
IgM-RF = IgM rheumatoid factor; ACPA = anti-citrullinated protein antibodies; 
CarP = anti-carbamylated protein antibodies; 95%CI = 95% confidence interval; 
PPV = positive predictive value; NPV = negative predictive value; LR + = positive 
likelihood ratio; LR – = negative likelihood ratio.
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Table 3. Baseline characteristics of ACPA-positive/Rheumatoid 
Factor-positive patients that or did not progress to RA to RA during 
2 year follow-up.
Patient characteristic
Convertors 
(N=12)
Non-convertors 
(N=6)
p-value
Age in years, mean (SD) 45 (15) 49.8 (11) 0.50
Female sex, n (%) 9 / 12 (75) 5 / 6 (83) 0.69
Family history of RA, n (%) 4 / 12 (33) 0 / 6 (0) 0.11
68-TJC, median (IQR) 5.0 (3–8) 5.5 (2–9) 0.87
CRP
Elevated CRP (>10 mg/L), n (%) 5 / 12 (42) 2 / 6 (33) 0.73
CRP-level, median (IQR) 4.7 (3–12) 4.2 (3–6) 0.32
IgM-RF level (IU/mL), mean (SD) 76.6 (77) 79.2 (64) 0.93
ACPA-level (U/mL), mean (SD) 222.8 (125) 211.0 (141) 0.87
MRI positive for inflammation
Any inflammation present, n (%) 9 / 10 (90) 5 / 6 (83) 0.70
Total RAMRIS score, median (IQR) 5.8 (3–19) 5.8 (4–11) 0.36
Legend:  
ACPA = anti-citrullinated peptide antibody; CRP = c-reactive protein; IgM-RF = 
immunoglobulin M rheumatoid factor; IQR = interquartile range; MRI = magnetic 
resonance imaging; RA = rheumatoid arthritis; RAMRIS = Rheumatoid Arthritis 
MRI scoring system; SD = standard deviation; TJC = tender joint count. Symptoms 
were noted by rheumatologists as reported by the patients. 
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Figure 1. Flowchart of the patient flow and development of clinical 
arthritis during two-year follow-up period of the present study.
Legend: 
Flowchart of the patient flow and development of clinical arthritis during two-year 
follow-up period of the present study.
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Figure 2. Kaplan-Meier One Minus Survival plots with 
combinations of Anti-Citrullinated Protein antibodies (ACPA) and 
Rheumatoid Factor (RF) and associated risks for progression to 
clinical arthritis over time.
Legend: 
With autoantibody-negative CSA-patients as reference (N=184), ACPA-negative/
RF-positive patients (N=25) had a HR of 2.6 (1.04-6.6), ACPA-positive/RF-negative 
(N=6) a HR of 8.0 (2.4-27.4) and ACPA-positive/RF-positive patients (N=26) a HR of 
10.5 (5.4-20.6) for progression to clinical arthritis.
Figure 3. Kaplan-Meier One Minus Survival plots with (A) ACPA-levels in ACPA-positive CSA patients and 
(B) RF-levels in RF-positive CSA-patients and associated risks for progression to clinical arthritis over time.
Legend:
A. The ACPA-positive patients in the second tertile (levels 96–325 U/ml, N=11) had a HR of 1.2 for progression to clinical 
arthritis (95%CI=0.39–3.9) compared to the patients in the lowest tertile (N=10). The ACPA-positive patients in the 
third and highest tertile (levels ≥326 U/ml, N=11) had a HR of 1.6 for progression to clinical arthritis (95%CI=0.50–4.8) 
compared to the patients in the lowest ACPA-level tertile.
B. The RF-positive patients in the second tertile (levels 11-40 IU/ml, N=17) had a HR of 1.6 for progression to clinical 
arthritis (95%CI=0.50–5.0) compared to the patients in the lowest tertile (N=17). The RF-positive patients in the third and 
highest tertile (levels ≥41 IU/ml, N=17) had a HR of 3.3 for progression to clinical arthritis (95%CI=1.1–9.6) compared to 
the patients in the lowest RF-level tertile.
Chapter 4 
Screening for two or three 
autoantibodies in persons at risk for 
RA – implications of current data for 
clinical practice
R.M. ten Brinck 1, L.A. Trouw 2, Annette H.M. van der Helm–van Mil 1,3
1. Department of Rheumatology, Leiden University Medical Center, Leiden, the 
Netherlands
2. Department of Immunohematology and Blood Transfusion, Leiden University 
Medical Center, Leiden, The Netherlands
3. Department of Rheumatology, Erasmus Medical Centre, Rotterdam, The 
Netherlands
Published as:
Ten Brinck RM, Trouw LA, van der Helm-van Mil AHM. Screening for two 
or three autoantibodies in persons at risk for RA: implications of current 
data for clinical practice. Rheumatology (Oxford) doi:10.1093/rheumatology/
key441
74 Chapter 4
Sir,
In recent years, research has focused on identifying novel autoantibodies 
and their value for early identification of rheumatoid arthritis (RA). A 
frequently studied novel autoantibody is anti-carbamylated protein (anti-
CarP)[1,2] Presence of this autoantibody at diagnosis of RA is associated 
with a higher disease activity and a more destructive disease course.
[3] The literature on the value of this autoantibody, in addition to the 
evaluation of anti-citrullinated protein antibodies (ACPA) and rheumatoid 
factor (RF), in persons at risk for RA was recently meta-analyzed.[4] It 
was demonstrated that combined presence of ACPA, RF and anti-CarP 
rarely occurred in control groups and therefore was highly specific for RA. 
Although promising, three issues need to be considered before it can be 
concluded that assessing three autoantibodies in the same individuals is 
more beneficial than evaluation of ACPA and RF only.
First, current summarized data were retrieved from case-control or nested 
case-control studies. Caution is advised when utilizing case-control studies 
for assessing diagnostic accuracy. Case-control studies comparing established 
patients with controls are typically used to screen the utility of a test and, if 
an effect in case-controls studies is observed, longitudinal studies in clinically 
relevant populations are subsequently needed to evaluate the diagnostic 
accuracy.[5] Effect sizes in this second step are often lower than observed in 
the first step: two- or three-fold lower effect sizes have been reported.[5,6] 
Especially studies comparing cases to healthy volunteers as controls harbor 
the risk of inflated estimates of diagnostic accuracy.[10] A second issue is 
what autoantibodies to test. Is presence of anti-CarP indeed of added value 
to ACPA and RF (that are already routinely determined in clinical practice)? 
Thirdly, the prognostic value may depend on the ‘at risk population’ and be 
different for persons without symptoms (e.g. first degree relatives) or patients 
seeking medical help because of symptoms. Observational longitudinal 
studies in several of these populations are crucial to decide if testing all three 
autoantibodies is of added value to identify patients with imminent RA. 
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To address these issue in patients that are considered to be in the 
symptomatic pre-arthritis phase, we performed additional analyses in 
our longitudinal cohort study on consecutive patients that presented with 
Clinically Suspect Arthralgia (CSA)[7] to evaluate the diagnostic accuracy 
of three positive autoantibodies for RA development.
241 patients with CSA, as described previously[7], presented with arthralgia 
of small joints of recent onset, without clinical arthritis and were considered 
to be at risk for progression to RA by their rheumatologist based on the 
clinical presentation (autoantibody status was generally unknown).[8] 
After inclusion, IgG ACPA (EliA CCP (anti-CCP2), Phadia, Nieuwegein, 
the Netherlands; positive if ≥7 U/ml)), IgM RF (in-house ELISA; positive if 
≥3.5 IU/ml) and IgG anti-CarP antibodies (in house ELISA based on the use 
of carbamylated fetal calf serum, and non-modified fetal calf serum as the 
coating antigens as a control as described previously[2]; cut-off equivalent to 
2 S.D. above the mean in a group of healthy controls) were determined. The 
outcome was clinical arthritis and diagnosis of RA after 1-year follow-up.
With autoantibody-negative patients as reference (n=184), specificity 
of presence of all three autoantibodies was high: 97% (95% confidence 
interval: 93–100%) with a sensitivity of 46% (19–73%). The positive 
predictive value (PPV) was 67% (36–97%), negative predictive value 
93% (88–98%), the positive likelihood ratio (LR) 14 (4.0–50) and negative 
LR 0.56 (0.34–0.92). These results confirm the high specificity of three 
autoantibodies. The PPV of ACPA+RF+anti-CarP+ in this group (n=9) 
was identical to ACPA+RF+anti-CarP– (also 67% (36–97%), n=9).[7] Thus 
the PPV did neither increase nor decrease after adding anti-CarP. In 
Cox proportional hazards regression analyses, the added value of Anti-
CarP as a third autoantibody in ACPA+/RF+ patients revealed a hazard 
ratio for Anti-CarP+ of 1.03 (95%CI 0.33–3.2; p=0.97; Figure 1), indicating 
no increased risk increase risk for RA in patients with three positive 
autoantibodies compared to ACPA- and RF-positive persons.
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Based on these data, the added value of testing anti-CarP as a third 
autoantibody in arthralgia patients presenting at secondary care would 
seem limited. Importantly, these data cannot be extrapolated to the setting 
of populations without symptoms. Future population-based longitudinal 
studies will have to demonstrate if a combination of three autoantibodies 
can contribute to the identification of at-risk patients in the stage preceding 
the onset of arthralgia.
In conclusion, in follow-up to results from well-conducted case controls 
studies, the first longitudinal data obtained in a clinically relevant 
population of arthralgia patients illustrate the phenomenon that case-
control studies may result in inflated effect sizes of diagnostic accuracy. 
At present, evidence is lacking to measure a third autoantibody on top of 
ACPA and RF in patients presenting with arthralgia in clinical practice. Our 
data should be interpreted in the context of the limitation of small absolute 
numbers, and more research in larger longitudinal studies is needed.
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Figure 1. Kaplan-Meier plot presenting no difference in 
progression to RA in patients with Clinically Suspect Arthralgia 
Legend: 
With CSA-patients that were positive for ACPA and RF, but not harbouring Anti-CarP 
antibodies as reference, ACPA+/RF+ patients that also had Anti-CarP had no higher 
risk for development of clinical arthritis: hazard ratio 1.03 (95%CI 0.33–3.2; p=0.97).
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Abstract 
Introduction: A phase of arthralgia may precede the emergence of 
rheumatoid arthritis (RA). Although several studies have focussed on 
biomarkers, the relevance of this phase for patients is less studied. It is 
unknown if patients already have functional limitations and if this is 
correlated to the extent of subclinical inflammation. Therefore we assessed 
functional disability in patients with Clinically Suspect Arthralgia (CSA), 
its association with MRI-detected subclinical inflammation, and its course 
during progression to clinical arthritis. 
Methods: From April 2012-March 2015, 241 patients had arthralgia for <1 
year and were, based on clinical presentation, considered at risk for RA 
by their rheumatologists. At baseline, Health Assessment Questionnaire 
(HAQ)-scores were determined and unilateral 1.5T MRI of MCP, wrist and 
MTP-joints made. The extent of MRI-detected subclinical inflammation was 
assessed by summing the synovitis, tenosynovitis and bone marrow edema 
scores (range 0-189). Patients were followed on arthritis development and 
HAQ-scores were repeated when clinical arthritis had developed.
Results: The median HAQ-score at presentation with CSA was 0.50. 
Higher MRI-inflammation scores were associated with higher HAQ-scores 
(β=0.017, 95%CI=0.004-0.030). During median 103 weeks follow-up, 44 
patients progressed to clinical arthritis. HAQ-scores ≥1.0 were associated 
with arthritis development (HR=2.50, 95%CI=1.03-6.10). Within converters, 
median HAQ-scores did not increase from presentation with CSA to 
arthritis development (0.88 and 0.75, p-value=0.36).
Conclusions: HAQ-scores ≥1.0 at presentation associated with the 
development of clinical arthritis. Functional limitations in the pre-arthritis 
phase of CSA were as serious as in the early clinical phase, demonstrating 
the relevance of CSA from patients’ perspectives. 
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Introduction
Within rheumatoid arthritis (RA) a symptomatic phase may precede the 
development of clinical arthritis[1]. A broad range of symptoms and signs 
has been described in this phase[2]. In addition, it has been established 
that presence of autoantibodies[3,4], increased levels of acute phase 
reactants[5] and Magnetic Resonance Imaging (MRI)-detected subclinical 
inflammation[6] are associated with progression to clinical arthritis. 
Although several biomarkers have been studied, it is still unknown to 
what extent patients with arthralgia at risk for RA experience functional 
disability. In addition, it is undetermined if functional disability in this 
disease stage is associated with subclinical inflammation and if the 
functional disability increases during progression to clinical arthritis.
The Health Assessment Questionnaire (HAQ) is a commonly used 
instrument to measure self-reported functional disability in patient 
groups[7]. From the general population it is known that HAQ-scores 
increase with age[8] and are higher for women[9]. The median HAQ-
score for patients presenting with RA is generally 1.0[9,10]. It has been 
demonstrated that MRI-detected inflammation in RA was associated with 
increased functional impairment at 6-years follow-up[11].
In order to increase the comprehension of patients’ experiences on physical 
functioning in a symptomatic pre-arthritis stage, this study evaluated 
patients without clinical arthritis but with arthralgia that were considered 
at risk for progression to RA by their rheumatologists (Clinically Suspect 
Arthralgia). This study assessed 1) the level of functional disability 
measured with HAQ-scores in CSA, 2) the association of functional 
disability with the severity of MRI-detected subclinical inflammation, 3) 
the association of functional disability with progression to clinical arthritis 
and 4) the course of HAQ-scores during progression from CSA to clinical 
arthritis.
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Methods
Patients
Two hundred and forty-one patients were consecutively included between 
April 2012-March 2015 in the Leiden Clinically Suspect Arthralgia (CSA) 
cohort. CSA-patients had recent-onset (<1 year) arthralgia of hand or feet 
joints and were considered at risk for RA based on the clinical expertise 
of the rheumatologists[6]. Per definition CSA was not present if patients 
presented with clinical arthritis or if another explanation for the symptoms 
(e.g. osteoarthritis or fibromyalgia) was more likely than imminent RA. 
Hence, as described previously[6], inclusion was mainly based on clinical 
expertise and patients with evident other diagnoses were not studied. 
Furthermore, laboratory results were largely unknown at first visit as 
general practitioners were discouraged to perform additional tests, hence 
inclusion in the cohort was largely based on the findings obtained at 
history taking and physical examination. At baseline, questionnaires were 
completed, among which HAQ and Visual Analogue Scale (VAS, range 
0–10) for pain. Within two weeks after inclusion, an MRI was performed. 
The design of the cohort is further described in reference 6. Baseline HAQ-
scores were missing in 37 patients (15.4%). No differences were found in 
baseline characteristics for the patients with known and unknown HAQ-
scores (Additional File 2).
Health Assessment Questionnaire
The Health Assessment Questionnaire Disability Index was used. It 
comprises 20 questions, covering eight categories: dressing and grooming, 
arising, eating, walking, hygiene, reach, grip and activities of daily living. 
Scores for each category consist of a scale, ranging 0–3, with 0 being no 
disability and 3 representing full disability. The scoring system is based 
on the highest abnormal response in each category. The total HAQ-score 
consists of an average of the eight categories.
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Subclinical inflammation detected by Magnetic Resonance Imaging
Unilateral contrast-enhanced MRIs were made of the 2nd-5th 
metacarpophalangeal, wrist and 1st-5th metatarsophalangeal joints of 
the most painful side, or the dominant side in case of equally severe 
symptoms at both sides. Patients were instructed not to use NSAIDs 24 
hours prior to MRI. An MSK-extremity 1.5 Tesla MRI-scanner was used. 
The detailed MR protocol is provided in Additional File 1. In short, 
before contrast-enhancement a T1-weighted sequence was acquired of 
MCP and wrist joints in the coronal plane. Postcontrast, T1-weighted, fat 
saturated sequences were acquired in coronal and axial planes. The foot 
was scanned with two protocols. In the first 78 patients a T1-weighted 
sequence and a T2-weighted fat saturated sequence were acquired in the 
axial plane (relative to the anatomical position), before contrast agent 
administration. In the remaining 163 patients postcontrast, T1-weighted, 
fat saturated sequences were acquired in axial and coronal planes. This 
provided more information while reducing scanning-times. MRIs were 
scored for bone marrow edema (BME) and synovitis as defined by the 
OMERACT Rheumatoid Arthritis MRI Scoring system (RAMRIS)[12]. 
Tenosynovitis was scored as described by Haavardsholm and colleagues 
(also applied at flexor and extensor tendons of 2nd-5th MCP-joints)[13]. 
The sum of scores for synovitis, tenosynovitis and BME yielded the total 
MRI-inflammation score; the total score ranged between 0-189. Scoring was 
performed by two independent trained readers (HWvS, LM) blinded to 
clinical data. Within-reader intraclass correlation coefficients (ICC) for the 
total MRI-inflammation score were 0.98 and 0.99; between-reader interclass 
correlation coefficient was 0.96. Mean scores of the two readers were used 
in analyses.
Follow-up
Scheduled follow-up visits were performed at 4,12 and 24 months. 
Additional visits took place at indication; either if preferred by the 
patient (because of an increase in symptom) or if felt necessary by the 
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rheumatologist). The patients included in this study were all followed for 
development of clinically apparent arthritis for ≥1 year. Medical files were 
studied for established arthritis until April 22nd 2016. Patients were not 
treated with disease-modifying anti-rheumatic drugs (including steroids) 
in the phase of CSA; NSAIDs were allowed. Time to clinical arthritis was 
defined as time from inclusion in the cohort to the date of first detection of 
clinical arthritis. Patients who did not develop arthritis were censored at 
the date that all medical files were studied on arthritis development or at 
the last follow-up visit. If patients developed clinical arthritis, the HAQ was 
repeated at that visit.
Statistical analyses
Univariable linear regression models were used to investigate the 
association between subclinical MRI-inflammation and HAQ-scores; 
models were adjusted for age at inclusion. Univariable Cox proportional 
hazards regression analyses were used to calculate hazard ratios for HAQ-
scores in relation to arthritis development. Patients were appointed into 
quartiles according to their total HAQ-score to create four subgroups with 
equal numbers. Cox regression was repeated with development of RA 
according to the 2010 classification criteria[14] as outcome. In multivariable 
Cox regression the analysis was adjusted for age, gender, presence of MRI-
subclinical inflammation and ACPA-status. A paired t-test was performed 
to compare HAQ-scores and VAS-scores for pain at presentation with CSA 
and after conversion to clinical arthritis; patients that completed the HAQ 
or VAS-score ≥1 week after DMARD-initiation were excluded from these 
analyses. SPSS, version 23.0 was used. P-values <0.05 were considered 
significant.
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Results
CSA-patients
Baseline characteristics of the 241 patients included are shown in Table 1. The 
mean age was 44.3 years, 78% were female. The median HAQ-score of the 
total group of patients at baseline was 0.50 (interquartile range: 0.25–0.88). 
HAQ-score and MRI-detected subclinical inflammation at presentation
The association between severity of MRI-detected subclinical inflammation 
and functional disability was corrected for age. CSA-patients that presented 
with higher total MRI-inflammation scores had higher HAQ-scores 
(β=0.017, 95%CI=0.004-0.030, p=0.010). This β indicates that per point 
increase in MRI-inflammation score, the HAQ-score increased with 0.017 
(for interpretation the MRI-inflammation score ranges between 0-189). The 
synovitis, tenosynovitis and bone marrow edema scores were also studied 
separately. Of the individual types of inflammation, the tenosynovitis 
score showed the strongest association with functional disability (β=0.046, 
95%CI=0.017–0.076), versus β=0.024 (95%CI=-0.008–0.057) and β=0.026 
(95%CI=-0.004–0.057) for synovitis and bone marrow edema respectively.
HAQ-scores at presentation and progression to clinical arthritis 
During a median follow-up period of 103 weeks, 44 patients progressed 
to clinical arthritis. The patients that progressed presented with higher 
baseline HAQ-scores than CSA-patients that did not progress (median 0.88 
versus 0.50). Four subgroups with equal numbers were created to study 
the association between HAQ-scores and progression to clinical arthritis in 
more detail (the quartiles contained four groups with HAQ-scores of <0.25, 
0.25–0.50, 0.63–0.88 and ≥1.0, Additional File 3). Patients with HAQ-scores 
≥1.0 had a significantly increased hazard on developing clinical arthritis 
(HR=2.50, 95%CI=1.03–6.10), compared to the patients with HAQ-scores 
<0.25 (Figure 1).
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Multivariable Cox regression was performed to investigate the association 
between HAQ-scores and arthritis development, adjusting for age, gender, 
ACPA-status and presence of MRI-detected subclinical inflammation. 
Higher HAQ-scores remained significantly associated with arthritis 
development with HAQ-scores <0.25 as reference: HR 2.6 (95%CI=1.05–
6.6) for HAQ-scores ≥1.0. The presence of a positive ACPA-test and the 
presence of MRI-detected subclinical inflammation were also significantly 
associated with arthritis development in this model (HR=6.7, 95%CI=3.4–
13.8 and HR=3.3, 95%CI=1.4–8.0 respectively). No significant associations 
were observed for age (HR=0.98, 95%CI=0.95–1.01) or gender (HR=0.88, 
95%CI=0.40–2.0). 
27 of the patients with arthritis fulfilled the 2010-criteria for RA[14] already 
at the first visit with clinical arthritis. Additional File 4 provides the results 
of sub-analyses with RA as outcome. Similar findings were obtained with the 
highest HR for the group of patients with a HAQ>1.0 (HR 2.7, 95%CI 0.85–8.5).
HAQ and VAS for pain at presentation with CSA and at arthritis 
development 
HAQ-scores at clinical presentation with CSA and after arthritis 
development (but before DMARD-initiation) were available in 25 patients. 
On group level, median HAQ-scores did not differ between the time of 
presentation with CSA and the time of presentation with clinically apparent 
arthritis: median 0.88 (IQR 0.38–1.2) versus 0.75 (IQR 0.38–1.3) respectively, 
p-value=0.36 (Figure 2). Intra-individual changes in HAQ-scores over 
time are shown in Additional File 5. Also in the subgroup of patients that 
fulfilled the 2010-criteria for RA (n=21), the median HAQ did not increase 
between presentation with CSA and clinical arthritis development (0.82 and 
0.75, p=0.47).
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The progression from CSA to clinical arthritis is based on an increase in 
local joint inflammation. As functional limitations may not only associate 
with inflammation, but also be a direct consequence of pain, we also 
explored the overall level of pain (measured on a VAS ranging 0–10) in 
CSA and at conversion to clinical arthritis. The VAS-score for pain showed 
a non-significant tendency towards an increase between the phase of 
CSA and that of early clinical arthritis (median 6.0 and 7.0 respectively, 
p-value=0.11, Figure 2). Thus despite an increase in inflammation and pain, 
functional disability was already maximal in the phase of CSA.
Discussion
This longitudinal study showed that patients that develop clinical arthritis 
already have functional limitations in the phase of arthralgia. HAQ-scores 
at group level were similar at the time of presenting with CSA and after 
emergence of clinical arthritis. Furthermore, severity of MRI-detected 
subclinical inflammation is associated with the severity of functional 
impairments. Together, these data demonstrate the functional relevance 
of the HAQ and MRI-detected subclinical inflammation in symptomatic 
patients in the pre-arthritis stage. This suggests that, although occurrence 
of clinically detectable arthritis is a major event from the rheumatologist’s 
perspective (as this is mostly the moment of initiation of DMARD-therapy), 
it is of less importance for patients from a functional perspective.
CSA-patients with HAQ-scores ≥1.0 in particular were at increased risk of 
progression to clinical arthritis. Interestingly, previous studies in early RA 
cohorts have shown that mean HAQ-scores at presentation were 1.0[9,10]. 
This suggests that functional impairments in the symptomatic pre-arthritis 
and early clinical phases are of similar severity. A presumption that is 
further supported by our findings that the CSA-patients that progressed 
88 Chapter 5
to clinical arthritis did not experience an increase in functional disability, 
in other words the maximal level of disability was already present when 
presenting with CSA.
Patients that presented with CSA but did not progress to clinical arthritis 
presumably also had more functional impairments than the general 
population, as their median HAQ was 0.50 and mean HAQ-score of an age-
related normal population (women aged 40-44 years) is approximately 0.08[8]. 
We observed that a HAQ ≥1.0 was associated with progression to clinical 
arthritis, independent of other predictors (age, gender, ACPA, MRI-
detected inflammation). Though this study was not aimed at identifying 
novel markers for progression from CSA to RA, but to explore the level 
of functional disability in patients with CSA and during progression to 
clinical arthritis. The question if a HAQ-score is valuable for diagnostic or 
prognostic purposes needs to be studied in further, larger studies.
The severity of functional disability was associated with the severity of 
MRI-detected subclinical inflammation, indicating that the functional 
impairments were in part related to (subclinical) inflammation. Previous 
studies in early arthritis or in RA also showed an association between 
MRI-detected inflammation and HAQ-scores within RA[11,15]. In one 
of these studies it was observed that MRI-detected tenosynovitis had 
the strongest association with functional disability in early arthritis.[15] 
Interestingly, also in patients with CSA we observed that tenosynovitis 
had the strongest association with functional disability. The beta of MRI-
detected tenosynovitis of 0.046 indicates that a MRI-inflammation score 
of 6 associated with an increase in HAQ of 0.27. Although statistically 
significant, the relatively small effect size indicates that the functional 
disability in CSA is only partly explained by (MRI-detected) subclinical 
inflammation.
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A potential weakness is that 37 patients did not complete the baseline 
HAQ. Because the baseline characteristics of the patients that had HAQ-
data and those without HAQ-data were similar, we believe that there is no 
important bias. 
Patients were not included if the treating rheumatologist considered another 
explanation for the arthralgia (e.g. osteoarthritis or fibromyalgia) more likely 
than imminent RA. Therefore, we think it is unlikely that patients with 
forms of (chronic) pain syndromes might have skewed the data towards 
higher HAQ-scores. Furthermore, we use medians for comparisons of HAQ- 
and VAS-scores as these are more resistant against outliers. 
Another potential limitation for the analyses is that both HAQ-scores 
and MRI-inflammation scores are assessed at semi-quantitative scales. 
However, the HAQ is one of the most important and validated patient-
reported outcomes in RA. 
Finally, it should be taken into consideration that the sample size of 
patients converting to clinical arthritis is relatively small. Our study is 
nevertheless the largest to date to investigate functional disability in 
patients with clinically suspect arthralgia.
Ideally, to fully evaluate the burden of clinically suspect arthralgia on 
functional disability, the functional status of the patients with CSA 
included in this study should be compared to age- and sex-matched 
controls from the general population. As such references were not available 
for the Dutch population, we could not perform such comparison. 
In conclusion, functional disabilities exist already in the symptomatic pre-
arthritis phase, with (on group level) a similar severity as when presenting 
with clinical arthritis. Although occurrence of clinically detectable arthritis 
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is a major event from the rheumatologist’s perspective (as then initiation of 
DMARD-therapy is warranted), the present data illustrate the importance 
of the symptomatic pre-arthritis phase from a functional perspective.
Supporting information 
Supplementary data is available at the website of RMD Open, or can be obtained 
by contacting the first author.
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Table 1. Patient characteristics (N=241) at baseline presentation with CSA. 
Patient characteristic 
Age in years, mean (SD) 44.3 (12.9)
Female sex, n (%) 187 (77.6)
Family history of RA, n (%) 71 (29.5)
Symptom duration in weeks, median (IQR) 18.4 (9.7–48.2)
Presence of morning stiffness ≥60 minutes * ‡, n (%) 80 (33.2)
BMI in kg/m2, median (IQR) 26.1 (23.6–29.9)
68-TJC, median * (IQR) 6 (3–10)
Current smoker, n (%) 54 (22.4)
Autoantibody status 
ACPA-positive (>7 U/mL), n (%) 32 (13.3)
IgM-RF-positive (>3.5 IU/mL), n (%) 51 (21.2)
Increased CRP (>10 mg/L), n (%) 53 (22.0)
Baseline VAS pain score, median (IQR) 5 (3–7)
Baseline HAQ-score *
First quartile (N=44) <0.25
Second quartile (N=62) 0.25 – 0.50
Third quartile (N=51) 0.63 –0.88
Fourth quartile (N=47) ≥1.0
Symptoms were noted by rheumatologists as reported by the patients.  
* Missing data were as follows: Morning stiffness (27), 68-TJC (4), HAQ-score (37). 
‡ The presence of symptoms refers to the presence of symptoms at the baseline visit.
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Legend: 
ACPA = anti-citrullinated peptide antibody; BMI = body mass index; CRP 
= C-reactive protein; ESR = erythrocyte sedimentation rate; HAQ = Health 
Assessment Questionnaire; IgM-RF = immunoglobulin M rheumatoid factor; IQR 
= interquartile range; RA = rheumatoid arthritis; SD = standard deviation; TJC = 
tender joint count.
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Figure 1. Kaplan-Meier One Minus Survival plot showing 
cumulative progression to clinical arthritis for CSA-patients 
divided in four groups based on their baseline HAQ-score.
Legend: 
Patients were appointed into quartiles according to their total HAQ-score to create 
four subgroups with equal numbers, see Additional File 3. Each line represents one 
HAQ-score quartile and cumulative progression to clinical arthritis. The lowest 
quartile contains patients with HAQ-scores <0.25 with N=44 was the reference 
group. The second quartile contains HAQ-scores 0.25–0.50 (N=62), with a HR 
for progression to clinical arthritis of 0.67 (95%CI=0.24–1.9). Patients in the third 
quartile had HAQ-scores 0.63–0.88 (N=51) with a HR for progression to clinical 
arthritis of 1.3 (95%CI 0.49–3.4). Finally, the quartile with the highest HAQ-scores 
contains HAQ-scores ≥ 1.0. (N=47).The hazard ratio for this quartile (HR=2.50, 
95%CI=1.03–6.10) was significantly elevated, compared to the lowest quartile. 
5Figure 2. Column bar graphs showing HAQ-scores and pain score on VAS (scale 0-10) that were 
collected at presentation with CSA and after progression to clinical arthritis but before DMARD 
initiation.
Legend: 
Column bar graphs showing HAQ-scores and pain score on VAS (scale 0-10) of 25 patients that were serially collected at 
presentation with CSA (left bar) and after progression to clinical arthritis but before DMARD initiation (right bar). A paired 
t-test for comparisons of median HAQ-scores and pain scores on VAS (scale 0-10) at both time points (CSA baseline inclusion 
and the moment of established arthritis) revealed no differences (p-value=0.36 and p=0.11, respectively).
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Abstract
Background: Anti-citrullinated protein antibodies (ACPA) associate with 
more severe joint erosions in rheumatoid arthritis (RA), but the underlying 
mechanism is unclear. Recent in vitro and murine studies indicate that 
ACPAs can directly activate osteoclasts leading to bone erosions and pain. 
This study sought evidence for this hypothesis in humans and evaluated in 
arthralgia patients at risk for RA whether ACPA associated with erosions 
(detected by MRI) independent of inflammation, and also independent of 
the presence of Rheumatoid Factor (RF). 
Methods: 507 patients with Clinically Suspect Arthralgia underwent 
ACPA- and RF-determination and 1.5T contrast-enhanced MRI of 
metacarpophalangeal, wrist and metatarsophalangeal joints at baseline. 
MRIs were scored for presence of local inflammation and erosions. 
Comparisons of erosion scores were performed using Kruskal-Wallis 
tests. To evaluate if inflammation is, in statistical terms, intermediary in 
the causal path of ACPA and erosions, three-step mediation analysis was 
performed using linear regression.
Results: ACPA-positive patients had higher erosion scores than ACPA-
negative patients (p=0.006). ACPA-positive patients without subclinical 
inflammation did not have higher erosion scores than ACPA-negative 
patients (p=0.68), in contrast to ACPA-positive patients with local 
inflammation (p<0.001). Mediation analyses suggested that local 
inflammation is in the causal path of ACPA leading to higher erosion 
scores. Compared to ACPA-negative/RF-negative patients, ACPA-positive/
RF-negative patients did not differ (p=0.30), but ACPA-positive/RF-positive 
patients had higher erosion scores (p=0.006).
Conclusions: The effect of ACPA on erosions is mediated by inflammation 
and is not independent of RF. 
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Background
Although anti-citrullinated protein antibodies (ACPA) are the most 
important risk factor for joint destruction in rheumatoid arthritis (RA), 
the underlying pathophysiological process is unclear. Traditionally, it 
is hypothesized that ACPAs can enhance inflammation[1] (for instance 
via immune complexes that stimulate macrophages to secrete pro-
inflammatory cytokines) and that inflammation is required for destruction, 
resulting in e.g. visible bone erosions on radiographs. Recent in vitro studies 
and mouse models have generated a new concept in which ACPA can 
directly induce osteoclast activation, followed by autocrine enhancement 
of osteoclast maturation and activation[2,3]. This may subsequently lead 
to bone loss (and pain) as observed in studies performed in vivo following 
injection of ACPA[2-5]. The findings that ACPA can be present long before 
synovitis is clinically detectable[6] and that sensitive imaging techniques 
have detected small erosions in arthralgia patients[7] fit with the hypothesis 
that joint inflammation is not necessary to generate erosions[5]. Despite 
observations made in vitro and in vivo in mice[2,3], there is presently little 
information available on data from ACPA-positive patients in the absence 
of local inflammation. Hence, it is not known if ACPA can lead to bone 
erosions only with concurrent presence of inflammation, or that ACPA 
induces direct osteoclast activation (leading to erosions without requiring 
concomitant inflammation) in humans as well. By performing association 
studies in patients that are in the disease phase of arthralgia without 
the presence of clinical synovitis, information on these relationships can 
be obtained as only part of the arthralgia patients display subclinical 
inflammation. Therefore, the arthralgia setting provides the possibility to 
study associations of ACPA, (local) inflammation and erosions.
Likewise, this setting can also answer whether the effect of ACPA –if any– 
is dependent on the presence of Rheumatoid Factor (RF). Studies within 
early (rheumatoid) arthritis, using high-resolution CT, have shown that 
combined presence of ACPA and RF is associated with the number and 
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size of erosions rather than ACPA individually[8]. In addition, it has been 
shown that early arthritis patients that harbour both ACPA and RF display 
increased osteitis scores as detected by Magnetic Resonance Imaging (MRI), 
in contrast to ACPA single-positive patients[9].
With the aim to find support that ACPAs themselves are directly linked 
to bone erosions in humans, this study in patients with Clinically Suspect 
Arthralgia evaluated whether 1) ACPA associated with higher erosion 
scores (detected by MRI) independent of the presence of inflammation, and 
2) whether higher erosion scores were associated with ACPA alone or with 
ACPA and RF combined.
Patients and Methods
Patients
507 arthralgia patients consecutively included in the Leiden Clinically 
Suspect Arthralgia cohort between April 2012 and September 2017 were 
studied. Clinically Suspect Arthralgia was defined as: recent-onset (<1-
year) arthralgia of small joints, without clinically detectable synovitis (i.e. 
joint swelling) at physical examination, while the treating rheumatologists 
considered the patients suspicious for progression to RA based on their 
clinical presentation[10]. General practitioners in our region rarely 
performed ACPA- or RF-testing before referral[11]; hence this infrequently 
affected inclusion decisions[10]. After inclusion, ACPA (EliA CCP (anti-
CCP2), Phadia, Nieuwegein, the Netherlands; positive if ≥7 U/mL), RF 
(as described previously, in-house ELISA[12]; positive if ≥3.5 IU/mL) and 
C-Reactive protein (CRP; positive if ≥5.0 mg/L) were determined. The cohort 
is described in detail in reference [10]. Informed consent was obtained in all 
subjects. The local medical ethical committee approved the study.
Within 1-2 weeks after inclusion, 1.5T contrast-enhanced MRI was 
made of MCP2-5, wrist and MTP1-5 joints of the most painful side (see 
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Supplementary Methods for MRI protocol). Disease modifying anti-
rheumatic drugs were not used, NSAIDs were stopped 24 hours before 
MRI. MRIs were scored for erosions, Bone Marrow Edema (BME), 
synovitis[13] and tenosynovitis[14] by two readers as described in the 
Supplementary Methods. Within-reader intraclass correlation coefficients 
(ICC) were 0.98 and 0.99; between-reader ICC was 0.96.
Inflammation
Inflammation was assessed in two ways: local inflammation was considered 
present if ≥1 joint had MR-detected BME, synovitis or tenosynovitis that 
was more than that observed in age-matched symptom-free controls[15] 
(Supplementary Methods). Secondly, ‘any inflammation’ was defined as the 
presence of either local subclinical inflammation (MRI-detected synovitis, 
BME or tenosynovitis) and/or an elevated C-Reactive Protein level. In 
this second analysis, ‘any (i.e. systemic) inflammation’ was taken into 
consideration as it could be argued that the presence of increased acute phase 
reactants in patients that have no subclinical joint inflammation as detected 
with MRI indicates that some inflammation is present in these patients.
Analyses
Comparisons of erosion scores were performed using Kruskal-Wallis tests. 
To evaluate if inflammation is, in statistical terms, intermediary in the 
causal path of ACPA and erosions, mediation analyses were performed 
as described by Baron and Kenny[16]. Here, linear regression was used 
to evaluate in three steps if local inflammation is a mediator in the causal 
path of ACPA presence and erosion score as outcome. First, the association 
between presence of ACPA and erosions was investigated. Second, the 
association between presence of ACPA and severity of local inflammation 
was investigated. Finally, both ACPA and local inflammation were entered 
and tested whether this effect was different from the association of ACPA 
alone and erosion score. The percentage of mediation was calculated. All 
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regression analyses were corrected for age. Additionally, a triple stratification 
was applied for ACPA, RF and local subclinical joint inflammation. Statistical 
Package for the Social Sciences (SPSS) version 23.0 was used.
Results
Patients with CSA had a mean age of 44 years, 77% were female and 
presence of local subclinical joint inflammation on MRI was observed in 
50% (N=255). 64% of the patients included met the EULAR definition of 
arthralgia suspicious for progression to rheumatoid arthritis (3/7 items 
present)[17]. Further characteristics are shown in Table 1.
ACPA with concomitant inflammation, but not ACPA alone, associated 
with higher erosion scores
First a comparison was made between all ACPA-positive patients and 
ACPA-negative patients: ACPA-positive patients had higher erosion scores 
than ACPA-negative patients (p=0.006; Figure 1A). Also the presence of 
MRI-detected subclinical inflammation was associated with higher erosion 
scores (p<0.001; Figure 1B).
Next, stratification was applied for both ACPA and local subclinical 
joint inflammation. After this stratification, it was observed that in the 
absence of local subclinical inflammation ACPA-positive (ACPA+/MRI–) 
patients did not have higher erosion scores than ACPA-negative (ACPA–
MRI–) patients (p=0.68). In contrast, ACPA-positive patients with local 
inflammation (ACPA+/MRI+) did express higher erosion scores than 
ACPA-negative patients without local inflammation (ACPA–MRI–; p<0.001; 
Figure 1C). Furthermore, comparing ACPA-positive patients without 
local inflammation (ACPA+MRI–) to ACPA-positive patients with local 
inflammation (ACPA+MRI+) revealed that the latter group had significantly 
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higher erosions scores (p=0.016, Figure 1C). This suggests that ACPA with 
concomitant inflammation, but not ACPA ‘alone’, associated with higher 
erosion scores. 
When ‘any inflammation’ (considering inflammation positive if: either 
local subclinical joint inflammation was present, or CRP was elevated) 
was studied, stratified analyses revealed similar results (Supplementary 
Figure 1). Also here, patients that had ACPA as well as inflammation 
present had higher erosion scores, in contrast to patients that had ACPA 
without concomitant inflammation (p=0.056). ACPA-levels within ACPA-
positive patients (comparing tertiles) were not associated with erosion score 
(Supplementary Figure 2).
Mediation analyses; local inflammation is in the causal path of ACPA and erosions
In three steps, it was studied if local inflammation is intermediary in 
the causal path of ACPA and erosions using mediation analyses. In 
linear regression analysis (Figure 2), the presence of ACPA significantly 
associated with erosion score (β 0.72; 95%CI 0.23-1.2; p=0.004). Likewise, 
presence of ACPA also significantly associated with the severity of local 
inflammation (β 3.2; 95%CI 1.8-4.6; p<0.001). Importantly, presence 
of ACPA no longer showed a significant effect on erosion score when 
corrected for inflammation (β 0.31 ; 95%CI -0.15-0.77; p=0.18). Together, 
these results indicate that subclinical inflammation is a mediator acting 
in the causal path of ACPA leading to erosions and the mediator could 
account for more than half of the total effect: (A*B) / (A*B + C’) = 0.57.
ACPA in the presence of RF, but not ACPA alone, associated with higher 
erosion scores
ACPA-positive patients with local inflammation were more often RF-
positive (81%) than ACPA-positive patients without local inflammation 
(67%, p=0.28). Stratification was therefore applied for ACPA and RF: 
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studying the combinations of ACPA-positivity and RF-positivity revealed 
that ACPA-positive/RF-negative patients had similar erosion scores as 
ACPA-negative/RF-negative patients (p=0.30). However, patients having 
both ACPA and RF had significantly higher erosion scores (p=0.006; Figure 
1D) as compared to ACPA-negative/RF-negative patients.
Finally, triple stratification for ACPA, RF and local subclinical joint 
inflammation was performed (Figure 3). First, we investigated if the 
single presence of ACPA or RF was associated with higher erosion scores. 
As compared to the ACPA–RF–MRI– reference group (median erosion 
score 1.0), no differences were found for patients only positive for ACPA 
(ACPA+RF–MRI–; median 1.0; p=0.85), nor single-positive for RF (ACPA–
RF+MRI–; median 0.5; p=0.35) or patients positive for both ACPA and RF, 
but without subclinical joint inflammation (ACPA+RF+MRI–; median 1.0; 
p=0.65). ACPA+RF+MRI- patients (median 1.0) did not have significantly 
higher erosion scores than ACPA-RF+MRI- patients (median 0.5; p=0.91). 
We then investigated if erosion scores were significantly higher if 
concomitant inflammation was present in addition to the presence of ACPA 
and/or RF. Compared to ACPA–RF–MRI– patients, significantly higher 
erosion scores were observed for ACPA-positive patients with concurrent 
inflammation (ACPA+RF–MRI+; median 2.0; p=0.033), as well as RF-
positive patients with concomitant inflammation (ACPA–RF+MRI+; median 
2.25; p=0.001). Finally, we studied the erosion scores in ACPA+RF+ patients. 
Whereas ACPA+RF+MRI- patients did not have higher erosion scores than 
the reference group, ACPA+RF+MRI+ patients did have higher erosion 
scores than the ACPA–RF–MRI– patients (median 2.5 versus 1.0; p<0.0001). 
The erosion score of the ACPA+RF+MRI+ patients was also higher than that 
of the ACPA+RF+MRI– patients (median 2.5 versus 1.0; p=0.039). Together 
these data showed that the presence of ACPA and/or RF is only associated 
with higher erosion scores if concomitant inflammation is present.
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Discussion
This study evaluated associations between ACPA, RF, (local) subclinical joint 
inflammation and erosions in arthralgia patients at risk for RA. Presence of 
ACPA alone, without inflammation, was not associated with higher erosion 
scores, in contrast to the combined presence of ACPA and inflammation. 
Mediation analyses revealed that local inflammation was intermediary in 
the causal path to erosions. These results indicate that joint inflammation 
has a role in the development of erosions in ACPA-positive individuals, and 
suggest that in vitro or mice model findings on the independent effect of 
ACPAs on erosions are in contrast to findings in humans.
Furthermore, the combination of ACPA and RF, rather than presence of 
ACPA alone, associated with erosions in arthralgia patients. These results 
align with those obtained in patients with early rheumatoid arthritis[8,9] 
and fuel the hypothesis that ACPAs alone are not the main and/or single 
pathogenic factor contributing to joint erosions. Although one can speculate 
how –or if– ACPAs contribute to joint erosions together with inflammation, 
results from association studies do not allow conclusions on biological 
mechanisms. 
Our results suggest that, in addition to ACPA, local joint inflammation is 
required for more severe erosive disease. Based on the mediation analysis 
we cannot definitely differentiate between full or partial mediation; 
the significance for ACPA from step 1 was lost in step 3 suggesting full 
mediation. However, as the beta was not zero, partial mediation cannot 
be excluded. Nonetheless, results of the mediation analyses supported the 
notion that erosions in ACPA-positive arthralgia rarely occurred without 
concomitant inflammation. This finding is in line with a previous study that 
showed that increased levels of CD19+ B cells and CXCL13 were observed 
in ACPA-positive RA and were associated with erosive disease[18].
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In this study, the use of sensitive high-quality MRI-data allowed us to 
detect erosions in a population in which the total burden of erosions is 
relatively low. In contrast to the setting of early inflammatory arthritis 
where all patients have current or recent joint inflammation, the arthralgia 
setting allows comparison of patients with and without inflammation.
Not all patients considered at risk for RA will develop arthritis over 
time, even though ACPA or (subclinical) inflammation might be present. 
However, because we addressed whether ACPA can directly mediate bone 
loss with/without concurrent inflammation, the study could be performed 
independent of the final clinical diagnosis. 
The obtained subgroups after stratification were small in some cases 
(especially the ACPA+RF–MRI– subgroup after triple stratification), which 
could lead to underpowered analyses and the possibility of a lack to 
find statistically significant differences. However, all analyses show that 
erosion scores are highest when both ACPA and inflammation are present 
simultaneously which strengthens the overall findings.
Finally, our study cannot address the question if the results are different for 
specific ACPA reactivities, as the presence of ACPA was evaluated using 
the commercially available CCP2 test.
Because a direct effect of ACPA on erosions has been suggested[5], we 
studied erosions in humans. Although loss of trabecular bone as observed 
in mice may be dissimilar from periarticular-located erosions in humans, 
including the underlying mechanisms, our results indicate that ACPAs 
do not directly contribute to the formation of bone erosions, one of the 
hallmarks of RA.
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Conclusions
In conclusion, the present data in patients with arthralgia showed that 
erosions are associated with the combined presence of ACPA and RF, 
rather than with ACPA alone, and preferentially occur in patients with joint 
inflammation. 
Supporting information 
Supplementary data is available at the website of Arthritis Research & Therapy, or 
can be obtained by contacting the first author.
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Figure 1. Histograms showing median erosion scores of patients with Clinically Suspect Arthralgia 
comparing ACPA-positive and ACPA-negative patients (A), patients positive or negative for local 
subclinical joint inflammation (B), ACPA-positivity and -negativity in relation to the concomitant 
presence of MRI-detected subclinical inflammation (C), or rheumatoid factor (D).
Legend: 
Histograms showing median erosion scores with the upper limit of the interquartile range (75th percentile).** indicates significance 
of p<0.01 level, * indicates significance of p<0.05 level, NS indicates non-significance. The following comparisons have been made: 
ACPA+ vs. ACPA– (Figure 1A; p=0.006) and MRI+ vs. MRI– (Figure 1B; p<0.001). Next, ACPA+MRI– vs. ACPA–MRI– patients (Figure 
1C; p=0.68), ACPA+MRI+ vs. ACPA–MRI– patients (Figure 1C; p<0.001) and finally ACPA+MRI– vs. ACPA+MRI+ (Figure 1C; p=0.016). 
ACPA+RF– patients vs. ACPA–RF– patients (Figure 1D; p=0.30) and ACPA+RF+ patients vs. ACPA–RF– patients (Figure 1D; p=0.006).
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Figure 2. Mediation analyses showing that inflammation is in the 
causal pathways of ACPA.
Legend: 
Schematic overview of the causal paths that were studied using mediation models 
as described by Baron and Kenny. The diagram illustrates the two causal paths 
that can lead to the outcome; a direct path from the independent to the outcome 
(C) and an indirect path from the mediator to the outcome (B). Finally, a path exists 
from the independent variable to the mediator (A). According to the description 
of Baron and Kenny, to test for mediation the following three regression analyses 
need to be performed[16]. (1) Regress the mediator on the independent variable 
(A); the independent variable should significantly affect the mediator. (2) Regress 
the dependent (outcome) variable on the independent variable (C); also here the 
independent variable should significantly affect the outcome. (3) Regress the 
dependent variable on both the mediator and the independent variable (B and 
C’ in one model); in case of mediation the mediator is significantly associated 
with the outcome and the effect of the independent variable on the outcome is 
less than in step 2 (partial mediation) or there is no effect at all (full mediation). 
In this study, the hypothesis was tested whether severity of local inflammation 
detected with MRI acts as a mediator in the causal path of the presence of anti-
citrullinated protein antibodies (ACPA) on the erosion score. The data revealed that 
inflammation mediated the effect of ACPA on bone erosions. The mediator could 
account for more than half of the total effect: (A*B) / (A*B + C’) = 0.57.
Figure 3. Histograms showing median erosion scores of patients with Clinically Suspect Arthralgia 
with triple stratification for ACPA, RF and local joint inflammation.
Legend: 
Histograms showing median erosion scores with the upper limit of the interquartile range (75th percentile). * indicates significance of p<0.01 level 
as compared to the ACPA–RF–MRI– group, ** indicates significance of p<0.01 level as compared to the ACPA–RF–MRI– group, NS indicates non-
significance as compared to the ACPA–RF–MRI– group. The following comparisons were made: ACPA–RF–MRI– patients (median erosion score 
1.0) vs. ACPA+RF–MRI– (median 1.0; p=0.85), ACPA–RF–MRI– vs. ACPA–RF+MRI– (median 0.5; p=0.35) and ACPA–RF–MRI– vs. ACPA+RF+MRI– 
(median 1.0; p=0.65). ACPA+RF+MRI- patients (median 1.0) vs ACPA-RF+MRI- patients (median 0.5; p=0.91). Next, ACPA–RF–MRI– patients were 
compared to ACPA+RF–MRI+ (median 2.0; p=0.033) and ACPA–RF+MRI+ patients (median 2.25; p=0.001). Finally, ACPA+RF+MRI+ patients were 
compared to ACPA–RF–MRI– patients (median 2.5 versus 1.0; p<0.0001), as well as ACPA+RF+MRI– patients (median 2.5 versus 1.0; p=0.039). The 
number of patients in each group was as follows: ACPA–RF–MRI– (n=214), ACPA+RF–MRI– (n=4), ACPA–RF+MRI– (n=26), ACPA–RF–MRI+ (n=174), 
ACPA+RF+MRI– (n=8), ACPA–RF+MRI+ (n=24), ACPA+RF–MRI+ (n=11) and ACPA+RF+MRI+ (n=46).
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Table 1. Baseline characteristics of the Clinically Suspect Arthralgia 
patients (N=507).
Patient characteristic 
Age in years, mean (SD) 44 (13)
Female sex, N (%) 390 (77)
Family history of RA, N (%) 147 (29)
Symptom duration in weeks, median (IQR) 17 (9 – 32)
Presence of morning stiffness ≥60 minutes, N (%) 182 (36)
Current smoker, N (%) 137 (27)
68-TJC, median (IQR) 6 (3 – 10)
Increased CRP (≥5 mg/L), N (%) 106 (21)
Presence of local subclinical joint inflammation, N (%) 255 (50)
Positive for EULAR-definition for arthralgia suspicious for 
progression to RA [17], N (%)
325 (64)
Autoantibody status 
Negative for IgM-RF and ACPA, N (%) 385 (76)
IgM-RF-positive (≥3.5 IU/mL), ACPA-negative, N (%) 52 (10)
ACPA-positive (≥7 U/mL), IgM-RF-negative, N (%) 15 (3)
IgM-RF-positive and ACPA-positive, N (%) 55 (11)
ACPA-level (U/ml) in ACPA-positive patients, median (IQR) 162 (35 – 340)
ACPA-level (U/ml) in ACPA-positive patients with-
out local joint inflammation, median (IQR)
129 (23 – 340)
ACPA-level (U/ml) in ACPA-positive patients with 
local joint inflammation, median (IQR)
191 (38 – 340)
Legend: 
ACPA = anti-citrullinated peptide antibody; CRP = C-reactive protein; IgM-RF = 
immunoglobulin M rheumatoid factor; IQR = interquartile range; RA = rheumatoid 
arthritis; SD = standard deviation; local subclinical joint inflammation = prevalence 
of MR-detected Bone Marrow Edema, synovitis or tenosynovitis was higher than 
that of age-matched symptom-free controls; TJC = tender joint count.
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Abstract
Introduction: Subclinical inflammation, detected by Magnetic Resonance 
Imaging (MRI), in patients with arthralgia is predictive for development of 
inflammatory arthritis (IA). However, within patients that develop IA, the 
course of inflammation at joint level during this transition is unknown. This 
longitudinal study assessed progression of inflammation at joint level.
Methods: 350 joints (unilateral MCPs, wrist, MTP-joints) of 35 patients 
presenting with Clinically Suspect Arthralgia (CSA) that progressed to IA 
were studied at presentation with CSA and subsequently when clinical 
synovitis was first identified at joint examination (median time-interval 
17 weeks). At both time-points, subclinical inflammation (bone marrow 
edema, synovitis, tenosynovitis) was evaluated with MRI and joint 
examination performed.
Results: At presentation with CSA, 71 joints showed subclinical 
inflammation. During progression to IA, 20% of these joints had resolution 
of inflammation, 60% had persistent inflammation and 20% progressed to 
clinical synovitis. Of all joints that had developed clinical synovitis (n=45), 
no prior subclinical inflammation was detected in 69%. Similar results were 
observed for ACPA-positive and ACPA-negative patients.
Conclusions: This longitudinal study demonstrated moderate correlations 
between joints with subclinical inflammation and joints that developed 
clinical synovitis. These data imply that IA development is a more systemic 
rather than a locally outgrowing process.
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Introduction
During pre-arthritis phases of rheumatoid arthritis (RA), subclinical 
inflammation can already be present.[1-3] Its presence in small joints 
in patients with arthralgia is predictive of inflammatory arthritis (IA) 
development.[1-3] Furthermore, on patient-level, progression to IA 
is uncommon in arthralgia patients without MRI-detected subclinical 
inflammation.[1] 
Although risk factor studies have made an enormous progress in 
our comprehension on the development of RA[4-6], many questions 
remain unanswered. One of these questions concerns the progression of 
inflammation on joint level during development of clinical synovitis. For 
instance, it is unknown how often joints with subclinical inflammation 
progress to clinical synovitis in the same joint, and vice versa, how often 
joints with clinical synovitis had (prolonged) preceding subclinical 
inflammation at the same location during the phase of arthralgia. 
Consequently, it is unclear whether IA development is a local outgrowing 
process where subclinical joint inflammation closely relates to subsequent 
clinical synovitis, or whether there is a more global deregulation where 
locations of subclinical inflammation and synovitis development are largely 
uncoupled. Exploration of these hypotheses necessitates longitudinal 
studies that start in a pre-arthritis phase. 
This longitudinal study at joint level in arthralgia patients that developed 
IA assessed the course of joint inflammation in this period. In sensitivity 
analyses, stratification was applied for anti-citrullinated protein antibodies 
(ACPA) status.
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Methods
Patients
350 small joints of 35 patients that presented with Clinically Suspect 
Arthralgia (CSA) and progressed to IA were evaluated. Patients presented 
at the rheumatology outpatient clinic of the Leiden University Medical 
Centre were included in a consecutive manner in the Leiden CSA cohort 
between April 2012 and September 2016. CSA was defined as recent-
onset (<1 year) arthralgia of small joints that was clinically considered 
at risk for IA by the rheumatologists without clinically evident arthritis. 
29 patients (83%) met the EULAR definition of arthralgia suspicious for 
progression to rheumatoid arthritis at baseline.[7] Patients included in the 
CSA-cohort were followed until synovitis development (detected at joint 
examination by an experienced rheumatologist) as described in [8]. In this 
study, CSA-patients that were included between April 2012–September 
2016 and progressed to IA were studied. Regular follow-up visits in the 
CSA-cohort were planned at 4, 12 and 24 months after baseline. If necessary 
(for instance when the patient experienced more symptoms or noticed a 
swollen joint) patients were seen in between the scheduled visits by their 
rheumatologist. This provided early access to rheumatology care if patients 
developed clinically evident synovitis and thus inflammatory arthritis was 
identified at the first opportunity. 
When IA was identified at patient level, individual joints could be in one 
of these states: clinical synovitis, MRI-detected subclinical inflammation 
but no clinical synovitis, or no inflammation. Tender joint count (68-TJC) 
and swollen joint count (66-SJC) for study purposes were performed by 
one assessor from a pool of six trained research nurses under supervision 
of an experienced rheumatologist. Regular reliability sessions are held to 
maintain a high interobserver correlation. All patients provided written 
informed consent. Ethics approval was provided by the local medical 
ethical committee under Ethics Approval Number NL38832.058.11.
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MRI 
Unilateral MRIs of wrist, MCP2–5, and MTP1–5 were performed at 
presentation with CSA (most painful side) and at first presentation with 
clinical synovitis (similar side as scanned at baseline). An ONI MSK 
Extreme 1.5T MRI scanner (GE Healthcare, Wisconsin, USA) was used, as 
described previously[1] and in the Supplementary Methods. Patients were 
instructed not to use NSAIDs 24 hours prior to MRI, with seven patients 
(20%) reporting daily use of NSAIDs at baseline. MRIs were evaluated 
for bone marrow edema (BME; range 0–72)) and synovitis (range 0–33) 
as described in [9], and tenosynovitis (range 0–54) as described in [10] by 
two independent experienced readers who were blind to clinical data and 
the order in time (all had interclass correlations ≥0.94, see Supplementary 
Table 1). Subclinical inflammation was considered present in clinically 
non-inflamed joints if the total inflammation score (summing the BME, 
synovitis and tenosynovitis scores and averaging the score of two readers) 
was ≥1. In other words: if either the BME, synovitis or tenosynovitis score 
was ≥1, subclinical inflammation was considered present in a joint. BME 
scores for the wrist joint were calculated for the bones lining the joint 
space: proximally the radius and ulna, distally the proximal carpal row 
(scaphoid, lunate, triquetrum and pisiform). Synovitis scores for the wrist 
joint were calculated by the radioulnar and radiocarpal compartment and 
tenosynovitis scores for all wrist flexors and extensors.
Analysis
Percentages were determined by evaluating inflammation in individual 
joints over time. Generalized Estimating Equations (GEE), using an 
unstructured correlation matrix, were used to investigate differences 
in time interval between the paired measurements in joints that did/
did not develop clinical synovitis, while holding in account that one 
patient contributed 10 joints. Sensitivity analyses were performed per 
inflammatory feature and by stratifying for ACPA status. Finally, a 
second (more stringent) definition was used for subclinical inflammation: 
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subclinical inflammation was considered present if it occurred in <5% of 
age-matched symptom-free persons at the same joint and for the same 
feature (henceforth referred to as “5% corrected definition”).
Results
Patient characteristics
Clinical characteristics are demonstrated in Table 1. Ten patients were 
ACPA-positive. 34 out of 35 patients (97%) had subclinical inflammation in 
≥1 joint that was evaluated with MRI at baseline. Median duration between 
presentation with CSA and development of IA was 17 weeks (interquartile 
range (IQR): 6–21). When clinical synovitis was identified at one of the 
subsequent visits, the median swollen joint count (66-SJC) was 2 (IQR: 1–5), 
and 23 patients (66%) fulfilled the 2010 ACR/EULAR classification criteria 
for RA.
Joints with subclinical inflammation during CSA predominantly remain 
in state of subclinical inflammation 
Further analyses were performed at joint level. At presentation with 
arthralgia, 71 out of 350 joints showed subclinical inflammation on 
MRI (Figure 1). Over time, 14 of these 71 joints (20%) had resolution 
of subclinical inflammation, 43 joints (60%) had persistent subclinical 
inflammation, and 14 joints (20%) progressed to clinical synovitis. 279 joints 
(80%) had no subclinical inflammation at baseline imaging.
Next, the absolute total inflammation scores were evaluated. The mean 
change in total inflammation score for all patients was 2.0 points (p=0.008). 
Summing BME, synovitis, tenosynovitis scores (yielding the total 
inflammation score) of the 43 joints that had subclinical inflammation at 
both time-points revealed that 16 joints (37%) had increasing inflammation 
scores (mean increase 1.8 points), 21 joints (49%) had identical 
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inflammation scores and 6 joints (14%) with subclinical inflammation had 
decreasing scores (mean decrease 1.4 points) despite still having scores >0 
for subclinical inflammation.
Most joints developing clinical synovitis had no preceding subclinical 
inflammation at presentation with CSA
In total, 45 MCP, wrist or MTP-joints developed clinically apparent 
synovitis in 21 patients; 20 joints in the feet (MTP) were swollen, 
whereas 25 joints in the hand (MCP or wrist) were swollen. The other 
14 patients had synovitis in ≥1 joint, but these joints were not evaluated 
on MRI. Of these 45 swollen joints, 31 joints (69%) had no preceding 
subclinical inflammation at presentation with arthralgia (Figure 1). A 
GEE investigating if swollen joints with or without preceding subclinical 
inflammation could have dissimilar times to arthritis revealed no difference 
in time intervals (β=1.3; p=0.71). Hence, the absence of preceding subclinical 
inflammation in joints with clinically apparent synovitis was not associated 
with a longer time interval. An MRI-example of a joint developing clinical 
synovitis whereas it showed no subclinical inflammation in the CSA-phase 
is presented in Figure 2A.
Analyses were repeated per inflammatory feature, revealing that 9% 
of joints (4 out of 45) with clinical synovitis had preceding BME in the 
CSA-phase. Similarly, 24% (11 out of 45 joints ) had prior MRI-detected 
synovitis. For tenosynovitis, only the MCP and wrist joints were evaluated: 
36% of joints (9 out of 25) had preceding tenosynovitis (Supplementary 
Figure 1A–C).
Resolution of subclinical inflammation was observed despite progression to IA
14 joints (in 11 different patients) had subclinical inflammation in the CSA-
phase which resolved over time, despite progression to IA at patient-level: 
an MRI-example is provided in Figure 2B.
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However, the majority of joints assessed (N=227/350; 65%) had no 
inflammation at either point in time (Figure 1).
Similar results observed for joints of ACPA-positive and ACPA-negative patients
As the pathogenesis of IA development presumably differs between ACPA-
positive and ACPA-negative disease, analyses were stratified for ACPA 
status. On patient-level, the interval between presentation with CSA and 
IA development was shorter for ACPA-positive disease (median 7 weeks, 
compared to 18 weeks in ACPA-negative disease). However, at joint level 
the percentages of joints that progressed from subclinical inflammation 
to clinical synovitis were similar (Supplementary Figure 2B). Likewise, 
analyses within ACPA-positive disease showed that 62% of joints with 
clinically apparent synovitis had no prior subclinical inflammation in the 
same joint, whereas in ACPA-negative disease this percentage was 72%.
Inflammation corrected for age-matched symptom-free persons yielded 
similar results (5% corrected definition)
Finally, a second definition of presence of MRI-detected subclinical 
inflammation was used. The values of normality of MRI-detected 
joint inflammation depends on age and should take into account the 
occurrence of inflammation in symptom-free persons. Therefore, in this 
second definition (5% corrected definition), subclinical inflammation was 
considered present after correction for the level of inflammation occurring 
in <5% of age-matched symptom-free persons at the same joint and for the 
same feature (a definition used previously [1,13]). With the 5% corrected 
definition, similar findings were obtained (Supplementary Figure 3), with 
the majority of small joints (84%) that developed clinical synovitis having 
no preceding phase lasting for weeks with subclinical inflammation in the 
same joint.
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Discussion
To our knowledge, this study was the first to perform longitudinal 
joint-level analyses in order to investigate progression of inflammation 
in patients converting from CSA to the earliest clinical phase of IA. On 
joint level, only moderate correlations were observed between presence 
of subclinical inflammation and subsequent development of clinical 
synovitis. The majority of joints with clinical synovitis had no subclinical 
inflammation in the same joint at the baseline observation.
The present joint-level observations on inflammatory progression fit 
best with the hypothesis of ‘global deregulation’, rather than that of a 
localized exacerbating process. Previous observations of increased markers 
of systemic inflammation in pre-arthritis phases may support this.[11] 
Additionally, our study showed only moderate correlations between 
inflammation on MRI and progression of synovitis as assessed by physical 
examination, with BME showing the lowest proportion of prior subclinical 
inflammation in the joints progressing to synovitis. Another study found 
that MRI-detected subclinical inflammation on is not only present in 
clinically swollen but also in non-swollen joints; in particular, BME 
frequently occurred in clinically non-inflamed joints.[12] 
Our results should be interpreted within the context of some 
methodological limitations. Considering that 10 joints (unilateral MCP, 
wrist and MTP-joints) per patient were studied, many synovial joints 
were not assessed. Furthermore, the total sample size was limited despite 
large availability of data on joint level. However, this study offers the 
first and largest longitudinal scrutiny of data on joint inflammation in 
arthralgia patients that progress to IA. Finally, the time interval between 
presentation with CSA and IA differed between individual patients, 
posing the possibility of dissimilarities in time intervals for joints with or 
without preceding subclinical inflammation. Nonetheless, a GEE model 
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incorporating each patient contributing 10 joints suggested no differences 
in time to arthritis for joints with or without preceding subclinical 
inflammation, indicating that results were not based on a few patients with 
longer time intervals.
An elementary, but sensitive, definition of subclinical inflammation 
(summed inflammation-score ≥1 per joint) was used. Reference values 
of normality for MRI-detected joint inflammation depending on age, 
inflammatory feature and joint were not included in this definition. When 
subclinical inflammation was defined as inflammation present in <5% of 
age-matched symptom-free persons at the same joint and for the same 
feature (5% corrected definition), similar findings were obtained. 
ACPA-positive and ACPA-negative disease have different risk factors, 
presumed differences in pathogenesis, and known dissimilarities in speed 
in progressing from CSA to IA.[14] However despite these differences, the 
observations on joint level on the relation between subclinical inflammation 
in the CSA-phase and clinical synovitis in the IA-phase were roughly similar 
in both groups. Larger studies validating these findings are required. 
MR-imaging depicts inflammation of different tissues around the joint. 
Stratified analyses showed that clinical synovitis was most often preceded 
by MRI-detected tenosynovitis. This fits previous observations that 
tenosynovitis had the highest predictive accuracy for RA development[1], 
and that tenosynovitis was an initial preclinical change in mouse models 
of arthritis development.[15] Although further studies are needed to 
explore this thoroughly, the combination of these findings suggests that 
tenosynovitis is a very early phenomenon. 
The ability of a clinician to detect swollen joints may be dissimilar between 
different joint groups (MCP, wrist and MTP joints) analysed in this paper. 
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Nevertheless, the number of swollen joints in the feet (MTP: 20 joints) 
was similar to the number of swollen joints in the hand (MCP and wrist: 
25 joints). Future studies could investigate the correlation between MRI-
detected subclinical inflammation in clinically swollen and non-swollen 
joints in the feet versus joints of the hand.
This study evaluated inflammation on MRI-scans in individual joints over 
time. Future studies with serial MR-imaging at more frequent time-points 
(and thus shorter intervals) in patients progressing from arthralgia to RA 
might further increase the understanding of inflammatory processes in 
small joints during IA development. 
In conclusion, this first longitudinal MRI study on joint level during 
progression from CSA to IA indicates that the course of subclinical 
inflammation is variable and showed that the majority of small joints that 
developed clinical synovitis had no subclinical inflammation in the same 
joint at the baseline observation.
Supporting information 
Supplementary data is available at the website of RMD Open, or can be obtained 
by contacting the first author.
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Table 1. Characteristics of the 35 patients at the time of 
presentation with arthralgia and at the consequent time of IA 
development 
Characteristic
Presentation with arthralgia
Age in years, mean (SD) 44 (13)
Female sex, N (%) 25 (71)
Family history of RA, N (%) 12 (39)
Tender joint count (68-TJC), median (IQR) 5 (4 – 10)
Increased CRP (≥5 mg/L), N (%) 6 (19)
Symptom duration (weeks), median (IQR) 17 (9 – 31)
Autoantibody status 
Negative for IgM-RF and ACPA, N (%) 19 (54)
Single IgM-RF-positive (≥3.5 IU/mL), N (%) 6 (17)
Single ACPA-positive (≥7 U/mL), N (%) 2 (6)
Positive for IgM-RF and ACPA, N (%) 8 (23)
At development of inflammatory arthritis
Fulfilled 2010 ACR/EULAR RA classification criteria, N (%) 23 (66)
Swollen joint count (66-SJC), median (IQR) 2 (1 – 5)
1 swollen joint, N (%) 10 (29)
2 swollen joints, N (%) 8 (23)
≥3 swollen joints, N (%) 17 (49)
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Legend: 
ACPA = anti-citrullinated peptide antibody; CRP = C-reactive protein; IgM-RF = 
immunoglobulin M rheumatoid factor; IQR = interquartile range; RA = rheumatoid 
arthritis; SD = standard deviation; SJC = swollen joint count; TJC = tender joint count. 
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Figure 1: Schematic depiction of categories of inflammation in 350 
small joints during progression from Clinically Suspect Arthralgia 
to Inflammatory Arthritis
Legend: 
Presence of subclinical joint inflammation was detected by Magnetic Resonance 
Imaging. An MR inflammation score ≥1 (sum of BME, synovitis or tenosynovitis 
in one joint, average of two readers) was defined as subclinical inflammation. At 
the time of IA development, individual joints could show clinically detectable 
joint swelling at physical examination, while this was per definition not possible 
at presentation with arthralgia. Please note that the Y-axis indicates categories of 
inflammation (below MRI-detection limit of inflammation / above MRI-detection 
limit but under clinical detection limit of synovitis at physical examination / above 
clinical detection limit of synovitis at physical examination (i.e. clinically detectable 
joint swelling)), not absolute MRI-inflammation scores.
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Figure 2: Examples of MR-imaging at presentation with CSA (top 
panel) and at IA development (bottom panel), showing joints that 
(A) from no inflammation to clinical synovitis and, (B) resolution 
of subclinical inflammation.
Legend:  
Presented in A. are: (top panel) left MCP joints with no subclinical inflammation 
as detected by MRI, and (bottom panel) left MCP joints of the same patient 
with synovitis in MCP5 and tenosynovitis in MCP2 and 5. According to clinical 
examination the patient developed clinical synovitis in the left MCP2 (depicted), 
left MCP5 (depicted), left PIP2 and right PIP5 joints (both not imaged). From a 
different patient (B.) are presented: (top panel) right wrist joint with tenosynovitis 
in the extensor carpi ulnaris tendon, and (bottom panel) right wrist joint of the 
same patient without MRI-detected subclinical inflammation despite progression 
to inflammatory arthritis on patient-level. The patient developed clinically 
apparent synovitis in the left PIP3 joint (not imaged). All images were made in T1-
weighted FSE sequence with frequency selective fat saturation in the axial plane 
after gadolinium contrast injection.
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Abstract
Objective: Subclinical joint inflammation in patients with arthralgia is 
predictive for progression to rheumatoid arthritis (RA). However, the time 
course in which bone marrow edema (osteitis), synovitis, and/or tenosynovitis 
progress is unsettled. This longitudinal study assessed the course of MRI-
detected subclinical joint inflammation during progression to RA.
Methods: Patients that progressed from Clinically Suspect Arthralgia 
(CSA) to RA underwent 1.5T MRI of MCP, wrist and MTP-joints at 
presentation with arthralgia and at first identification of synovitis assessed 
through physical examination (n=31). MRIs were evaluated for osteitis, 
synovitis, tenosynovitis, and erosions by two readers, blinded for clinical 
data and order in time. To estimate changes in MRI scores between the 
asymptomatic state and CSA-onset, scores of MRI-features at CSA-baseline 
were compared to scores from age-matched symptom-free persons.
Results: At presentation with CSA, synovitis and tenosynovitis scores were 
higher than scores from age-matched symptom-free persons (p=0.004 
and p=0.001, respectively). ACPA-positive arthralgia patients also had 
increased osteitis scores (p=0.04). Median duration between presentation 
with arthralgia and RA development was 17 weeks. During progression 
to RA, synovitis and osteitis increased significantly (p=0.001 and p=0.036 
respectively), in contrast to tenosynovitis and erosion scores. This pattern 
was similar in both ACPA-subsets, although statistical significance was 
reached for synovitis and osteitis in ACPA-negative, but not in ACPA-
positive RA.
Conclusion: Increased tenosynovitis and synovitis scores at CSA-onset and 
the increase in synovitis and osteitis during progression to RA suggest an 
‘outside-in’ temporal relationship of arthritis development; in particular for 
ACPA-negative RA. For ACPA-positive RA further studies are needed. 
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Background
Rheumatoid Arthritis (RA) can be diagnosed at the time patients present 
with clinically detectable inflammatory arthritis (swollen joints). It is 
known that immunological alterations are present long before that.[1] 
For instance, Magnetic Resonance Imaging (MRI)-detected subclinical 
inflammation is present weeks to months before arthritis becomes clinically 
apparent in patients presenting with Clinically Suspect Arthralgia (CSA) 
and has been shown predictive for RA development.[2] Nonetheless, a 
long-standing question is where inflammation starts in the joint, or in what 
order the different tissues of the joints (synovium, tenosynovium and bone) 
become inflamed during the development of RA.
Several hypotheses about the chronology of arthritis development 
prevail. Firstly, it has been postulated that synovitis is an initial process 
that is succeeded by bone involvement. This is the traditional ‘outside-in 
hypothesis’, presuming that inflammation of the synovium precedes bone 
marrow edema (or osteitis).[3-7] Alternatively, it has been suggested that 
RA is a primary bone marrow disease, which subsequently encroaches 
upon the synovial membrane; this is the ‘inside-out hypothesis’, with 
osteitis preceding synovitis, a hypothesis that has become popular after 
imaging and histological studies had revealed the presence of osteitis 
at locations with MRI-detected osteitis in patients with RA.[4,7,8] It has 
also been hypothesized that these processes could emerge and progress 
simultaneously with microscopic bone canals allowing transduction of 
inflammation from the outside (synovium) to the inside (bone marrow) 
and vice versa.[4,7,9] Finally, mouse models of arthritis development 
have shown that tenosynovitis was the initial preclinical change.[10] 
Extrapolation to humans would suggest that neither synovitis nor osteitis, 
but tenosynovitis is the primary feature of joint inflammation.[10] For the 
development of bone erosions (instead of the development of clinically 
apparent inflammatory arthritis) similar hypotheses have been postulated, 
with the primary inflammation located inside[11,12], or outside the bone 
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respectively.[13] Altogether, temporal relationships are yet unknown and 
can be discovered by longitudinal imaging studies that start in pre-arthritis 
phases of the disease.
To address the question on the chronological order in which the different 
tissues of the joints become inflamed, this longitudinal MRI study 
investigated the course of MRI-detected subclinical joint inflammation 
(synovitis, tenosynovitis, osteitis) and erosions in patients that presented 
with arthralgia and progressed to RA. MRIs were performed longitudinally 
at presentation with arthralgia and at development of RA. Although no 
MRIs were made in the asymptomatic phase of these patients, the MRI-data 
obtained at presentation with arthralgia were compared to data obtained in 
age-matched symptom-free persons, to estimate the course of inflammation 
before presentation with arthralgia. Finally, as anti-citrullinated protein 
antibodies (ACPA)-positive and ACPA-negative RA are considered 
as different disease subsets with differences in the underlying 
pathophysiology, analyses were stratified for ACPA-positive and ACPA-
negative RA to explore if there are differences in the chronological order in 
which different articular tissues become inflamed.
Patients and Methods
Patients
We longitudinally followed patients that presented with Clinically Suspect 
Arthralgia (CSA) between April 2012-September 2016. The Leiden CSA-
cohort consecutively included patients that presented at the rheumatology 
outpatient clinic of the Leiden University Medical Centre without clinically 
evident arthritis, but with recent-onset (<1 year) arthralgia of small joints 
that was considered at risk for RA by their rheumatologists based the 
clinical presentation.[14] A detailed description of the in- and exclusion 
criteria of the Leiden CSA-cohort and the study protocol are described 
in [15]. Absence of clinical arthritis at baseline was ascertained through 
physical examination by an experienced rheumatologist.
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Regular follow-up visits in the cohort were planned at 4, 12 and 24 months. 
If necessary (for instance when the patient experienced more symptoms 
or noticed a swollen joint) patients were seen in between scheduled visits 
by their rheumatologist. Hence, logistics were arranged such that patients 
in this cohort had very easy access to rheumatology care and clinically 
evident inflammatory arthritis was identified at the first opportunity. The 
outcome was clinically apparent arthritis, identified at joint examination 
by an experienced rheumatologist. Previous studies revealed that ~20% 
of patients that presented with CSA progressed to clinically apparent 
inflammatory arthritis.[2] 
For this study we selected the patients included in the CSA cohort that 
developed clinically apparent RA. A flowchart is provided in Figure 1. 
From a total of 416 patients included in the CSA-cohort during the studied 
period, 76 were diagnosed with RA. Serial MR imaging was performed at 
baseline and at arthritis development (but before DMARDs were started). 
Of the 76 RA-patients, serial MRIs were available in 35 patients. In 41 
patients serial imaging was not available because: 4 patients had contra-
indications for gadolinium contrast, 3 patients progressed to RA in a very 
short period of time and 34 patients were lacking serial MR imaging due to 
logistical reasons. 
35 patients were diagnosed with RA and had serial MR imaging available. 
Four out of these 35 patients did not receive a recipe for a DMARD at the 
visit clinical arthritis was identified (3 patients subsequently had resolution 
of arthritis, 1 patients received a recipe the next visit). Thus, in total 31 
patients with a clinical diagnosis of RA and immediate prescription of 
DMARDs were studied. Notably, fulfilment of the 2010 classification 
criteria was not required to define RA as ACPA-negative patients need 
>10 involved joints to fulfil these criteria[16], and this can be hampered 
by DMARD-initiation. Nonetheless, despite this theoretical threshold, 21 
patients (68%) fulfilled the 2010 criteria for RA at arthritis development. 
It is important to note that DMARDs (including corticosteroids) were not 
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prescribed in the phase of arthralgia.
Symptom-free persons
Serial MRIs were not made in the period preceding presentation with CSA. 
To infer on the course of MRI-detected subclinical inflammation over time 
before the phase of CSA, the MRI data from the 31 CSA-patients were 
compared to data from symptom-free persons.[17] Symptom-free persons 
were matched based on age in a 1:2 ratio. These 62 symptom-free persons 
had no history of inflammatory rheumatic diseases, no joint symptoms 
during the last month and no evidence of synovitis at physical examination. 
The persons were retrieved from the general population; the recruitment 
procedure is described in [17]. Because gender (p=0.10), increased BMI 
(p=0.59) and smoking (p=0.21) had no effect on MRI-detected inflammation, 
matching was not performed on these factors.
MRI
Unilateral MRIs of wrist, MCP2–5, and MTP1–5 joints were performed 
at presentation with CSA (most painful side) and at first presentation 
with clinical synovitis (similar side as scanned at baseline). A total of 
18 tenosynovitis locations were scored in each patient: 10 at the wrist, 
including 6 extensor compartments and 4 regions on the volar side (the 
flexor digitorum profundus and flexor digitorum superficialis, the flexor 
pollicis longus, the flexor carpi ulnaris, and the flexor carpi radialis), 
and 8 locations at MCP joints 2–5 (paired flexor tendons and extensor 
tendons of the fingers). An ONI MSK Extreme 1.5T MRI scanner (GE 
Healthcare, Wisconsin, USA) was used, as described previously[2] and 
in the Supplementary Methods. All patients were instructed not to use 
NSAIDs 24 hours prior to MRI, with only seven patients (23%) reporting 
the daily use of NSAIDs at baseline. The serial MRIs were scored blinded 
for clinical data and order in time by two readers for osteitis, erosions, and 
synovitis as described in [19], and tenosynovitis as described in [20]. Mean 
scores of two readers were studied. Additional information on the scoring 
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is provided in the Supplementary Methods. Three readers contributed to 
the scoring of the MRIs. Within-reader intraclass correlation coefficients 
(ICC) and between-reader ICC were all >0.90 and are also presented in 
Supplementary Table 1. Results of MR imaging were not shared with the 
treating rheumatologists.
Analyses
Paired t-tests were used. Longitudinal modelling was performed using 
Generalized Estimating Equations (GEE): the scores of the different 
inflammatory features and erosions were studied over time. The GEE 
models, utilizing an unstructured correlation matrix, corrected for the 
influence of age, gender and time to progression to RA and baseline 
score per feature. Residuals of GEE modelling were checked for normal 
distribution. Statistical analyses were carried out using the Statistical 
Package for the Social Sciences (SPSS, version 23.0). P-values <0.05 were 
considered significant.
Results
Patients
Characteristics of the 31 RA-patients studied were similar to the total 
group of 76 patients diagnosed with RA, except for a lower frequency of 
ACPA-positivity in the studied group (Supplementary Table 2). Baseline 
characteristics of the 31 patients studied are presented in Table 1. The 
mean age was 44 years, 71% was female, the median tender joint count 
(68-TJC) was 5 (interquartile range (IQR): 4–10), 42% was Rheumatoid 
Factor-positive and 29% was ACPA-positive. These characteristics are 
in line with previous research in CSA patients.[15] The median interval 
between presentation with arthralgia and progression to RA was 17 weeks. 
The characteristics of the 31 patients at the time of identification of RA 
are also presented in Table 1. The DMARDs that were initiated after RA 
development are presented in Supplementary Table 3.
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MRI-data at presentation with arthralgia compared to that of age-
matched symptom-free controls 
Compared to age-matched symptom-free persons from the general 
population, CSA patients had increased tenosynovitis (mean 1.7 versus 0.27; 
p<0.001) and synovitis scores (2.2 versus 0.93; p<0.001; Figure 2). Osteitis 
scores (1.9 versus 1.4; p=0.35) and erosion scores (1.7 versus 1.8; p=0.53) were 
not significantly elevated (Figure 2) at presentation with arthralgia.
Inflammation increased during progression from arthralgia to 
rheumatoid arthritis
During progression from arthralgia to RA, the mean osteitis score increased 
from 1.9 to 2.7 (p=0.036), and the mean synovitis score from 2.2 to 3.4 
(p=0.001; Figure 2). Tenosynovitis and erosion scores did not increase 
significantly (mean 1.7 to 2.0; p=0.35 and 1.7 to 1.9; p=0.092, respectively; 
Figure 2). Next, GEE models were constructed, allowing longitudinal data 
comparisons of MRI inflammatory scores. These models corrected for 
gender, age at inclusion, time interval to RA and the score of each feature 
(e.g. osteitis) at presentation with CSA. GEE modelling demonstrated that 
only synovitis scores (β=1.0; p=0.004) were significantly higher at time of 
RA development than at presentation with arthralgia.
Stratification for ACPA-status 
Finally, it was explored if results were different in ACPA-positive and ACPA-
negative RA patients, although absolute numbers were small (n=9 and n=22, 
respectively). ACPA-positive patients had higher osteitis scores (p=0.04), 
synovitis scores (p<0.001) and tenosynovitis scores (p<0.001) at presentation 
with arthralgia, as compared to age-matched symptom-free persons. ACPA-
negative patients had higher synovitis scores (p=0.02) and tenosynovitis 
scores (p=0.001), but the osteitis score was not different (p=0.24). Erosion 
scores were not different from age-matched symptom-free persons in both 
ACPA-positive and ACPA-negative patients at presentation with arthralgia.
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Over time, during progression from arthralgia to RA, ACPA-status did 
not change for any of the patients. In ACPA-negative patients, osteitis and 
synovitis score increased significantly (1.1 to 1.7; p=0.03 and 1.8 to 2.9; 
p=0.003, respectively) during progression from arthralgia to RA, whereas 
tenosynovitis and erosion scores remained stable (Figure 3). In ACPA-positive 
patients no statistical significance was obtained but osteitis scores increased 
from 3.6 to 5.2 (p=0.22), and synovitis from 3.1 to 4.5 (p=0.13). Tenosynovitis 
scores were 1.7 and 2.3 (p=0.32) and erosion scores were 2.4 and 2.6 at 
presentation with arthralgia and RA respectively (p=0.62; Figure 3). 
Finally, analyses were repeated for autoantibody positive (positive for 
either RF and/or ACPA; n=16) and auto-antibody negative patients (n=15). 
Similar results were obtained as for ACPA-positive and ACPA-negative 
RA-patients as described above (data not shown).
Discussion
In order to increase the understanding of the chronological order of joint 
inflammation during the development of RA, serial MRIs were made 
in RA-patients at the time of presentation with arthralgia and at first 
identification of RA. This revealed that synovitis and osteitis increased 
during the symptomatic pre-arthritis phase. In addition, data on MRI-
detected subclinical inflammation obtained at presentation with arthralgia 
were compared with data from age-matched symptom-free persons. This 
showed that synovitis and tenosynovitis scores were higher in patients 
with arthralgia, suggesting that these features had already increased at 
presentation with arthralgia. The erosion scores did not increase, neither 
in the asymptomatic nor during the symptomatic phase preceding the 
identification of RA. Together, these results suggest that tenosynovitis and 
synovitis are the earliest inflammatory features. Subsequently, synovitis 
and osteitis increased over time in the symptomatic pre-arthritis phase, 
whereas erosions did not yet increase before RA had become apparent. 
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This implies that inflammation mainly starts outside the bone (fitting the 
outside-in hypothesis), after which osteitis develops, which poses the joint 
at risk for structural damage development in the phase of clinically evident 
RA (if left insufficiently treated).
Stratification for ACPA-status showed that synovitis and osteitis progressed 
similarly during the symptomatic pre-arthritis phase in both ACPA-
subsets, but that ACPA-positive arthralgia patients already had higher 
osteitis scores at presentation with arthralgia. This could be explained 
by a longer symptom duration of ACPA-positive patients at presentation 
with arthralgia: median symptom duration at baseline was 22 weeks in 
ACPA-positive CSA patients, and 15 weeks in ACPA-negative CSA patients 
(Supplementary Table 3). As established previously, ACPA-positive 
RA has a more gradual onset of symptoms.[21] ACPA-positive patients 
may, therefore, have presented in a slightly later phase of the disease. 
Alternatively, this finding could also imply a different chronology of joint 
inflammation in ACPA-negative and ACPA-positive RA, with osteitis being 
one of the first inflammatory features in ACPA-positive RA. This could be 
in line with the associations of autoantibody status and osteitis scores as 
observed in the phase of classifiable RA.[22] 
There are several limitations to this study. A limitation is that the analyses 
were done on the sum of synovitis, osteitis and tenosynovitis scores 
observed in 310 joints, 1023 bones and 868 tendons. Whilst it would be 
interesting to perform similar analyses on individual joint/bone/tendon 
level, this was not done because of low numbers of joints/bones/tendons 
with subclinical inflammation. Larger studies are needed to this end.
Another limitation is the sample size. Although all patients that developed 
RA from a total cohort of consecutive CSA patients (with serial MR imaging 
available) were studied, the absolute number (n=31) is rather small. Future 
longitudinal imaging studies are therefore required to validate the results. 
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Nonetheless, the present study is the largest longitudinal MRI study in a 
population of patients that converted from arthralgia to RA that is available 
to date.
Analyses were stratified for ACPA to explore differences between these 
subgroup, although especially the ACPA-positive subgroup was rather 
small. This may be explained by more intramuscular corticosteroid 
injections in ACPA-positive patients, preventing the performance of an 
MRI before DMARD initiation. Larger future studies, especially in ACPA-
positive convertors are needed.
Another limitations is that MRIs were made at first presentation with 
CSA and at development of RA, but no scans were made in between. 
Furthermore, patients were included at first presentation with clinically 
suspect arthralgia and were not scanned in an asymptomatic phase. 
Although some information on the chronology of joint inflammation in 
this disease phase was obtained by comparison of data obtained in age-
matched symptom-free persons, this analysis was cross-sectional in nature 
and therefore less reliable than longitudinally collected data. Hence, future 
longitudinal imaging studies would be still highly relevant to further 
increase our understanding of RA development. 
In our study, T1-weigthed fat suppressed sequences were obtained. These 
were previously demonstrated has a strong correlation with T2-weighted 
fat suppressed sequences in three studies.[23–25] Furthermore, persistent 
osteitis was strongly associated with erosive progression using these 
sequences.[11] Taken together, these findings demonstrate the osteitis is 
an established risk factor for the development of articular bone erosions 
regardless of the acquired sequence. The lack of finding a significant 
increase in osteitis scores between asymptomatic persons and arthralgia 
patients is more likely to be caused by the (early) disease stage in which 
the patients were assessed than a difference due to the scanning protocol. 
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Nevertheless, replication of our results using T2-weighted fat suppressed 
sequences is warranted.
Future serial imaging studies performed in the asymptomatic phase until 
development of RA would be useful to further elucidate the chronology 
in which the different articular tissues become inflamed. However, 
this cannot be easily accomplished as the 5-year positive predictive 
value of ACPA in the general population is approximately 5%.[26,27] 
Consequently, 20 symptom-free ACPA-positive persons would need to be 
followed for several years with serial MRIs to acquire longitudinal data 
of one RA patient. Studying 30 ACPA-positive RA patients already in the 
asymptomatic phase would require serial imaging in ~600 ACPA-positive 
symptom-free persons during several years of follow-up. Hence, although 
challenging, studying temporal relationships of inflammatory features 
during progression from the asymptomatic to the symptomatic pre-arthritis 
phase is a subject for follow-up research.
Animal studies have demonstrated that tenosynovitis was the earliest 
inflammatory joint feature in murine models.[10] Studies in CSA patients 
have also revealed that, of all three inflammatory features, tenosynovitis is 
the strongest predictor for RA development.[2] The current data, showing 
that tenosynovitis is a very early phenomenon, denotes the importance 
of inflammation of synovial tendon sheaths in very early phases of RA 
development.
The erosion score did not increase in the pre-arthritis phase, in contrast 
to the osteitis score. Previous research has revealed that osteitis that 
persisted in the early clinical phase of RA was strongly associated with 
erosion development (OR ~60) at the same location.[11] CSA-patients in 
this study had very early access to rheumatologic care in case of symptom 
deterioration or if they suspected joint swelling. Therefore, we expect that 
patients were seen very shortly after clinical synovitis had developed. In 
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addition, the median duration to development of RA was relatively short 
(17 weeks). Both factors may explain why articular bone erosions were not 
(yet) increased during the studied period. Based on MRI-data collected in 
early arthritis patients[11], we anticipate that the bones with osteitis at RA 
presentation were at risk for development of erosions, but the time period 
was too brief for actual erosive progression. This is in line with previous 
studies showing that MRI detected erosions predominantly developed in 
joints with persistent osteitis.[11] 
Imaging using ultrasound (US) can be used to assess the presence of 
synovitis and tenosynovitis. Our data, obtained in the earliest disease 
phases, could suggest that US could suffice for assessment of these features. 
However, ultrasound cannot depict osteitis which may also provide 
valuable information. Studies in larger patient groups are needed before 
the present findings can be translated to clinical practice, though the 
present data contributes to our understanding of clinical arthritis and RA 
development.
Conclusions
In sum, the data provided on RA-patients suggests an increase of 
tenosynovitis and synovitis scores before the onset of arthralgia. Our 
study demonstrated that synovitis and osteitis scores increased during 
progression from arthralgia to clinical arthritis, suggesting an ‘outside-in’ 
temporal relationship of arthritis development, particularly in ACPA-
negative RA. For ACPA-positive RA further studies are needed.
Supplementary information 
Supplementary data is available at the website of Arthritis Research & Therapy, or 
can be obtained by contacting the first author.
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Table 1. Characteristics of the RA-patients at presentation with Clinically Suspect Arthralgia and at first 
identification of clinical arthritis and age-matched symptom-free volunteers 
At presentation with 
arthralgia (n=31)
At presentation with RA 
(n=31)
Age-matched symp-
tom-free volunteers (n=62)
Age in years, mean (SD) 45 (14) -- -- 44 (13)
Female sex, n (%) 22 (71) -- -- 38 (61)
Symptom duration in weeks, median (IQR) 17 (9-32) -- -- n/a
Presence of morning stiffness ≥60 minutes, n (%) 11 (35) 24 (77) 0 (0)
68-TJC, median (IQR) 5 (4–9) 7 (5–12) 0 (0–0)
66-SJC, median (IQR) 0 (0–0) 2 (1–5) 0 (0–0)
Increased CRP (≥5 mg/L), n (%) 6 (19) 7 (29) n/a
Autoantibody status 
IgM-RF-positive (≥3.5 IU/mL), n (%) 13 (42) 13 (42) n/a
ACPA-positive (≥7 U/mL), n (%) 9 (29) 9 (29) n/a
Any antibody-positive (either RF or ACPA) 16 (52) 16 (52) n/a
Legend: 
ACPA = anti-citrullinated peptide antibody; CRP = C-reactive protein; IgM-RF = immunoglobulin M rheumatoid factor; IQR 
= interquartile range; N/A = not applicable or not assessed; RA = rheumatoid arthritis; SD = standard deviation; SJC = swollen 
joint count; TJC = tender joint count.
Figure 1. Flowchart of selection of RA patients studied from the total CSA cohort
Legend: 
Patient characteristics of the different groups are provided in Supplementary Table 2.
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Figure 2. MRI features of joint inflammation and erosions in 
patients that developed RA
Legend: 
MRIs were performed at presentation with arthralgia and at diagnosis of RA. MRIs 
were not made in the asymptomatic phase but the course of local inflammation 
before presentation with arthralgia was estimated by comparisons with age-
matched symptom-free persons (1:2 ratio to patients). Since these data were not 
measured longitudinally, data are presented in dashed lines. * indicates statistical 
significance at p<0.05 level.
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Figure 3. MRI features of joint inflammation and erosions in 
patients that developed RA stratified for ACPA status
Legend: 
MRIs were performed at presentation with arthralgia and at diagnosis of RA. MRIs 
were not made in the asymptomatic phase but the course of local inflammation 
before presentation with arthralgia was estimated by comparisons with age-
matched symptom-free persons (1:2 ratio to patients). Since these data were not 
measured longitudinally, data are presented in dashed lines. * indicates statistical 
significance at p<0.05 level for a paired t-test.
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Abstract
Introduction: Arthralgia and MRI-detected subclinical inflammation can 
precede development of clinically evident Rheumatoid Arthritis (RA). 
However, part of the patients presenting with Clinically Suspect Arthralgia 
(CSA) do not progress to RA. In these ‘non-progressors’, we aimed to study 
frequencies of spontaneous improvement of arthralgia, and its relation with 
the course of subclinical inflammation.
Methods: Between April 2012-April 2015, 241 patients were considered at 
risk for RA based on the clinical presentation and included in the CSA-
cohort. 152 patients with complete data on clinical follow-up did not 
develop clinical arthritis, of which 98 underwent serial 1.5T MRI-scans 
(wrist, MCP2-5, and MTP1-5 joints) at baseline and after two-years. MRI-
scans were scored for synovitis, tenosynovitis and bone marrow oedema 
(summed: MRI-inflammation score). MRI-scores were compared to scores 
of symptom-free persons.
Results: After two-year follow-up, 33% of the ‘non-progressors’ had 
complete resolution of symptoms; 67% had no symptom resolution 
and were diagnosed as: persistent CSA (44%), osteoarthritis (10%) and 
tendinomuscular complaints (13%). With symptom-free controls as 
reference, patients without resolution did not have increased MRI-scores 
at any time-point. However, patients achieving resolution of symptoms 
had increased MRI-inflammation scores at baseline (4.0 vs. 2.6, p=0.037), 
but not after two-years (3.0 vs 2.6; p=0.57) and during follow-up their MRI-
inflammation score decreased significantly (p=0.036). 
Conclusions: A subgroup of CSA-patients that did not progress to RA had 
spontaneous improvement of symptoms and resolution of subclinical 
joint inflammation. This time-relationship suggests that symptoms and 
inflammation were causally related in these patients. Further research is 
needed to identify mechanisms underlying resolution of inflammation.
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Introduction
Rheumatoid arthritis (RA) can be preceded by a phase of preclinical disease 
with signs and symptoms, in which joint swelling cannot yet be identified 
through physical examination.[1] More than 90% of patients that develop 
RA had MRI-detected subclinical inflammation in small joints in the 
symptomatic phase of Clinically Suspect Arthralgia (CSA). However, of all 
patients that are identified as having CSA, a large part (up to 80%) do not 
progress to clinically evident RA.[1] Thus far, most longitudinal studies 
performed in patients considered at risk for RA focussed on progression 
from arthralgia to RA[1,2], since (early) identification of individuals that 
will develop RA is a key point from a clinician’s perspective. However, 
there is also a group of patients that were considered at risk for RA but 
over time do not develop RA, meaning that in hindsight they possibly 
have not been truly ‘pre-RA’. This subgroup of patients is unexplored and 
the course and outcome of joint symptoms and subclinical inflammation 
in these patients is yet unknown. From a clinical perspective, knowledge 
of the course of these symptoms could be useful. Moreover, despite non-
progression, subclinical joint inflammation could be present in (part of) 
these patients at first presentation and comprehension on the natural 
course and severity of subclinical inflammation, and its relationship with 
spontaneous disappearance of arthralgia, increases our understanding on 
spontaneous resolution occurring in patients at risk phases of RA. 
Longitudinal studies performed in the disease phase of early 
undifferentiated arthritis (UA) have shown that clinical synovitis 
resolved spontaneously in 10–40%, without intervention with disease-
modifying antirheumatic drugs (DMARDs).[3,4] Based on these data, it 
can be hypothesized that a similar (or even larger) percentage of patients 
with CSA will show spontaneous resolution of joint symptoms. In 
addition, as arthralgia is associated with the presence of local subclinical 
inflammation[5], it could be hypothesized that there is a causal relation and 
that resolution of symptoms is connected to improvement of subclinical 
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inflammation presuming. Furthermore, it could be presumed that patients 
with persistent symptoms had more severe subclinical inflammation at 
presentation and during follow-up compared to patients with symptom 
resolution.
We aimed to increase understanding of the course of symptoms in 
patients that presented with CSA but did not progress to RA. Therefore 
the percentage of patients with symptom resolution and with persistent 
symptoms during two-year follow-up were determined. The scores of 
MRI-detected inflammation, and the time relationship with evanescence 
of symptoms, were studied. Finally MRI-data were compared to MRI-
data obtained from age-matched symptom-free persons from the general 
population to estimate if MRI-detected joint inflammation returned to 
normal values.
Methods
Patients
Between April 2012-April 2015, 241 patients were included in the CSA cohort: 
CSA patients had no clinically evident arthritis, but recent-onset (<1 year) 
arthralgia of small joints that was clinically considered at risk for RA by the 
rheumatologist at first presentation at the outpatient clinic. The cohort has 
been described before in [6]. Routine follow-up visits were performed at 4, 
12 and 24 months. If necessary (for instance when the patient experienced 
more symptoms or noticed a swollen joint) patients were seen in between 
scheduled visits by their rheumatologist. Hence, logistics were arranged 
such that patients in this cohort had very easy access to rheumatologic care; 
should a patient develop clinically evident IA, this was identified at the first 
opportunity. None of the patients were treated with DMARDs (including 
corticosteroids) during the course of the study. At the baseline visit, IgG ACPA 
(EliA CCP (anti-CCP2), Phadia, Nieuwegein, the Netherlands) and IgM RF 
(as described previously, in-house ELISA[7]) were determined. The cut-off for 
ACPA positivity was >7 U/ml, and for RF positivity it was >3.5 IU/ml.
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A flowchart of inclusion is provided in Figure 1. As this study focused 
on patients that did not convert to RA over time, 45 patients that were 
diagnosed with RA during follow-up (clinical synovitis identified at 
physical examination by experienced rheumatologists, 19% out the total 
n=241) were excluded. From the subsequent total of 196 eligible patients, 
44 patients were excluded because of inappropriate inclusion (n=5), or 
were lost to follow-up during the two-year course of the study (n=39). This 
resulted in complete clinical and follow-up data in 152 patients. Of these, 
98 patients also had complete serial imaging data at two-year follow-up. 
Reasons for incomplete serial imaging were: contra-indications for contrast-
enhanced MR-imaging or not willing to undergo (repeated) MR-imaging. 
Indications of potential selection bias at the different stages of the flowchart 
(n=241: all patients presenting with CSA, vs. n=196: eligible non-converting 
patients, vs. n=152: non-converting patients with complete follow-up data, 
vs. n=98: non-converting patients with complete follow-up data and serial 
imaging) were evaluated by comparing baseline characteristics between 
different patient groups. All patients provided written informed consent. 
Ethics approval was provided by the local medical ethical committee.
Assessment of symptom resolution 
The main outcome was patient-reported resolution of symptoms. This 
was assessed at the routine follow-up visits by asking patients to answer 
a written question if they considered their symptoms completely resolved 
or not (by literally inquiring: “are your symptoms still present”; yes or no). 
Patients in whom initial presenting features were resolved, but with new 
joint symptoms were classified in the non-resolution group. Resolution of 
any related symptom (as judged by patients themselves) at the 24 months 
visit was used as definition for symptom resolution. 
In addition to this main outcome, pain scores on a Visual Analogue Scale 
(VAS: scale 0–10) were collected to evaluate the robustness of the main 
outcome; the course in VAS pain was also studied. Furthermore, 68 tender 
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joint counts (68-TJC) were studied. After two years without conversion 
to clinical arthritis, patients were mostly referred back to their GP with a 
clinical conclusion, unless rheumatologist and/or patients felt that longer 
follow-up at the rheumatology outpatient clinic was required. The clinical 
diagnosis after 2-years was also studied.
Symptom-free persons
To make inferences on the presence and severity of MRI-detected 
subclinical inflammation as compared to the general population, MRI data 
from the 98 CSA-patients were matched to data of MRI-detected subclinical 
inflammation from symptom-free persons.[8] Matching was based on age 
in a 1:1 ratio, since age was previously proven to influence the severity 
of MRI-detected subclinical inflammation[9]. Since sex was previously 
demonstrated to have no effect on MRI-detected inflammation[8,10] 
matching was not performed on sex. The 98 symptom-free persons had 
no history of inflammatory rheumatic diseases, no joint symptoms during 
the last month and no evidence of synovitis at physical examination. The 
symptom-free persons were recruited from the general population, as 
described in [8]. 
MRI 
Unilateral MRIs of wrist, MCP2–5, and MTP1–5 were performed 
at presentation with CSA (most painful or in case of equally severe 
symptoms the dominant side) and at two-year follow-up (when follow-
up ended) of that same side. An ONI MSK Extreme 1.5T MRI scanner (GE 
Healthcare, Wisconsin, USA) was used, as described previously[1] and in 
the Supplementary Methods. Patients were instructed not to use NSAIDs 
24 hours prior to MRI, with 22 patients reporting daily use of NSAIDs 
at baseline. MRIs were evaluated for bone marrow oedema (BME; range 
0–72), synovitis (range 0–33) [11], and tenosynovitis (range 0–54) [12]. These 
three features were summed in the total MRI-inflammation score. Each MRI 
was scored by two readers, who belonged to a pool of four experienced 
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readers (all had interclass correlations ≥0.90, see Supplementary Table 1). 
The mean scores of two readers was studied. All readers were blinded to 
clinical data and the order in time. MRI data were never reported to the 
clinicians in any phase of the study. Additional information on the scoring 
method is provided in the Supplementary Methods.
Analyses
Unpaired t-tests were used to compare patients with symptom-free 
persons. For analyses over time, paired t-tests were used. To evaluate if 
MRI-inflammation scores changed over time, analyses using measures of 
MRI-detected subclinical inflammation were confined to patients with a 
baseline total MRI-inflammation score of >0, as a baseline score of 0 would 
not be able to further decrease. 82 patients (84%) had a baseline MRI with a 
total MRI-inflammation score >0 (Figure 1). 
For consistency, total MRI-inflammation scores on group-level for the same 
82 patients were compared to scores of age-matched symptom-free persons. 
Furthermore, a sub-analysis within autoantibody-positivity (ACPA- and/or 
RF-positive; 19% of patients) CSA-patients was applied. Finally, sensitivity 
analyses were performed on the patients meeting the EULAR definition 
of arthralgia suspicious for progression to RA with ≥3 points (n=63).
[13] Statistical analyses were carried out using the Statistical Package for 
the Social Sciences (SPSS; version 23.0). P-values <0.05 were considered 
significant. Total MRI-inflammation scores are reported as mean.
Results
Patient characteristics 
The baseline characteristics of patients at the different stages in the 
flowchart (Figure 1) did not show relevant differences, as shown in Table 1. 
Baseline characteristics of the patients with complete clinical follow-up and 
156 Chapter 9
MRI data at baseline and at two-year follow-up (n=98) are demonstrated 
in Table 2. Patients presenting with CSA that did not progress to RA were 
female in 74%, had a mean age of 47 years, a median 68-TJC of 5 joints, 
and 19% carried RA-related autoantibodies (RF and/or ACPA). These 
characteristics are comparable with previous reports on patients from 
the Leiden CSA cohort[1,14], although the percentage of autoantibody-
positive patients was lower in this study in non-progressors, since the 
presence of autoantibodies is a risk factor for progression to RA[1,14] 
and autoantibodies were thus less often observed in the non-converting 
patients. MRI-detected inflammation was not associated with increased 
C-reactive protein levels (p=0.38).
Resolution of symptoms over time
In the total group of 152 non-converting patients, 38% (57 patients) indicated 
to have resolution of symptoms after two years follow-up and 63% (95 
patients) had no symptom resolution. Similarly, in the group of 98 patients 
with serial imaging, 33% of patients (n=32) reported resolution of symptoms 
whereas 67% (n=66 patients) did not. In addition, in the 54 patients without 
serial MRIs, 25 experienced symptom resolution (46%) whereas 29 patients 
did not experience resolution of symptoms (54%). A chi-squared test 
comparing the number of patients experiencing symptom resolution in 
the groups of patients with and without serial MRI showed no significant 
difference (p=0.09). The percentages of patients with complete clinical and 
imaging data indicating to experience resolution of symptoms (n=32) at the 
follow-up visits at 4, 12, and 24 months are indicated in Figure 2. 
Within the patients that had complete clinical and MRI data, the patients 
that indicated to have resolution of symptoms had a larger decrease in 
VAS pain scores over time than patients without resolution of symptoms 
(decrease in VAS pain of 2.9 versus 0.77; p<0.001; Figure 3). At baseline, 
the median 68-TJC was 4 in patients with resolution and 6 in patients 
without resolution. After 2 years the median TJC was 0 in the patients with 
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symptom resolution, while this was significantly higher in the patients 
without symptom resolution (Mann-Whitney U test: p=0.02). Several 
other characteristics of both groups evaluated at two-year follow-up 
are presented in Table 3. Although resolution of symptoms was initially 
assessed with one question, these results show that patients that reported 
to have symptom resolution improved in other measures for pain.
Patients with remaining symptoms were diagnosed as: persistent CSA 
because of persistent inflammatory type of arthralgia according to the 
rheumatologists (n=43; 44% of all non-converters), osteoarthritis (n=10; 10% 
of all non-converters) and tendinomuscular complaints (n=13; 13% of all 
non-converters). 
At disease presentation, the proportion of patients that used NSAIDs on 
a daily basis was equally distributed between patients with or without 
resolution of symptoms (22% versus 23%; p=0.89). After two-year follow-
up, 9% of the patients with persistent symptoms used NSAIDs on a daily 
basis, whilst NSAIDs were not used in the group with symptom resolution, 
which is in line with absence of symptoms.
Clinical characteristics of patients with and without symptom resolution
Patients that later-on achieved symptom resolution had no differences 
in baseline characteristics at baseline; Table 2 displays the patient 
characteristics for the 152 non-converting patients with complete clinical 
follow-up data, as well as the 98 non-converting patients with serial MRIs. 
The mean baseline total MRI-inflammation score was slightly higher 
in patients that would eventually achieve symptom resolution (3.5) as 
compared to patients with persistent symptoms (2.7), but this was not 
statistically significant (p=0.33). 
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Association between symptom resolution and improvement of MRI 
inflammation
The mean total MRI-inflammation scores of the 82 patients with a baseline 
total MRI-inflammation score >0 were compared to MRI-scores of similar 
age-matched symptom-free persons to infer if the MRI-inflammation 
scores at the different time points exceeded the level of MRI-detected 
inflammation prevalent in the general population. Other characteristics of 
the symptom-free persons are provided in Supplementary Table 2. 
In the group of CSA patients that achieved resolution of symptoms over 
time, the mean MRI-inflammation score was higher than that of symptom-
free persons at baseline (4.0 vs 2.6; p=0.04; Figure 4). In contrast, the 
patients that did not report resolution of symptoms did not have higher 
MRI inflammation scores at baseline (mean 3.3 and 2.9 respectively; p=0.26; 
Figure 4). 
After two-year follow-up, the mean total MRI-inflammation score in 
patients with resolution of symptoms decreased to a level similar to that of 
symptom-free persons (3.0 vs 2.6; p=0.57; Figure 4), whereas the patients 
without resolution of symptoms still had no differences in their total MRI-
inflammation scores (mean 2.7 vs 2.9; p=0.68; Figure 4). Comparison of 
the individual inflammatory features as detected by MRI are provided in 
Supplementary Figure 1; the decrease in total MRI-inflammation-score was 
mostly due to decrease in tenosynovitis and synovitis.
Finally, the difference of the total MRI-inflammation scores over time 
were evaluated between baseline and two-year follow-up (Figure 4). The 
CSA patients with resolution of symptoms had a statistically significant 
decrease in MRI-inflammation score (difference 0.98; paired t-test: p=0.036). 
In the CSA patients that did not convert to RA and had no resolution of 
symptoms the decrease was smaller (difference 0.44) and did not reach 
statistical significance (paired t-test: p=0.09). 
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Together, in patients with resolution of symptoms, MRI inflammation 
scores were increased at first presentation and normalized after symptom 
resolution, whereas patients that remained having symptoms (but did not 
progress to RA) did not have increased inflammation scores at any time 
point, with age-matched controls as reference. 
Although the group of patients without resolution of symptoms was 
a heterogenous group in terms of final diagnosis, none of the separate 
diagnoses had a significant difference in MRI-inflammation score over 
time: persistent CSA (p=0.37), osteoarthritis (p=0.60), and tendinomuscular 
complaints (p=0.79). Separate matching of the patients with persistent 
CSA compared to symptom-free persons revealed no differences in total 
MRI-inflammation score at baseline (3.4 vs 2.8; p=0.25), or at two-year 
follow-up (2.6 vs 2.8; p=0.83). Matching of patients finally diagnosed with 
osteoarthritis and tendinomuscular complaints with symptom-free persons 
was not performed due to small patient numbers.
Sub-analyses: autoantibody-positive patients 
Although the presence of autoantibodies in CSA is associated with an 
increased risk on RA development, part of the patients with autoantibodies 
did not progress. In line with previous studies that reported a PPV of >60% 
for ACPA-positive patients[1,14], part of the autoantibody-positive patients 
did not progress to RA during two-year follow up. In our data 19% of the 
non-converting patients were either ACPA- or RF-positive. There was no 
conversion in ACPA- or RF-status in any direction over 2 years’ time. 
Within the group of ACPA- or RF-positive non-converting patients (n=19), 
7 patients (37%) had symptom resolution over time and 12 patients (63%) 
had no resolution of symptom. The total MRI-inflammation score decreased 
from 5.0 to 3.3 (difference 1.8; paired t-test: p=0.21) in the patients with 
resolution of symptoms. In the patients without resolution of complaints, 
the total MRI-inflammation score reduced from 2.4 to 1.9 (difference 0.55; 
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paired t-test: p=0.19). Comparison of MRI-scores with symptom-free 
persons, as stratified by resolution of symptoms, was not performed due to 
insufficient statistical power.
Sensitivity analysis: patients meeting the EULAR definition 
A sub-analysis was performed in the patients that met the EULAR 
definition of arthralgia suspicious for progression to RA.[13] 64% of the 
CSA patients that did not develop RA fulfilled the EULAR definition of 
arthralgia suspicious for progression to rheumatoid arthritis with ≥3 items 
present. Also in this subgroup, 37% of the patients achieved spontaneous 
resolution of symptoms. 
Similar findings were obtained when patients meeting the EULAR 
definition and with a baseline total MRI-inflammation score >0 were 
compared to MRI-scores of similar age-matched symptom-free persons. 
The patients experiencing resolution had higher MRI-inflammation scores 
at disease presentation than symptom-free controls (p=0.04), while the 
scores were no longer increased at the time of symptom resolution (p=0.53). 
Patients without resolution of symptoms (that did not progress to RA) did 
not have significantly increased MRI-inflammation scores at any time point 
(Supplementary Table 3). Over time, MRI-inflammation scores decreased 
in the patients with symptom resolution, (4.6 to 3.1; p=0.02). In patients 
without symptom resolution, scores did not decrease: 3.3 to 3.2; p=0.67.
Discussion
Patients with Clinically Suspect Arthralgia are considered to be at risk for 
RA development by their rheumatologists. Most research done in the field 
of “RA risk” is focussed on the subgroup of patients that indeed progress to 
RA. However, a large proportion of the patients that are considered to have 
an increased risk do not actually develop IA and RA. Here, we studied 
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the group of non-converting patients and observed various outcomes. A 
considerable part of the patients that initially had presented with CSA 
continued to be characterized as CSA after two-year follow-up. A smaller 
part of the patients developed other explanations for their complaints. 
Interestingly, both latter groups of patients did not have increased MRI-
inflammation scores of small joints as compared to age-matched symptom-
free persons. Furthermore, approximately one-third of the non-converting 
patients had resolution of symptoms over time. These patients had 
increased MRI-detected subclinical inflammation at baseline, which also 
resolved over time. This time relationship suggests that the subclinical 
inflammation was related to the presence of symptoms and the phenotype 
of CSA. In our view, this is the most interesting group of patients: these 
patients may indeed have been pre-RA but one of several final switches 
required for actual progression to RA were not turned “on” and the disease 
process resolved without intervention.
Our study is the first to quantify the percentage of patients presenting 
with CSA that will have resolution of symptoms over time. It consists 
of one-third of all non-progressing patients and 27% of all patients that 
were identified as having CSA by rheumatologists. Interestingly, previous 
studies done in patients with UA showed that clinical synovitis resolved 
in 10–40%[3,4], which is a similar range of spontaneous dissolvement. 
Similar as seen here, patients with spontaneous resolution were more often 
autoantibody-negative than patients with progression to arthritis. Despite 
the association with the absence of autoantibodies, the pathophysiologic 
mechanisms mediating spontaneous resolution or absence of progression 
are not elucidated yet. Our study served to identify this group of patients. 
Future studies are required to increase our understanding on the biological 
mechanisms involved.
This study had several limitations. First, patients were analysed during 
two-year follow-up and patients that did not progress to RA could still 
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develop IA after the follow-up of the study ended. However, as the Leiden 
University Medical Centre is the only referral centre in the region, it is 
unlikely that patients will visit another centre should symptoms reoccur. 
This allowed us to study if patients had returned to our Rheumatology 
department after the formal final regular follow-up visit at two years. 
After an average of 5 years after the baseline visit, none of the patients 
had returned to be diagnosed with RA, indicating that patients truly did 
not develop RA. In addition, patients that had indicated that symptoms 
had disappeared after two years could theoretically experience renewed 
symptoms later-on in life. However, this would not affect the current 
findings that resolution of symptoms was paralleled by resolution of 
subclinical inflammation. 
A further limitation of our study is the small number of patients included. 
Especially the number of patients that was ACPA-positive and not 
progressed to RA is small, which warrants future studies with larger 
numbers of included patients to allow statistically more powerful analyses 
than our current, mostly exploratory, analyses.
Another limitation is that part of the patients did not complete follow-up, 
or did not consent to undergo another MRI. Although missing data was 
presumably not at random as patients with less severe symptoms are more 
likely to retract from follow-up, the patient characteristics of the different 
groups were quite similar (Table 1), arguing against a major bias. However, 
the percentage of patients experiencing symptom resolution in the group 
that did not have complete imaging data over two years was slightly larger 
(46%) than the percentage of patients with complete imaging data (33%) 
which could be a potential source of bias, although the difference was 
not significantly different. Possibly patients who experienced symptom 
resolution slightly less often felt the need to undergo imaging studies after 
two years. 
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Finally, since patients with baseline MRI-scores of >0 were studied, 
regression to the mean could have occurred. Furthermore, scores of MRI-
detected inflammation were studied on a group-level rather than joint-
level to decrease the possibility of type 1 error due to multiple testing. 
Nevertheless, we demonstrated that baseline scores in the patients with 
resolution significantly exceeded the level of MRI-detected subclinical 
inflammation of symptom-free persons, but not in the patients without 
resolution of symptoms.
The main outcome was patient-reported resolution of symptoms. No 
validated questionnaire exists of patients with arthralgia at risk for 
RA and we assessed this outcome using a single written question. The 
robustness of this outcome was illustrated by decreasing VAS pain scores 
and diminishing tender joint counts in the patients with resolution and 
therefore we considered this to be a valid question that was interpreted 
well and uniformly by patients themselves. 
Finally, DMARD therapy (including steroids) was not allowed and not 
prescribed during the course of the CSA study, but NSAIDs were allowed. 
NSAIDs were stopped before MR-imaging. It could be questioned if 
NSAIDs played a role in disease resolution. However, NSAIDs are 
generally not considered as disease-modifying therapy, and the frequency 
of NSAIDs use at baseline was similar in the patients with and without 
symptom resolution. 
In conclusion, one-third of all patients with CSA that did not convert to 
IA or RA during two-year follow-up had resolution of symptoms and 
improvement of subclinical joint inflammation. This time relationship is 
suggestive for a causal relation of the subclinical inflammation and the 
phenotypic presentation of CSA. Further research is needed to identify 
mechanisms that are involved in resolution of disease processes.
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Supplementary information 
Supplementary data is available at the website of Arthritis Research & Therapy, or 
can be obtained by contacting the first author.
165Chapter 9
9
References
1  van Steenbergen HW, Mangnus L, 
Reijnierse M, et al. Clinical factors, 
anticitrullinated peptide antibodies and 
MRI-detected subclinical inflammation 
in relation to progression from clinically 
suspect arthralgia to arthritis. Ann 
Rheum Dis 2016;75:1824–30. doi:10.1136/
annrheumdis-2015-208138
2  Nam JL, Hunt L, Hensor EMA, et al. 
Enriching case selection for imminent 
RA: the use of anti-CCP antibodies 
in individuals with new non-specific 
musculoskeletal symptoms – a cohort 
study. Ann Rheum Dis 2016;75:1452–6. 
doi:10.1136/annrheumdis-2015-207871
3  Hazes JMW, Luime JJ. The epidemiology 
of early inflammatory arthritis. Nat Rev 
Rheumatol 2011;7:381–90. doi:10.1038/
nrrheum.2011.78
4  Machold KP, Landewe R, Smolen JS, et al. 
The Stop Arthritis Very Early (SAVE) trial, 
an international multicentre, randomised, 
double-blind, placebo-controlled trial on 
glucocorticoids in very early arthritis. Ann 
Rheum Dis 2010;69:495–502. doi:10.1136/
ard.2009.122473
5  Burgers LE, ten Brinck RM, Van der Helm-
van Mil AH. Is joint pain in patients with 
arthralgia suspicious for progression 
to rheumatoid arthritis explained by 
subclinical inflammation? A cross-sectional 
MRI study. Rheumatology doi:10.1093/
rheumatology/key220
6  van Steenbergen HW, van Nies JAB, 
Huizinga TWJ, et al. Characterising 
arthralgia in the preclinical phase of 
rheumatoid arthritis using MRI. Ann 
Rheum Dis 2015;74:1225–32. doi:10.1136/
annrheumdis-2014-205522
7  van der Linden MPM, Batstra MR, Bakker-
Jonges LE, et al. Toward a data-driven 
evaluation of the 2010 American College of 
Rheumatology/European League Against 
Rheumatism criteria for rheumatoid 
arthritis: Is it sensible to look at levels 
of rheumatoid factor? Arthritis Rheum 
2011;63:1190–9. doi:10.1002/art.30200
8  Mangnus L, van Steenbergen HW, 
Reijnierse M, et al. Magnetic Resonance 
Imaging-Detected Features of Inflammation 
and Erosions in Symptom-Free Persons 
From the General Population. Arthritis 
Rheumatol 2016;68:2593–602. doi:10.1002/
art.39749
9  Mangnus L, van Steenbergen HW, 
Lindqvist E, et al. Studies on ageing and 
the severity of radiographic joint damage 
in rheumatoid arthritis. Arthritis Res Ther 
2015;17. doi:10.1186/s13075-015-0740-0
10  ten Brinck RM, van Steenbergen HW, van 
der Helm–van Mil AHM. Sequence of joint 
tissue inflammation during rheumatoid 
arthritis development. Arthritis Res Ther 
2018;20. doi:10.1186/s13075-018-1756-z
11  Østergaard M. An introduction to the 
EULAR-OMERACT rheumatoid arthritis 
MRI reference image atlas. Ann Rheum Dis 
2005;64:i3–7. doi:10.1136/ard.2004.031773
12  Haavardsholm EA, Østergaard M, Ejbjerg 
BJ, et al. Introduction of a novel magnetic 
resonance imaging tenosynovitis score 
for rheumatoid arthritis: reliability in 
a multireader longitudinal study. Ann 
Rheum Dis 2007;66:1216–20. doi:10.1136/
ard.2006.068361
13  van Steenbergen HW, Aletaha D, 
Beaart-van de Voorde LJJ, et al. EULAR 
definition of arthralgia suspicious for 
progression to rheumatoid arthritis. Ann 
Rheum Dis 2017;76:491–6. doi:10.1136/
annrheumdis-2016-209846
14  ten Brinck RM, van Steenbergen HW, van 
Delft MAM, et al. The risk of individual 
autoantibodies, autoantibody combinations 
and levels for arthritis development in 
clinically suspect arthralgia. Rheumatology 
2017;56:2145–53. doi:10.1093/rheumatology/
kex340
Table 1. Comparison of baseline patient characteristics between different stages of the flowchart as 
presented in Figure 1.
Patient characteristic N=241 N=196 N=152 N=98
Age in years, mean (SD) 44 (13) 44 (13) 45 (13) 47 (13)
Female sex, N (%) 187 (78) 152 (77) 118 (78) 73 (74)
Family history of RA, N (%) 71 (30) 52 (27) 43 (28) 28 (29)
Symptom duration in weeks, median (IQR) 18 (10 – 48) 17 (9 – 30) 17 (9 – 33) 17 (9 – 43)
Presence of morning stiffness ≥60 minutes, N (%) 80 (33) 61 (35) 49 (32) 29 (30)
68-TJC, median (IQR) 6 (3 – 10) 6 (2 – 11) 6 (2 – 10) 5 (2 – 10)
VAS pain score, median (IQR) 5 (3 – 7) 5 (3 – 7) 5 (3 – 7) 5 (3 – 6)
≥3 items on EULAR definition of arthralgia suspi-
cious for progression to RA[13], N (%) 178 (74) 141 (72) 100 (66) 63 (64)
Increased CRP (≥5 mg/L), N (%) 53 (22) 39 (20) 29 (19) 19 (19)
Autoantibody status 
Negative for IgM-RF and ACPA, N (%) 184 (76) 166 (84) 125 (82) 79 (81)
ACPA- or RF-positive, N (%) 57 (24) 31 (16) 27 (18) 19 (19)
Legend: 
ACPA = anti-citrullinated peptide antibody (positive if: ≥7 U/mL); CRP = C-reactive protein; IgM-RF = immunoglobulin M 
rheumatoid factor (positive if: ≥3.5 IU/mL); IQR = interquartile range; RA = rheumatoid arthritis; SD = standard deviation; TJC = 
tender joint count. 
Table 2. Baseline characteristics of the Clinically Suspect Arthralgia patients with complete clinical follow-up 
(N=152) and complete clinical follow-up as well as MRI data at baseline at two-year follow-up (N=98)
Complete clinical follow-up (N=152) Complete clinical follow-up and MRI data (N=98)
Patient characteristic Symptom resolution  
(n=57)
No symptom resolu-
tion (n=95)
Symptom resolution  
(n=32)
No symptom resolution 
(n=66)
Age in years, mean (SD) 44 (13) 46 (13) 46 (14) 47 (13)
Female sex, N (%) 40 (70) 79 (82) 20 (63) 53 (80)
Family history of RA, N (%) 17 (30) 26 (27) 10 (31) 18 (27)
Symptom duration in weeks*, median (IQR) 17 (9 – 30) 17 (9 – 41) 18 (15 – 32) 17 (9 – 50)
Morning stiffness ≥60 minutes, N (%) 22 (39) 27 (28) 10 (31) 19 (29)
68-TJC*, median (IQR) 5 (2 – 8) 6 (2 – 12) 4 (2 – 7) 6 (2 – 13)
≥4 tender joints, N (%) 33 (58) 61 (64) 18 (56) 43 (65)
Increased CRP (≥5 mg/L), N (%) 12 (21) 17 (18) 9 (28) 10 (15)
Autoantibody status 
Negative for IgM-RF and ACPA, N (%) 43 (75) 71 (75) 25 (78) 54 (82)
ACPA- or RF-positive, N (%) 9 (16) 18 (19) 7 (22) 12 (18)
ACPA-positive, N (%) 5 (9) 6 (6) 3 (9) 4 (6)
Legend: 
ACPA = anti-citrullinated peptide antibody (positive if: ≥7 U/mL); CRP = C-reactive protein; IgM-RF = immunoglobulin M rheumatoid 
factor (positive if: ≥3.5 IU/mL); IQR = interquartile range; RA = rheumatoid arthritis; SD = standard deviation; TJC = tender joint count; 
VAS = visual analogue scale. *Missing data were as follows: symptom duration in weeks (n=4), 68-TJC (n=1).
Table 3. Characteristics of the 98 patients with and without resolution of symptoms at two-year follow-up
Patient characteristic 
Symptom resolution  
(n=32)
No symptom  
resolution (n=66)
P-value
68-TJC, median (IQR) 0 (0 – 0) 1 (0 – 4) 0.02
Presence of morning stiffness ≥60 minutes, N (%) 5 (16) 14 (21) 0.56
HAQ-score, mean (SD) 0.18 (0.40) 0.60 (0.50) 0.09
VAS pain score, mean (SD) 0.87 (1.5) 4.2 (2.4) <0.001
VAS fatigue score, mean (SD) 3.7 (3.3) 5.6 (2.6) 0.003
Legend: 
IQR = interquartile range; SD = standard deviation; TJC = tender joint count; VAS = visual analogue scale, range 0-10. 
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Figure 1. Flowchart of the different patient populations 
Legend: 
FU = follow-up.
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Figure 2. Percentage of patients reporting resolution of symptoms 
per follow-up visit presented for all patients (N=32) that had 
resolution of symptoms
Legend: 
Percentage of patients reporting resolution of symptoms per regular follow-up visit 
at 4, 12 and 24 months.
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Figure 3. VAS pain scores over time for patients with and without 
resolution of symptoms (N=98). 
Legend: 
* indicates significance at the P<0.05 level, ** indicates significance at the P<0.01 
level.
Figure 4. Mean total MRI-inflammation scores over time for patients with and without resolution of 
symptoms (N=82).
Legend: 
The grey area indicates the mean and 95% confidence interval (dashed lines specify the upper and lower limit of the interval) of 
the total MRI-inflammation score in age-matched symptom-free persons. Considered in this Figure are patients with a baseline 
total MRI-inflammation score >0. At baseline, in the group without resolution of complaints the mean total MRI-inflammation 
score was not different as compared to symptoms-free persons (p=0.26). Patients with resolution did have higher scores than 
symptoms-free persons (p=0.04). After two-year follow-up, patients without and with resolution of symptoms both did not have 
higher scores (p=0.68 and p=0.57, respectively). * indicates significance at the P<0.01 level, N.S. indicates non-significance.
Chapter 10
Summary and future perspectives
174 Summary
Summary
This thesis focused on investigating the early identification of Rheumatoid 
Arthritis (RA), assessing the burden of disease, and enhancing 
understanding of disease mechanisms in the earliest disease phases. Many 
of the studies in this thesis focused on data from the Leiden Clinically 
Suspect Arthralgia (CSA) cohort. The CSA cohort is an inception cohort 
at the rheumatology outpatient clinic of the Leiden University Medical 
Centre, in Leiden, the Netherlands. CSA patients had recent-onset (<1 
year) arthralgia of hand (MCP, PIP, wrist) or feet (MTP) joints, and they 
were considered at risk for RA, based on the clinical expertise of the 
rheumatologists.
Part 1: Predicting progression to RA 
In the first part of this thesis, chapters 2, 3 and 4 focused on the 
identification of RA and progression to RA in its earliest phases. Chapter 5 
evaluated the burden of disease during progression to RA.
Despite acknowledging recommendations in national and international 
guidelines on prompt referral of patients presenting with possible 
inflammatory arthritis (IA), general practitioners (GPs) indicate to 
feel uncertain in their proficiency to detect synovitis through joint 
examination.[1] Considering the need of early identification of RA, our 
objective in chapter 2 was to develop and validate a rule composed of 
clinical characteristics to assist GPs and other physicians in identifying 
inflammatory arthritis (IA) when in doubt.
 
This was investigated in the Leiden Early Arthritis Recognition Clinic 
(EARC); a screening clinic for patients in whom GPs suspected – but were 
unsure of – the presence of IA. In this cross-sectional study, associations 
with IA were found for: male gender, age ≥60 years, symptom duration 
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<6 weeks, morning stiffness >60 minutes, a low number of painful joints 
(1–3 joints), presence of patient-reported joint swelling, and difficulty with 
making a fist. In order to derive a tool that is easy to use in routine clinical 
practice in primary care, a simplified model was generated by rounding 
the obtained β’s from the multivariable regression model to the nearest 
0.5. This resulted in a simplified rule consisting of seven items and a total 
score ranging from 0 to 7.5 with corresponding predicted risks of IA. This 
rule showed reasonable discriminative ability for IA and could assist 
physicians in decision-making in patients with suspected IA, increasing 
appropriateness of health care utilization. 
Furthermore, a simulation was run for the rule with a prevalence of 
inflammatory arthritis set at 20%. This simulation was performed to mimic 
applicability in primary care settings, as this setting will likely have a lower 
prevalence of IA than the EARC-setting (which was situated in between 
primary and secondary care). Our simplified rule was implemented in 
a web application that provides probabilities on the presence of current 
IA for individual patients that can be accessed online. The CARE tool 
presented in chapter 2 is different from other studies that derived tools 
to facilitate triage of patients that have been referred to secondary or 
tertiary care.[2–4] The CARE tool did not aim to prioritize patients that 
have been referred already, but rather assist in the decision-making and 
referral process. The tool aims to facilitate recognition of IA (as this would 
necessitate prompt referral to a rheumatologist) rather than forming a 
longitudinal study to predict development of a specific diagnosis (e.g. RA) 
later-on.
Chapter 3 assessed the risks for arthritis development of three different 
autoantibodies: ACPA, RF and/or anti-carbamylated protein antibodies 
(anti-CarP). ACPA and RF are already tested routinely in current 
clinical practice. Anti-CarP is a novel autoantibody that has gained 
popularity over the last few years.[5] Assessed separately, associations for 
arthritis development were observed for both ACPA, RF and anti-CarP 
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antibodies. However, correcting for simultaneous presence of the three 
autoantibodies revealed that only ACPA was significantly associated with 
arthritis development. The positive predictive values (PPVs) for arthritis 
development within 2 years were: 63% for ACPA, 53% for RF and 50% 
for anti-CarP antibodies. Concurrent presence of ACPA and RF yielded 
a PPV of 67%. Although the serum levels of ACPA were not significantly 
associated with increased progression to clinical arthritis, this was the 
case for RF levels. Our data implicates that ACPA confers the highest 
risk for arthritis development and is of additive value to RF. However, 
clinicians and researchers alike should be aware that this implicates that 
>30% of ACPA-positive/RF-positive CSA patients did not develop arthritis 
despite having arthralgia and positive autoantibodies. Thus, both CSA 
and information on autoantibodies are still insufficient for accurately 
identifying imminent autoantibody-positive RA.
It is noteworthy that PPVs are dependent on enrichment (i.e. prevalence) 
of cases in cohort studies, meaning that the same test may yield different 
results depending on the setting. Patients that are identified as having CSA 
by rheumatologists comprise a small group of all patients presenting with 
arthralgia to secondary care (<6%).[6] As a consequence, the CSA-patients 
evaluated in chapter 3 likely had higher prior chances to develop RA than 
patients with non-specific arthralgia in secondary or primary care. In 
chapter 4, the implications of screening for two or three autoantibodies in 
persons at risk for RA was investigated. We found no additional predictive 
value was found for testing an autoantibody additive to ACPA and RF.
In chapter 5, we assessed functional disability in patients with CSA. 
Although several studies have focused on biomarkers to identify patients 
in the arthralgia phase preceding RA, the disease burden of this phase for 
patients is less studied. We found that scores of functional disability on the 
Health Assessment Questionnaire Disability Index (HAQ-DI) were already 
elevated during the phase of CSA: 0.50 for all patients. This was in line 
with HAQ-DI scores from ACPA-positive arthralgia patients from another 
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study.[7] A score on the HAQ-DI of 0 indicates no difficulty, whereas a 
score of 1 represents some difficulty. Furthermore, we established that 
higher MRI-inflammation scores were associated with higher functional 
disability. Interestingly, during follow-up, increased scores of functional 
disability (≥1.0) were associated with subsequent development of arthritis. 
Previous studies in early RA cohorts have shown that mean HAQ-scores at 
presentation were also 1.0.[8,9] Moreover, within patients converting to RA, 
scores of functional disability did not increase from presentation with CSA 
to arthritis development (0.88 and 0.75, respectively). Together, these data 
show that functional limitations in the symptomatic pre-arthritis phase of 
CSA were as serious as in the early clinical phase or RA, with the maximal 
level of disability in this phases of disease already present when presenting 
with CSA. These findings illustrate the relevance of the arthralgia phase 
from a patients’ perspective. 
Thus, in conclusion of the first part of this thesis, the early recognition 
of RA could (possibly) be further enhanced by the use of the CARE 
tool, perchance with the addition of other clinical parameters and 
autoantibodies. Nevertheless, there remains a large proportion of patients 
that cannot be accurately identified despite a suspect pattern of signs and 
symptoms, as well as information on autoantibodies.
Part 2: Disease mechanisms involved in progression from CSA to RA 
The second part of this aimed to provide insights into the processes 
involved in development of RA by understanding the biological 
mechanisms (chapter 6) and longitudinal investigations using MRI to study 
inflammation at joint level (chapter 7), and at the patient level (chapter 
8) over time. In chapter 8, the longitudinal diagnoses as well as their 
mutual time relationship with MRI-detected subclinical inflammation were 
scrutinized.
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ACPAs are hypothesized to directly activate osteoclasts, which lead to 
bone erosions and pain in RA. In chapter 6, evidence was sought for this 
hypothesis in humans. It evaluated whether in patients with arthralgia who 
are at risk of RA, ACPA is associated with erosions as detected by MRI, 
independent of inflammation, and also independent of the presence of 
rheumatoid factor (RF). 
Indeed, ACPA-positive patients had higher erosion scores than ACPA-
negative patients. Nevertheless, this mechanism was likely mediated by 
concurrent presence of inflammation: ACPA-positive patients without 
concomitant subclinical inflammation did not have higher erosion scores 
than ACPA-negative patients. This was in contrast to ACPA-positive 
patients with local inflammation, whom had higher erosion scores 
than ACPA-negative patients. Mediation analyses suggested that local 
inflammation lies in the causal path of ACPA leading to higher erosion 
scores. Stratification was also applied for ACPA and RF: compared 
to ACPA-negative/RF-negative patients, ACPA-positive/RF-negative 
patients did not differ in terms of erosions as detected by MRI, but ACPA-
positive/RF-positive patients did have higher erosion scores. Finally, 
triple stratification for ACPA, RF and inflammation demonstrated that the 
presence of ACPA and/or RF is only associated with higher erosion scores if 
concomitant inflammation is present.
 
It is intriguing to speculate how –or if– ACPAs contribute to joint erosions 
together with inflammation. However, since chapter 6 was an association 
study, it does not allow conclusions on biological mechanisms. The results 
align with those obtained in patients with early rheumatoid arthritis[10,11] 
and fuel the hypothesis that ACPAs alone are not the main and/or single 
pathogenic factor contributing to joint erosions and consequent destruction. 
In sum, the effect of ACPA on erosions is mediated by inflammation and is 
not independent of RF.
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Within patients that develop IA, the course of inflammation at joint level 
during the transition from CSA to RA is unknown. Chapter 7 assessed 
progression of MRI-detected subclinical inflammation at the joint level. It 
was investigated if development of clinical arthritis as imaged fitted better 
with the idea that arthritis development is a local outgrowing process, 
or whether the data are more in line with the hypothesis of a systemic 
deregulation; in this case locations of subclinical inflammation and 
synovitis development were largely uncoupled.
 
350 joints of 35 patients presenting with CSA (with all patients 
subsequently developing clinical arthritis) were studied at presentation 
with CSA and subsequently when clinical synovitis was first identified 
at physical examination. At presentation with CSA, 71 joints showed 
subclinical inflammation. During progression to IA, 20% of these joints 
had resolution of inflammation, 60% had persistent inflammation and 20% 
progressed to clinical synovitis. Of all joints that had developed clinical 
synovitis, no prior subclinical inflammation was detected in 69%. The 
present joint-level observations on inflammatory progression fit best with 
the hypothesis of ‘global deregulation’, rather than that of a localized 
exacerbating process. Previous observations of increased markers of 
systemic inflammation in pre-arthritis phases may support this.[12] 
As only moderate correlations were demonstrated in chapter 7 between 
joints with subclinical inflammation and joints that developed clinical 
synovitis, our data implies that development of RA is a more systemic, 
rather than a locally outgrowing process. 
Like in chapter 7, the study in chapter 8 assessed the course of MRI-
detected subclinical joint inflammation during progression to RA, only 
now on a patient level. Several hypotheses contrast each other on this 
course. Firstly, it has been postulated that synovitis is an initial process 
that is succeeded by bone involvement (‘outside-in hypothesis’).[13–16] 
Alternatively, it has been suggested that RA is a primary bone marrow 
disease, which subsequently encroaches upon the synovial membrane 
180 Summary
(‘inside-out hypothesis’).[14,17,18] Lastly, it has been hypothesized that 
these processes could emerge and progress simultaneously.[14,19] 
To address this outstanding question, patients were studied that 
progressed from CSA to RA. At presentation with CSA, synovitis and 
tenosynovitis scores were higher than scores observed in age-matched 
symptom-free persons, which suggests that these had already increased in 
the phase preceding first presentation with arthralgia. At first presentation, 
ACPA-positive arthralgia patients also had increased osteitis scores. 
During progression to RA, synovitis and osteitis increased significantly, in 
contrast to tenosynovitis and erosion scores. This pattern was again similar 
in both ACPA-subsets, although statistical significance was reached for 
synovitis and osteitis in ACPA-negative, but not in ACPA-positive RA. The 
increased tenosynovitis and synovitis-scores at CSA-onset and the increase 
in synovitis and osteitis during progression to RA suggest an ‘outside-in’ 
temporal relationship of arthritis development; particularly for ACPA-
negative RA. For ACPA-positive RA further studies are needed.
 
As synovitis and osteitis mostly increased during the symptomatic pre-
arthritis phase, our data implies that inflammation mainly starts outside the 
bone (fitting the ‘outside-in hypothesis’). Only later on (after presentation 
with CSA) does osteitis increase. Presence of BME then poses the joint at 
risk for structural damage development in the phase of clinically evident 
arthritis (if left insufficiently treated).[20] It needs to be noted that absolute 
patient number were rather small in chapter 8. The group of ACPA-positive 
RA patients comprised only 9 persons and therefore the statistical power to 
detect an effect was likely low.
Finally, the outcomes in CSA patients not progressing to RA are unknown. 
Chapter 9 determined the course of joint symptoms and mutual time 
relationships with MRI-detected subclinical inflammation. After two years 
follow-up, one-third of patients that did not convert to clinical arthritis 
had complete resolution of symptoms; whereas two-third of patients had 
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persistent symptoms. Interestingly, in all patients presenting with CSA, the 
progression rate to RA is approximately 20%.[21] Consequently, of the 80% 
of patients not converting to RA, two-third did not experience resolution 
of complaints (53% of all CSA), whereas one-third of the patients in this 
study had resolution of symptoms (27% of all CSA). Studies in UA patients 
showed that clinical synovitis will spontaneously resolve in 10-40% of 
patients[22,23], which is a similar range of spontaneous dissolvement of 
symptoms as in CSA.
 
Next, total MRI-inflammation scores (sum of bone marrow edema, 
synovitis and tenosynovitis) were compared to symptom-free persons for 
both patients with resolution of symptoms and patients with persistent 
symptoms. In the group with persistent complaints, scores were not 
different at baseline and after two years follow-up compared to symptom-
free persons. Contrarily, patients with resolution had elevated scores 
at baseline, but no longer at two-year follow-up; which would suggest 
dissolvement of MRI-detected subclinical inflammation over time. This 
mutual time relationship may suggests that subclinical inflammation 
was causally related to arthralgia. Taken together, our data showed that 
spontaneous resolution is possible in the phase of CSA and that patients 
presenting with CSA that had spontaneous resolution of symptoms also 
had dissolvement of subclinical inflammation. 
All studies in this part analysed disease mechanisms and MRI-detected 
subclinical inflammation in the development of RA. Interestingly, 
resolution of symptoms and subclinical inflammation (as detected by 
MRI) was possible in CSA-patients. Furthermore, the studies in patients 
converting to RA suggested that progression of clinical arthritis is a 
systemic inflammatory process that follows an ‘outside-in’ temporal 
relationship in which synovitis is an initial process that is succeeded by 
bone involvement. 
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Future perspectives and conclusions
In recent decennia, major advances have been booked in the early 
identification and treatment of patients with RA. These advances, in 
combination with improved treatment strategies, have dramatically 
improved the long-term outcomes. Four decades ago, the treatment of 
RA consisted of a combination of resting, physiotherapy and analgesics. 
Patients and physicians accepted debilitating deformities due to structural 
articular bone damage. Patients would often enter the physician’s 
consulting room using a wheelchair. Recently however, diagnostic 
workup and treatment of RA patients has improved so considerably 
that wheelchairs are hardly present anymore in the waiting room of a 
rheumatology outpatient clinic. Structural deformities are becoming 
less and less prevalent because disease activity can be reasonably well-
controlled.
One of the keys to this advancement lies in the early identification of RA. 
The last decade has been a rapid current of important discoveries in early 
RA. Although it is still a novel and relatively young area of research, in 
Clinically Suspect Arthralgia (CSA) the rheumatologists will rely on pattern 
recognition of signs and symptoms to recognize RA before clinically 
swollen joints can be identified at physical examination. A combination of 
arthralgia in the small joints of hand and feet, functional limitations with 
morning stiffness might suggest the development of RA.
Several strategies for early identification exist, one of which is the 
aforementioned approach of CSA. Recognition of CSA requires the clinical 
expertise of a rheumatologist, and general practitioners (GPs) might be 
lacking this expertise due to the low incidence of patients with actual 
inflammatory arthritis despite a large numbers of presentations with 
musculoskeletal symptoms. Considering the need for accurate prediction 
models to estimate which patients will progress to RA over time, we 
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developed the CARE tool in chapter 2. External validation of the results 
presented in chapter 2 is required.
First of all, because a setting in between primary and secondary (the Early 
Arthritis Recognition Clinic) was used, its true discriminative ability for IA 
needs to be confirmed when actually used in a primary care setting. These 
validation studies in actual primary care setting will have to demonstrate 
if the CARE tool can truly function as an addition to current diagnostic 
workup by GPs.
As mentioned in chapter 2, the addition of other (clinical) variables might 
increase the discriminative ability for RA and may be a subject of future 
studies. Examples of additional variables include the “squeeze test“ of 
MCP joints, or imaging abnormalities. The value (and possible addition or 
exclusion) of each variable in the rule needs to be analyzed in primary care 
setting.
Furthermore, GPs in the Netherlands function as a strict gatekeeper for 
physicians in secondary care, such as rheumatologists. As this system is 
not applied world-wide, there are large global differences in availability 
and accessibility of rheumatologic care. The CARE tool may be used to 
overcome these differences, but studies in other countries are warranted to 
evaluate the performance of the CARE tool in other regions.
Finally, the simulation that was performed in chapter 2 used an estimation 
of the prevalence of IA when GPs were in doubt to mimic a primary care 
setting. This estimation was derived from all available literature on this 
subject (and was set at 20%), but was based on only two studies.[24,25] 
Future studies will need to investigate the actual prevalence of IA when the 
GP feels uncertain about its presence.
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Another avenue of research to potentially extend knowledge in the field of 
rheumatology could be a study of cost-effectiveness of early recognition. If 
the ‘window of opportunity’ hypothesis is correct, then there is a confined 
period in which RA is most susceptible to the disease-modifying effects of 
treatment. Consequently, one would expect that patients that have been 
recognized within this window need less second- or third-line treatment 
options. Since second- or third line options often include expensive 
biological DMARDs (e.g. adalimumab, etanercept) or targeted synthetic 
DMARDs (e.g. tofacitinib or baricitinib), a big economic benefit could 
possibly be made. However, increased early recognition will require more 
time-investment of rheumatologists and therefore the exact yield is still to 
be determined. 
The main limitation of chapter 3 was the number of patients that 
could be studied in the stratified subgroups according to autoantibody 
combinations. Studying only a limited number of patients will lead to 
small statistical power and thus introduces the possibility of erroneously 
failing to reject a null hypothesis that is actually false (type II error). 
Despite a larger number of patients and a longer duration of follow 
up than a previous study investigating the risk conferred by ACPA in 
CSA patients[21], more accurate hazard ratios and absolute risks could 
potentially be calculated by inclusion of larger numbers. 
Future studies investigating accurate identification of patients at risk for 
RA will likely look into new biomarkers of disease. For this end, further 
understanding of the pathophysiology of RA is needed. In recent years, 
another post-translational modification of proteins[5], carbamylation, was 
identified to be affected in the early phases of RA. The role of this novel 
autoantibodies (anti-carbamylated protein antibody) in the diagnostic 
workup of RA will need to be investigated in future studies to assess if 
it will become the next autoantibody to regularly test in addition to RF 
and ACPA, as is now common practice in Western countries. The letter 
in chapter 4 showed that testing anti-CarP as a third autoantibody in 
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patients with CSA had limited added value for positive predictive value 
of development of clinical arthritis. Future studies in disease stages that 
precede CSA could investigate if testing anti-CarP as a third autoantibody 
has additional value to RF and ACPA, for instance by screening individuals 
to identify those at high(est) risk for developing RA. 
Furthermore, the value of these autoantibodies can be different in the 
different stages of RA. Future population-based cohort studies will have to 
demonstrate if a combination of three autoantibodies can contribute to the 
identification (screening) of at-risk patients before the onset of arthralgia.
With structural joint damage becoming increasingly rare, the position of an 
(if not the most) important outcome measure has shifted towards functional 
ability of patients. As demonstrated in chapter 5, CSA patients already 
suffer from increased functional disability as compared to the general 
population. This demonstrated the impact of RA on the daily living of RA 
patients, even in its earliest phases. Functional disability did not further 
increase after identification of clinical arthritis, demonstrating the relevance 
of CSA from patients’ perspectives. This is an interesting opposition of the 
clinician’s perspective, where the identification of clinical arthritis is the key 
and forms the start sign to initiate treatment. To study if this opposition 
is also present for other patient-reported outcomes (fatigue, work ability, 
health-related quality of life, etc.), future studies in CSA patients could be 
performed of these outcome measures. 
The most important outcome measures in future studies of RA remain to 
be determined. One might wonder if these need to encompass objective 
outcome measures, such as abnormalities in laboratory findings or imaging 
abnormalities. Otherwise, more subjective patient-reported measures 
could be considered, which comprise pain, health-related quality of life or 
stress. Future studies could look into developing entirely new instruments 
of assessing outcomes. A distinction between “generic” (suitable for 
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many diseases and conditions) and “disease-specific” (limited to use in 
one or a few disease conditions) instruments needs to be appraised when 
developing a new tool/questionnaire to assess patient outcomes.
Despite increasing rarity, structural joint damage still is an important 
outcome measures in RA research. Structural damage is caused by a 
discrepancy between bone formation and bone loss, and articular bone 
erosions (as evaluated by MRI) were evaluated in chapter 6. Future 
longitudinal studies could look into the value of erosions as detected by 
MRI in CSA patients. For instance, it could be investigated if an erosion as 
observed on MRI can be predictive for future erosions or joint destruction 
that can be observed on radiographs in patients that develop RA. However, 
it needs to be noted that a large number of patients will need to be studied 
over time for this end as erosions are increasingly rare. 
Furthermore, considering that chapter 6 was an association study, 
the biological mechanism could not be investigated. Elucidating this 
mechanism may be a subject of new studies unraveling the mechanism of 
articular joint erosions.
All the longitudinal studies investigating MRI-detected subclinical 
inflammation in this thesis (chapter 7–9) have the limitation of small 
absolute patients numbers. For conclusions with more statistical power, 
larger groups (especially the number of ACPA-positive RA patients) will 
be needed. Larger patient numbers could enable more detailed sensitivity 
analyses that compare autoantibody-positive patients with antibody-
negative patients, which could enhance insight in disease processes in the 
earliest phases of RA. 
Interestingly, as was established in chapter 9, not all patients with CSA will 
progress to RA and spontaneous resolution of CSA was possible in about 
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27% of CSA patients over time. This is of interest to further understand the 
mechanisms underlying development of RA. Future studies could look 
into the (biological) mechanisms that work in patients that despite having 
subclinical inflammation as depicted by MRI will not convert to clinical 
arthritis. 
Ideally, validation should be performed of the results from all the 
longitudinal MRI-studies investigating disease mechanisms in this thesis. If 
MRIs could be performed at more frequent time points, the course of MRI-
detected subclinical inflammation in the phases preceding identification of 
RA could be studied in more detail.
With an increasing number of tests and biomarkers available, the physical 
and physiological burden these tests could place on a patient must not be 
forgotten.[26] Future qualitative and quantitative studies may look into 
disease perceptions and cognitions of patients in the preclinical phases. 
Nonetheless, with early identification likely further improving over the 
coming decennia, the research agenda will likely shift to treatment in 
increasingly early phases of RA. The ‘window of opportunity’ hypothesis 
presumes the existence of an early period in which RA is most susceptible 
to DMARD treatment. Right now, DMARD-free sustained remission 
functions as the best proxy available to actually curing RA. Future research 
will show if treatment in these early phases will lead to delay of the 
occurrence of RA, or that disease processes will be altered in such a way 
that manifestation of RA can be prevented in its entirety. Several trials are 
currently ongoing in the world that will look into starting RA treatment in 
these early phases.[27–31] The results are expected to arrive within 5 years 
and will likely determine the guidelines of treatment for decades to come.
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For subsequent studies, a shift towards using real-world data from patient 
files could be strived for. Patient data is currently stored in electronic files, 
which poses a (potential) goldmine of data yet to be delved. Nonetheless, 
cohort studies and clinical trials will remain instrumental in the future of 
research, as these studies can specify clear inclusion and exclusion criteria 
to select and analyse harmonized groups of patients. However, if world- 
or continent-wide initiatives can be launched to share mined anonymized 
data from patients files, the number of patients that can be studied could 
in theory be very large. The consequent statistical power that can be 
generated could allow observations in groups of patients that normally 
couldn’t be studied due to their rarity. The generalizability of real-life data 
is an important deliberation, but reduction of “noisy data” (by filtering 
procedures or standardized registration) will be a challenge. Physicians 
will in the future need to be aware that whatever is entered in patient files 
may at a later point anonymous be mined for research purposes. However, 
before mining of data from patient files is possible, strict regulations will 
need to be implemented to ensure the patients’ privacy. 
Overall, most importantly, there remains a need to replicate the results of 
this thesis. Possibly, other centres in the Netherlands – or elsewhere in the 
world – could establish similar but independent cohorts of CSA patients to 
this end. 
In conclusion, this thesis showed that although early identification is 
increasingly improving, there remains a large proportion of patients that 
cannot be accurately identified despite a suspect pattern of signs and 
symptoms, as well as information on autoantibodies. Furthermore, the 
burden of disease is already substantial during the symptomatic pre-
arthritis phase of CSA. Future studies will have to provide evidence for 
the effectiveness of preventing persistent RA and functional disability with 
prescribing DMARD treatment in the phase of CSA. 
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Introductie
Reumatoïde artritis
Reumatoïde artritis (RA) is een chronische, inflammatoire gewrichtsziekte 
die gekenmerkt wordt door persisterende synovitis en systemische 
inflammatie.[1] Er kan permanente schade ontstaan aan de gewrichten 
door destructie van kraakbeen en bot.[1] Indien onbehandeld, dan zal RA 
in de meerderheid leiden tot verslechtering van het fysiek functioneren, 
het kunnen uitvoeren van alledaagse taken en aanleiding geven tot een 
verminderde arbeidsparticipatie en -productiviteit.
RA is één van de meest frequent voorkomende inflammatoire 
gewrichtsziekten, en geschat wordt dat ongeveer 1% van de bevolking 
door RA aangedaan is.[2] De typische presentatie van “klassieke” 
RA is een vrouw van middelbare leeftijd, met subacute sluimerende 
polyarticulaire en symmetrische artralgie en zwelling van de kleine hand- 
en voetgewrichten. Doorgaans zijn de metacarpophalangeale (MCP), 
proximale interphalangeale (PIP), pols en metatarsophalengeale (MTP) 
gewrichten aangedaan. Andere kenmerken klachten en symptomen 
omvatten ochtendstijfheid, moeheid en gewichtsverlies. Verder kunnen 
ook extra-articulaire manifestaties bestaan, zoals huidafwijkingen 
(reumanoduli), pulmonale of cardiale betrokkenheid, verminderd mentaal 
welbevinden en vasculitis.[3,4] Bij het lichamelijk onderzoek moet altijd 
gekeken worden naar de aanwezigheid en verdeling van pijnlijke en 
gezwollen gewichten. Het laboratoriumonderzoek kan aanwijzing geven 
voor verhoogde concentraties van autoantistoffen: anti-citrullinated protein 
antibodies (ACPA of anti-CCP) en reumafactor (RF). Verder kunnen ook 
acute fase eiwitten zoals C-reactief protein (CRP) en de bezinkingssnelheid 
van erytrocyten (BSE) verhoogd zijn in RA.
Vroege identificatie van RA
Het vroegtijdig herkennen van RA is een belangrijk speerpunt binnen de 
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reumatologie, omdat dit de mogelijkheid zal bieden tot het tijdig starten 
van behandeling. De update van de EULAR aanbevelingen uit 2016 voor 
behandeling van RA geeft aan dat disease-modifying antirheumatic drugs 
(DMARDs) direct gestart moeten worden zodra de diagnose RA gesteld 
is.[5] De onderliggende gedachte hieraan is de mogelijkheid van een 
“window of opportunity”; een vroege ziekteperiode waarin RA het meest 
gevoelig is voor het effect van behandeling. De huidige consensus is dat 
DMARDS het beste effect hebben als de onderliggende ziekteprocessen nog 
niet volledig uitgerijpt zijn. Omgekeerd is aangetoond dat het later starten 
van behandeling geassocieerd is met slechtere ziekte-uitkomsten, waarbij 
er meer schade aan gewrichten werd gezien en lagere percentages van 
remissie van ziekte werden bereikt.
Echter, het vroeg herkennen van RA is een uitdaging voor clinici in 
zowel eerste als tweede lijn. Met name in de eerste lijn is er een hoge 
incidentie van consultatie voor gewrichtsklachten, terwijl de incidentie van 
daadwerkelijk RA juist laag is.[6] Hoewel de prevalentie van consultatie 
voor gewrichtsklachten ongeveer 2405 per 10,000 per jaar bedraagt[6,7], zal 
de gemiddelde fulltime huisarts slechts één nieuwe patiënt met RA zien per 
jaar.[8]
Om de uitdaging van correcte vroegherkenning van RA te ondervangen 
zijn in de literatuur in recente jaren verschillende strategieën voorgesteld 
voor het identificeren van “at risk” groepen. Zo omvat één strategie de 
identificatie van deze “at risk” groep door middel van het testen van 
aanwezigheid van autoantistoffen (ACPA en RF) in het serum. Als deze 
autoantistoffen aanwezig zijn wordt de betreffende persoon als “at risk” 
beschouwd voor het ontwikkelen van RA.[9,10] Een voordeel van deze 
strategie is dat het makkelijk toe te passen is, ook in de eerste lijn, omdat 
evaluatie door een reumatoloog niet noodzakelijk is voorafgaand aan het 
inzetten van labonderzoek. Een nadeel is dat een deel van de patiënten die 
RA zullen ontwikkelen deze autoantistoffen (nog) niet hebben, en daarmee 
onterecht als niet “at risk” zullen worden beschouwd.
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Een andere strategie is het identificeren van patiënten “at risk” door 
gebruik te maken van klinische evaluatie door een reumatoloog. 
Deze zal dan op basis van klinische expertise en door middel van 
patroonherkenning in anamnese en lichamelijk onderzoek een patiënt 
inschatten als zijde “at risk”. De herkenning van een zeker klachtenpatroon 
zal – al dan niet onbewust – door reumatologen in de dagelijkse kliniek 
reeds toegepast worden en kan leiden tot de identificatie van patiënten met 
Clinically Suspect Arthralgia (CSA). Slecht een klein deel van alle patiënten 
die door een reumatoloog in de tweede lijn geëvalueerd worden voldoen 
aan dit specifieke klachtenpatroon: <6%.[11] Pas na herkenning van CSA 
zullen laboratoriumonderzoek en verder aanvullend onderzoek toegepast 
worden. Een voordeel van deze aanpak is dat zowel patiënten met als 
zonder autoantistoffen bestudeerd kunnen worden, alsook de mogelijkheid 
tot het onderzoek van het onderscheidend vermogen van aanvullende 
diagnostiek door middel van bloedonderzoek of beeldvorming. Een 
nadeel van deze aanpak is dat het een zekere mate van subjectiviteit omvat 
omdat CSA omkaderd is door de klinische expertise van de betreffende 
reumatoloog. 
Om inclusie van homogene groepen patiënten tussen verschillende studies 
te kunnen waarborgen heeft een EULAR taskforce recent een definitie 
opgesteld voor artralgie die verdacht is voor progressie tot RA.[12] De 
betreffende karakteristieken staan benoemd in Tabel 1. 
196 Nederlandse samenvatting
Tabel 1. EULAR definitie van karakteristieken van artralgie “at risk” voor het 
ontwikkelen van RA
Anamnese:
•	 Kort bestaande gewichtsklachten (duur <1 jaar)
•	 Symptomen gelokaliseerd in MCP gewrichten
•	 Duur van ochtendstijfheid ≥60 min
•	 Symptomen het ergst in de vroege ochtend 
•	 Positieve eerstegraads familieanamnese voor RA 
Lichamelijk onderzoek:
•	 Moeite met het maken van een vuist
•	 Positieve “squeeze test” van de MCP gewrichten
Het CSA cohort
In dit proefschrift is veelvoudig gebruik gemaakt van data verkregen uit 
het CSA cohort van het Leids Universitair Medisch Centrum (Leiden, 
Nederland). In dit inceptiecohort zijn sinds 2012 patiënten geïncludeerd die 
op basis van hun klachtenpatroon door hun reumatoloog verdacht werden 
van RA in wording. Per definitie hadden alle patiënten kort bestaande (<1 
jaar) artralgie aan de hand- (MCP, PIP of pols) of voetgewrichten (MTP) en 
werden zij beschouwd als “at risk” voor het ontwikkelen van RA op basis 
van hun eerste bezoek aan de reumatoloog. Omdat CSA beschouwd wordt 
als het ziektestadium vóór het daadwerkelijk ontstaan van de kenmerkende 
gewrichtsontsteking (artritis) van RA, hadden patiënten géén CSA als artritis 
reeds aanwezig bij het eerste bezoek. Dientengevolge zouden patiënten met 
reeds bestaande artritis niet geïncludeerd worden in het CSA cohort. Een 
andere reden om niet geïncludeerd te worden in het CSA cohort was als er 
een duidelijk andere verklaring bestond voor de gewrichtsklachten, waarbij te 
denken valt aan tekenen van fibromyalgie (aanwezigheid van tenderpoints) of 
artrose (bijvoorbeeld Heberden of Bouchard noduli). 
Aangezien huisartsen in de regio van het LUMC ontraden werd om te 
testen op de aanwezigheid van autoantistoffen vóór verwijzing naar een 
reumatoloog waren de ACPA- en RF-status vaak onbekend bij eerste 
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presentatie. Bij het eerste bezoek werd, na het verkrijgen van informed 
consent en inclusie in het CSA cohort, verder aanvullend onderzoek ingezet 
door middel van laboratoriumonderzoek en beeldvorming (röntgenfoto’s 
en MRI). 
Patiënten werden daarna prospectief gevolgd met geplande bezoek op 4, 
12 en 24 maanden na het eerste bezoek. Indien nodig (bijvoorbeeld als een 
patiënt verergering van de klachten ervaarde of een gezwollen gewricht 
bemerkte) werden zij tussendoor gezien door de reumatoloog. Zodoende 
werd gewaarborgd dat het ontstaan van artritis bij de eerste mogelijkheid 
werd herkend. Follow-up in het CSA cohort werd beëindigd als artritis 
werd vastgesteld, of anders na het laatste bezoek op 24 maanden.
De patiënten in het CSA cohort werden geïncludeerd op basis van 
een klinische verdenking door de reumatoloog. Het voldoen aan de 
bovengenoemde EULAR definitie voor artralgie “at risk” voor RA[12] 
was dus geen voorwaarde, maar de betreffende kenmerken werden wel 
bekeken en konden dus achteraf toegepast worden. 
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Doelen van dit proefschrift
Dit proefschrift heeft zich toegelegd op de vroege fases van Reumatoïde 
Artritis (RA). Omdat voorgaande studies lieten zien dat individuen met 
positieve autoantistoffen in ongeveer 30–50% daadwerkelijk converteerden 
tot RA[9,13–16], bleef er een noodzaak bestaan tot het meer accuraat 
kunnen identificeren van RA in wording. Verder is gekeken naar de impact 
die de vroege ziektefase van CSA heeft op de functionele beperkingen die 
ervaren worden door patiënten. Tot slot hebben we onderzoek gedaan naar 
de verschillende processen die van invloed zijn in de vroege fases van RA.
Verder is in dit proefschrift gekeken naar de ziektelast, en is getracht het 
begrip van de mechanismen in de vroegste fasen van RA beter te begrijpen. 
Veel van de studies in dit proefschrift hebben zich gefocust op data 
afkomstig uit het CSA cohort in het Leids Universitair Medisch Centrum.
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Deel 1: Progressie tot RA en geassocieerde ziektelast
In het eerste deel van dit proefschrift, te weten hoofdstukken 2, 3 en 4, is de 
focus gelegd op de factoren die bijdragend kunnen zijn in de identificatie 
van RA en progressie tot RA in haar vroegste fasen. Hoofdstuk 5 evalueerde 
de ziektelast gedurende progressie tot RA. 
Ondanks het onderkennen van de aanbevelingen in nationale en 
internationale richtlijnen tot het snel verwijzen van patiënten met mogelijke 
inflammatoire artritis (IA), geven huisartsen nog steeds aan zich niet 
zeker te voelen in hun eigen vaardigheden tot het opsporen van synovitis 
door middel van gewichtsonderzoek.[17] Gezien de noodzaak tot vroege 
identificatie van RA, betrof het doel van hoofdstuk 2 het ontwikkelen 
en valideren van een klinische beslisregel, bestaande uit klinische 
karakteristieken, waarbij de huisarts geholpen kan worden met het 
herkennen van IA wanneer hij/zij in twijfel is.
Dit onderzoek werd verricht door middel van data verkregen uit de Leidse 
Early Arthritis Recognition Clinic (EARC); een screeningskliniek waarbij 
patiënten verwezen kunnen worden wanneer de huisarts IA vermoedde. 
In dit dwarsdoorsnedeonderzoek werden associaties gevonden met het 
ontwikkelen van IA voor de volgende variabelen: het mannelijk geslacht, 
een leeftijd ≥60 jaar, een symptoomduur van <6 weken, ochtendstijfheid 
>60 minuten, een laag aantal pijnlijke gewrichten (1–3 gewrichten), de 
aanwezigheid van patiënt-gerapporteerde gewrichtszwelling en moeite 
met het maken van een vuist. Voor gebruik in de dagelijkse kliniek van 
de huisarts werd een model gemaakt waarbij de verkregen β’s uit het 
multivariabele regressiemodel werden versimpeld door af te ronden naar de 
dichtstbijzijnde 0.5. Dit resulteerde in een beslisregel bestaande uit 7 items 
en een score lopend van 0 tot 7.5 met bijbehorende voorspelde risico’s op 
IA. De beslisregel had een redelijk onderscheidend vermogen voor IA en 
zou huisartsen kunnen bijstaan bij het maken van beslissingen bij patiënten 
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waarbij IA wordt vermoed, zodat de juiste zorg ingezet kan worden.
Het onderzoek bevat ook een simulatie van de beslisregel waarin de 
prevalentie van inflammatoire artritis op 20% werd gezet. Deze simulatie 
werd verricht om de toepasbaarheid van de regel na te bootsen in een 
eerstelijnssetting, aangezien er in deze setting waarschijnlijk een lagere 
prevalentie zal zijn dan in de EARC (gesitueerd tussen de eerste en tweede 
lijn). Onze beslisregel is beschikbaar gemaakt in een webapplicatie waarbij 
voorspelde risico’s op het bestaan van IA worden gegeven. De zogenoemde 
CARE tool, zoals gepresenteerd in hoofdstuk 2, onderscheid zich van 
andere studies waarin regels werden ontwikkeld in het feit dat zij zich 
niet richt op het triëren van patiënten die reeds naar de tweede of derde 
lijn zich verwezen.[18–20] De CARE tool richt zich daarentegen juist op 
het assisteren in het maken van beslissingen en het eventueel inzetten van 
een verwijzing voor de juiste patiënten. De beslisregel richt zich op het 
faciliteren van vroege herkenning van IA (aangezien hier snelle verwijzing 
naar een reumatoloog nodig zal zijn), en is dus géén longitudinale studie 
waarbij voorspelling van een specifieke diagnose (bijvoorbeeld RA) op een 
later punt wordt beoogd.
In hoofdstuk 3 werden risico’s op het ontwikkelen van klinische artritis 
onderzocht voor drie verschillende autoantistoffen: ACPA, RF en/of anti-
carbamylated protein antibodies (anti-CarP). ACPA en RF worden in de 
reguliere zorg getest bij (vrijwel) alle patiënten met RA. Anti-CarP is een 
nieuwe autoantistof waar veel onderzoek naar is verricht in recente jaren.
[21] Wanneer onafhankelijk van elkaar beschouwd werden associaties 
gevonden met het ontwikkelen van klinische artritis voor zowel ACPA, RF 
als Anti-CarP. Echter, wanneer er gecorrigeerd werd voor het gelijktijdig 
aanwezig zijn van deze drie antistoffen was alleen ACPA nog significant 
geassocieerd met het ontwikkelen van artritis. De positief voorspellende 
waarden (in het Engels: “positive predictive value” of “PPV”) voor het 
ontwikkelen van artritis binnen 2 jaar waren: 63% voor ACPA, 53% voor 
RF en 50% voor anti-CarP. Het gelijktijdig aanwezig zijn van ACPA en RF 
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in een patiënt gaf een PPV van 67%. Hoewel hogere titers van ACPA niet 
geassocieerd waren met hogere kansen op het ontwikkelen van artritis, 
gold dit wel voor RF. Onze data impliceren dat ACPA het hoogste risico 
met zich meebrengt voor het ontwikkelen van RA, en bovendien van 
toegevoegde waarde is bovenop het testen van RF. Desondanks moeten 
zowel clinici als onderzoekers zich bewust zijn van het omgekeerde van de 
PPV van 67% van ACPA en RF. Dit zal betekenen van nog altijd >30% van 
de artralgie patiënten die zowel ACPA- als RF-positief zijn geen RA zullen 
ontwikkelen. Dit deed ons concluderen dat het aanwezig zijn van CSA en 
antistoffen nog altijd onvoldoende accuraat is om antistof-positieve RA te 
voorspellen.
Het dient opgemerkt te worden dat PPVs afhankelijk zijn van de 
prevalenties van “cases” in cohortstudies, wat wil zeggen dat dezelfde 
(serum)test andere resultaten kan geven afhankelijk van de setting waarin 
deze getest wordt. Patiënten die geschouwd worden als CSA door hun 
reumatologen zijn slechts een kleine groep van alle patiënten die zich met 
artralgie presenteren in de tweede lijn (<6%).[11] Dientengevolge hebben de 
onderzochte patiënten uit hoofdstuk 3 een hogere kans op het ontwikkelen 
van RA dan patiënten met non-specifiek artralgie in de eerste of tweede 
lijn. In hoofdstuk 4 zijn de implicaties onderzocht van het testen van twee 
of drie autoantistoffen. Daarbij werd geen toegevoegde waarde gevonden 
van het testen van een aanvullende autoantistof in toevoeging tot ACPA en 
RA in patiënten met CSA.
In hoofdstuk 5 zijn de functionele beperkingen onderzocht die 
gerapporteerd werden door patiënten met CSA. Hierbij hebben we 
gevonden dat de scores van functionele beperking, onderzocht middels 
de Health Assessment Questionnaire Disability Index (HAQ-DI) al 
verhoogd waren in de fase van CSA: 0.50 voor alle patiënten. Deze score 
kwam overeen met de HAQ-DI gerapporteerd in een andere studie met 
ACPA-positieve artralgie patiënten.[22] Een score van 0 op de HAQ-DI is 
een indicatie van geen moeilijkheden met het uitvoeren van functionele 
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taken, waar 1 een indicatie is van enige moeilijkheid. Bovendien vonden 
we dat hogere scores van inflammatie (zoals gedetecteerd met MRI) 
geassocieerd waren met meer functionele beperkingen. Interessant genoeg 
vonden we dat, gedurende follow-up, dat verhoogde HAQ-DI scores 
(≥1.0) geassocieerd waren met het later ontwikkelen van klinische artritis. 
Eerdere studies in patiënten met vroege RA lieten zien dat de gemiddelde 
HAQ-scores hier ook ongeveer 1.0 waren.[23,24] Een eveneens interessante 
bevinding was dat scores van functionele beperkingen niet verder 
toename van het moment van presentatie met CSA tot het daadwerkelijk 
ontwikkelen van artritis (0.88 en 0.75, respectievelijk). Samengenomen laten 
deze data zien dat functionele beperking al van eenzelfde ernst waren in 
de symptomatische pre-artritis fase van CSA als de vroegste fasen van RA, 
waarbij het maximum aan beperkingen in deze fasen als bereikt was bij 
eerste presentatie met CSA. Deze bevindingen kunnen als illustratie dienen 
van de relevantie van de artralgie fase vanuit het perspectief van de patiënt. 
Als conclusie van dit deel van het proefschrift geldt dat betere 
vroegherkenning van RA (mogelijkerwijs) bereikt kan worden door het 
gebruik van de CARE beslisregel, mogelijk verreikt door kennis over 
andere klinische kenmerken of wellicht autoantistoffen. Desondanks 
kan een aanzienlijk deel van de patiënten met antistof-positieve ziekte in 
wording nog onvoldoende herkend worden ondanks de aanwezigheid 
van een suggestief patroon van klinische tekenen en symptomen en de 
aanwezigheid van autoantistoffen en functionele beperkingen. 
203Nederlandse samenvatting
11
Deel 2: Ziekteprocessen in de ontwikkeling van RA
In het tweede deel van het proefschrift hebben we getracht meer inzicht te 
verkrijgen in de ziekteprocessen in de vroege fasen van RA door onderzoek 
te doen naar de biologische mechanismen (hoofdstuk 6), en hebben we 
longitudinale studies gedaan door middel van MRI en inflammatie bekeken 
op zowel het gewrichts- (hoofdstuk 7) als het patiënt-niveau (hoofdstuk 8) 
over tijd.
Van ACPAs wordt gedacht dat zij directe activatie geven van osteoclasten, 
wat zal leiden tot erosies (en pijn) in RA patiënten. In hoofdstuk 6 zochten 
we bewijs voor deze theorie in mensen, waar eerdere studies vooral in 
proefdieren verricht waren. Het hoofdstuk evalueerde of, in patiënten met 
artralgie, ACPA geassocieerd was met erosies, al dan niet onafhankelijk 
van onderliggende inflammatie of het gelijktijdig aanwezig van RF. Zoals 
verwacht hadden ACPA-positieve patiënten hogere scores voor erosies op 
MRI dan ACPA-negatieve patiënten. Echter, dit proces lijkt gemedieerd te 
worden door gelijktijdige aanwezigheid van inflammatie: ACPA-positieve 
patiënten zonder inflammatie hadden een gelijke erosie-score als ACPA-
negatieve patiënten. Dit in tegenstelling tot ACPA-positieve patiënten 
met lokale inflammatie, waarin significant hogere erosie scores werden 
geobserveerd. Een mediatie analyse toonde aanwijzingen dat inflammatie 
in het causale pad ligt van ACPA leidend tot hogere erosie scores. In een 
analyse met drievoudige stratificatie werd aangetoond dat ACPA en/of RF 
alleen met hogere inflammatie-scores geassocieerd zijn indien gelijktijdige 
inflammatie aanwezig is. 
Van de patiënten die IA zullen ontwikkelen is onbekend hoe het verloop 
van inflammatie op gewrichtsniveau zich afspeelt. In hoofdstuk 7 werd 
MRI-gedetecteerde subklinische inflammatie bekeken over tijd. Er werden 
een tweetal theorieën onderzocht: of artritis een lokaal uitgroeiend proces 
is, of dat er meer gedacht dient te worden aan een systemisch probleem 
204 Nederlandse samenvatting
waarbij locaties van lokale subklinische inflammatie grotendeels los staat 
van de gewrichten waarin artritis zal ontstaan.
In deze studie werden 350 gewrichten onderzocht van 35 patiënten met 
CSA (die allen zouden converteren tot artritis in ten minste één gewricht). 
Van alle gewrichten waarin uiteindelijk synovitis zou worden vastgesteld, 
was in 69% van de gevallen geen subklinische inflammatie te zien tijdens 
het baseline bezoek. Dit zou het beste passen bij de theorie van een 
systemisch proces, wat grotendeels ondersteund wordt door voorgaande 
studies waarin reeds verhoogde markers van systemische inflammatie 
worden gevonden in het laboratoriumonderzoek in de pre-artritis fase.[25]
Net als in hoofdstuk 7 werd in hoofdstuk 8 gekeken naar het verloop van 
MRI-gedetecteerde subklinische inflammatie tijdens progressie tot RA, 
alleen in dit geval op het patiëntniveau. De twee geldende theorieën over 
ontwikkelen van artritis zijn de “outside-in hypothese” [26–29] (waarbij 
synovitis voorafgaat aan betrokkenheid van de botten) en de “inside-out 
hypothese” [27,30,31] (waarbij RA gezien wordt als primaire ziekte van 
het beenmerg en de synoviale membraan pas later in de ziekte aangedaan 
zal zijn). Om deze uitstaande vraag te onderzoeken werd gekeken naar 
patiënten die allen converteerden van CSA naar RA. Bij presentatie met 
CSA waren met name de synovitis- en tenosynovitis-scores hoger in CSA 
patiënten dan in gezonde controles. Tijdens de progressie tot RA werden 
met name toename in de scores gezien van synovitis en beenmerg oedeem. 
Dit patroon, waarbij synovitis en tenosynovitis eerst verhoogd waren, en 
pas later beenmerg oedeem zichtbaar werd past het beste bij de “outside-in 
theorie” in de ontwikkeling van RA. Het behoeft nog wel verder onderzoek 
of dit geldt voor zowel ACPA-positieve als ACPA-negatieve patiënten. 
Tot slot is er nog veel onbekend over de uitkomsten in patiënten die 
niet zullen converteren tot RA. In hoofdstuk 9 werd het ziektebeloop 
onderzocht in deze patiënten, alsook de samenhang tussen het beloop 
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van symptomen en MRI-gedetecteerde subklinische inflammatie. Na twee 
jaar follow-up had een derde van de patiënten resolutie van symptomen, 
terwijl twee derde juist persisterende symptomen ervaarde. Opvallend was 
dat de baseline totale MRI-inflammatie scores in de patiënten die resolutie 
ervaarden significant hoger waren dan scores in gezonden controles, 
terwijl dit niet gold voor de patiënten zonder resolutie. Na twee jaar 
was in beide groepen geen verschil meer te zien met gezonde controles, 
waarbij de scores van patiënten met resolutie van symptomen ook een 
significante daling toonden over de tijd. Samengenomen lieten onze data 
zien dat resolutie van symptomen mogelijk is na een fase van CSA en dat 
de patiënten die resolutie van hun symptomen ervaarden ook resolutie van 
subklinische inflammatie hadden. 
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Conclusies en toekomstperspectieven
In recente decennia zijn er grote stappen geboekt in de vroege identificatie 
en behandeling van patiënten met RA. Door deze vooruitgangen zijn 
de uitkomsten op lange termijn van deze patiënten drastisch verbeterd. 
Waar een veertigtal jaar geleden de behandeling van RA nog bestond 
uit rust, fysiotherapie en analgetica, zijn de rolstoelen en ernstige 
gewrichtsdeformaties bijna verdwenen uit de wachtkamers bij de 
Reumatologie. Vroegherkenning van ziekte heeft hier een grote bijdrage 
aan geleverd en de afgelopen jaren heeft het Clinically Suspect Arthralgia 
(CSA) cohort hier een belangrijk onderdeel van uitgemaakt. Voor de 
herkenning van een patiënt met CSA is klinische expertise benodigd, 
waarbij een patroon van gewrichtsklachten, functionele beperkingen en 
ochtendstijfheid gedestilleerd kan worden. Ook het lichamelijk onderzoek 
maakt een belangrijk deel van het reumatologisch onderzoek uit, waarbij 
het gewrichtsonderzoek nog altijd als gouden standaard geldt voor het 
vaststellen van synovitis. 
Juist het herkennen van het klachtenpatroon en het gewrichtsonderzoek 
is iets wat door huisartsen zelf als lacune in de eigen expertise wordt 
aangegeven. Validatie van de resultaten uit hoofdstuk 2 in de eerstelijns 
setting is daarom van belang. Zoals ook in hoofdstuk 2 reeds aangegeven 
zou de discriminatoire waarde van de voorspelregel nog verder verbeterd 
kunnen worden door het toevoegen van extra variabelen. Hierbij valt te 
denken aan de “squeeze test” van MCP gewrichten, of afwijkingen op 
beeldvormend onderzoek. Ook dit zou verder onderzocht kunnen worden 
in een echte setting van de eerste lijn.
Het systeem waarin de Nederlandse huisartsen functioneren als 
poortwachter voor de tweede lijn wordt niet wereldwijd toegepast, en 
dientengevolge zijn er grote verschillen aan te wijzen in de beschikbaarheid 
en toegankelijkheid van reumatologische zorg. Hoewel de CARE tool uit 
207Nederlandse samenvatting
11
hoofdstuk 2 zou kunnen functioneren als verlaging van de drempel voor 
beschikbaarheid van zorg in de tweede lijn, moet de validiteit van de regel 
verder onderzocht worden in andere regio’s wereldwijd.
Tot slot is in hoofdstuk 2 een simulatie verricht waarbij een schatting werd 
gemaakt op de prevalentie van IA wanneer huisartsen twijfelden. Deze 
schatting is afgeleid uit eerdere literatuur, maar baseert zich slechts op 2 
studies.[32,33] Toekomstige studies zouden verder kunnen onderzoeken 
hoe vaak IA daadwerkelijk aanwezig is in het geval van twijfel bij de 
huisarts.
Een andere onderzoeksrichting voor de toekomst van de reumatologie zou 
zich kunnen richten op de kosteneffectiviteit van de vroege herkenning 
van RA. Als de hypothese over een “window of opportunity” klopt, dan 
zou verwacht mogen worden dat patiënten die juist binnen dit tijdsbestek 
correct herkend worden als RA minder vaak tweede of derdelijns 
behandeling nodig zullen hebben, zoals biological DMARDs of de nieuwe 
targeted synthetic DMARDs. Echter, extra inspanning in vroegherkenning 
zal ook meer tijd vereisen van de reumatoloog, waarbij de precieze netto 
opbrengst nog onderzocht moet worden. 
De belangrijkste limitatie van een aantal analyses in dit proefschrift was 
het beperkte aantal patiënten dat onderzocht kon worden, met name in de 
gestratificeerde subgroepen. Bij onderzoek met kleine patiëntengroepen 
bestaat er – door kleine statistische “power” – een grotere kans op het 
onterecht verwerpen van de nulhypothese (type II fout). Inclusie van 
grotere groepen patiënten in de toekomst zou tot een grotere power moeten 
leiden, met als gevolg meer accurate hazard ratio’s en absolute risico’s.
De belangrijkste uitkomstmaten in toekomstige studies over RA staat 
nog ter discussie. Enerzijds zouden de uitkomstmaten vooral objectieve 
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maten moeten omvatten, zoals afwijkingen in het labonderzoek of op 
beeldvorming. Anderzijds zouden ook subjectieve (door de patiënte 
gerapporteerde) maten bekeken moeten worden; te denken valt aan pijn, 
kwaliteit van leven, ervaren stress of functionele beperkingen. Ook hier zou 
verder onderzoek naar verricht kunnen worden.
Voorts bevatte dit proefschrift meerdere onderzoeken waarbij vooral 
wordt gekeken naar associaties op het niveau van patiënten en groepen 
van patiënten. Hierbij valt te denken aan, bijvoorbeeld, de associatie 
tussen inflammatie en erosies in hoofdstuk 6. Deze studies lieten niet toe 
om het onderliggende biologische mechanisme verder te onderzoeken. 
Toekomstige studies zouden zich hier op kunnen richten. 
Verder zouden er onderzoeken verricht kunnen worden ter validatie van de 
verschillende longitudinale studies die betrekking hadden op inflammatie 
te zien is met MRI. Zo zouden deze studies ook MRI-scans kunnen 
verrichten op meer frequente tijdspunten om de relaties over tijd in meer 
detail te kunnen bekijken. 
Verder dient niet te vergeten te worden dat het steeds groter wordende 
arsenaal aan testen en biomarkers ook een grotere druk op de patiënt legt.
[34] Zowel kwalitatief als kwantitatief onderzoek zou verricht kunnen 
worden om meer te weten te komen over ziekteperceptie en cognitie van 
patiënten in de preklinische fasen van RA.
Niettemin zal, door de steeds beter wordende vroege herkenning van RA, 
de onderzoeksagenda zich op gaan schuiven naar behandeling in steeds 
vroegere fasen van RA. Op dit moment is aanhoudende remissie van 
ziekte zonder de noodzaak tot het gebruiken van DMARDs (“DMARD-
free sustained remission”) de beste afgeleide beschikbaar voor het 
daadwerkelijk genezen van RA. Door vroeger te behandelen hopen 
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onderzoekers in de komende jaren, in verschillende trials[35–39], bewijs te 
verzamelen dat het optreden van RA in het geheel voorkomen kan worden. 
Resultaten van deze trials zullen in de komende 5 jaar gaan verschijnen 
en zullen waarschijnlijk bepalend gaan zijn voor de richtlijnen voor de 
behandeling van RA van de komende decennia. 
Tot slot blijft voor alle onderzoeken in dit proefschrift gelden dat validatie 
van resultaten, zoals dat voor de gehele wetenschap geldt, noodzakelijk is. 
In conclusie is in dit proefschrift aangetoond dat hoewel de vroege 
identificatie van RA steeds verder verbeterd wordt, er nog altijd een grote 
groep patiënten bestaat die niet accuraat herkend kan worden ondanks een 
kenmerkend patroon van klachten, en de beschikbaarheid van informatie 
over aan- of afwezigheid van antistoffen. Verder is de ziektelast van RA al 
verhoogd in de pre-artritis fase van CSA. Toekomstige studies zullen het 
bewijs moeten gaan leveren wat de mogelijkheden zijn tot het voorkomen 
van persisterende RA en functionele klachten door het voorschrijven van 
behandeling met DMARDs tijdens de fase van CSA.
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